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Transcriptional regulation 
The genomic DNA sequence carries information in two fundamental forms: first, in transcribed 
genes that specify mRNAs and other functional non-coding RNAs; second, in regulatory 
sequences that control the expression levels and patterns of those genes. The initial paradigms 
of gene regulation were established by studying transcription in prokaryotes, which mainly rely on 
promoter-proximal DNA sequences to control transcription1. In unicellular organisms, this 
information can determine absolute levels of transcription and also mediate gene expression 
changes in response to external stimuli. Metazoan organisms present a challenge in this regard 
since a single cell originates diverse cell-types, which have distinct morphology and function, and 
constitute the different structures present in an adult multicellular organism. The advent of next-
generation sequencing (NGS) technologies enabled comparing the genomes of different species, 
and these studies revealed that organismal complexity and genome size do not correlate in a 
linear manner2. Therefore, morphological and developmental complexity are not a direct product 
of increased number of genes but, instead, of alternative mechanisms. Notably, complexity can 
arise by diversifying the patterns of gene expression, both in space and time, within an organism. 
In metazoans, transcriptional control is dependent not only on promoters but also on distal cis-
regulatory elements known as enhancers. The uncoupling of enhancers from their target 
promoter was first demonstrated when Banerji et al. showed that the SV40 enhancer is able to 
increase the expression of a heterologous gene (-globin) over a distance of 10 kb3. Recent 
studies provided dramatic examples of very long-range interactions between enhancers and 
promoters in vertebrate genomes. For example, the expression of SHH and MYC is regulated by 
distal enhancers that map more than 1 Mb from their promoter region4,5. The regulation of 
promoters by enhancers at a distance opens the door for complex transcriptional regulation, 
whereby a gene can be differentially expressed in distinct cell-types and in response to different 
environmental cues. A well-studied example is the regulation of even-skipped in Drosophila, 
which is expressed in seven distinct stripes along the length of the embryo due to the action of 
five different enhancers6. Thus, it is very likely that the distal location and modular organization of 
enhancers enabled the development of multiple cell-types and contributed to the evolutionary 
diversity of metazoans.  
Hallmarks of enhancer elements 
Enhancers were first characterized by gain-of-function reporter assays in immortalized cell 
lines3,7. These seminal studies defined enhancers as DNA sequences that can activate 
transcription independently of their distance and orientation relative to the target promoter. This 
flexibility is a hallmark of enhancer elements and remains part of their functional definition to date. 
Enhancers are commonly located in intergenic regions or within the introns of protein-coding 
genes. However, this flexibility poses a great challenge to catalog the full set of enhancers 
present in the human genome. Whereas promoters can be identified simply by sequencing the 5’ 
end of genes, no such clear-cut criterion exists that can locate an enhancer and its target 
gene(s).  
A central feature of enhancers is their ability to function as binding platforms for 
transcription factors (TFs). The DNA sequence of enhancers is usually 200-500 bp long and 
contains clustered recognition sites for multiple TFs. The conservation of these sequences is 
often used to identify putative enhancers8, and several studies indicate that their activity is largely 
cell-type and specie specific9. In general, several TFs are required for the activation of 
enhancers, including lineage-specific and signal-responsive factors that ensure the integration of 
intrinsic and extrinsic cues at these elements. The ability of TFs to activate transcription on 
chromatin templates is dependent on the recruitment of coactivator proteins, such as p30010,11. 
These factors often lack DNA-binding capacity, but instead function as histone modifiers, 
chromatin remodelers or recruiters of general TFs and RNAPII. Surprisingly, it was found that 
general TFs and RNAPII also bind to enhancer regions, leading to the production of enhancer-
associated RNAs (eRNAs)12,13. The expression of eRNAs correlates with enhancer activity and 
there is abundant evidence supporting a role for these transcripts in gene regulation (see section 
8
516213-L-bw-lopes
Processed on: 2-1-2018 PDF page: 9
“Functional roles of eRNAs”). The binding of TFs at enhancers is associated with regions 
depleted of nucleosomes that are highly sensitive to DNA nucleases like DNase I14. However, 
nucleosomes immediately adjacent to enhancer regions are marked with specific histone 
modifications, namely H3K4me1 and H3K27Ac15-17. Notably, H3K4me3 is associated with gene 
promoters, which usually exhibit low levels of H3K4me1 at the transcription start site. These 
“chromatin signatures”, often in combination with DNase I hypersensitivity and coactivator 
binding, are frequently used to annotate enhancers in a genome-wide scale18-21. Based on such 
experiments, it was suggested that there are approximately one million enhancers in the human 
genome20,21. However, dozens of histone modifications remain to be tested and, therefore, a 
comprehensive census of enhancers based on chromatin signatures remains a subject of 
speculation. 
Mechanisms of enhancer function 
Enhancers play a central role in controlling spatiotemporal gene expression, which is essential to 
specify different cell lineages during development (reviewed in6). Still, the nature of enhancer-
promoter communication is one of the outstanding mysteries of transcriptional regulation. More 
than 30 years passed since the discovery of the archetype SV40 enhancer, and yet, we do not 
fully understand the mechanisms of this process. It is generally accepted that enhancers activate 
transcription by delivering essential factors to the gene promoter, which stimulate the formation of 
the preinitiation complex (PIC) or the transition from initiation to elongation. There are several 
models that try to explain how enhancers communicate with promoters over long distances22, but 
two of them stand out from the remaining: “looping” and “tracking”. The first postulates that 
enhancers and promoters interact directly while the intervening DNA sequence is looped out23. 
The latter proposes that enhancers diffuse along the chromatin fiber in search of a target 
promoter24. Nevertheless, both models agree that the mechanism of action of enhancers requires 
direct interactions with the gene promoter. In recent years, the looping model as received 
abundant support through the results obtained by Chromosome Conformation Capture (3C) and 
its derivatives (4C, 5C and Hi-C)25-28. These studies revealed that enhancers and promoters are 
extensively engaged in interactions within multiple loci in mammalian genomes29. The fact that 
enhancers often colocalize with the promoters they regulate was interpreted as the result of direct 
enhancer-promoter interactions, which are required for the activation of gene expression. This 
hypothesis is supported by several studies that found a strong correlation between active 
transcription and enhancer-promoter interactions. For example, knockout of TFs that are required 
for -globin expression results in the loss of colocalization of the gene promoter with its locus 
control region (LCR)30,31. Additionally, it was shown that some enhancers can exhibit a preference 
for specific classes of promoters, such as the ones containing a canonical TATA box32,33, further 
supporting a direct communication between these regulatory elements. Nonetheless, it is not 
clear whether the spatial colocalization of enhancer and promoter regions is a cause or 
consequence of gene expression. Deng et al. addressed this question by tethering Ldb1 to the 
promoter of -globin via an artificial zinc finger (ZF) protein34,35. They found that ZF-Ldb1 was 
sufficient to establish a loop between -globin and its LCR, recruit RNAPII and activate gene 
expression. These results support a causal role for DNA looping in gene activation and 
demonstrate that forced chromatin interactions can overcome tightly regulated developmental 
mechanisms. 
Topology of enhancers and their regulatory landscapes  
Evidence supporting enhancer-promoter interactions are part of a bigger picture showing that 
nuclear organization is a major determinant of gene expression. Imaging experiments revealed 
that interphase chromosomes tend to occupy discrete areas, called “chromosome territories”, 
rather than spreading throughout the nucleus36. Furthermore, individual chromosomes are 
organized in series of topologically associating domains (TADs), which are megabase-sized 
regions containing 5-10 genes and a few hundred enhancers37,38. TADs have similar boundaries 
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in all human cell-types examined to date and display high frequency of self-interactions as 
measured by Hi-C39-41. Accordingly, TADs have been proposed to constrain enhancer-promoter 
interactions because the vast majority of DNA contacts occur within the TADs39,41. This 
hypothesis explains why enhancer-promoter interactions mainly occur in cis and are limited in 
length within a chromosome. Still, it does not answer the question: how do enhancers 
communicate with the right promoter(s) in time and space? 
In the nucleus, gene loci can colocalize on the basis of shared associations with specific 
factors, such as RNAPII. Visualization of RNAPII or nascent mRNAs suggested that transcription 
is localized to a limited number of foci, known as “transcription factories”42,43. This term was 
proposed to explain the observation that active gene loci located in the same or even separate 
chromosomes tend to colocalize in the nucleus. In addition to RNAPII, other factors are organized 
into discrete foci and can, either directly or indirectly, bring distal loci into close proximity with 
each other. In this regard, CTCF (CCCTC-Binding Factor) has emerged as a key player in 
chromatin organization and gene regulation. CTCF is a transcriptional regulator that binds DNA 
through its ZF domains. Strikingly, it is the only known protein to bind to insulators (also known as 
boundary elements) and mediate this type of activity in vertebrates44. The main function of 
insulators is to block genes from being affected by the transcriptional activity of neighboring loci. 
Therefore, they limit the action of transcriptional regulatory elements to defined regions, and 
effectively partition the genome into discrete realms of expression. The activity of insulators is 
mainly defined by their ability to block enhancer-promoter communication and prevent spreading 
of heterochromatin (reviewed in45). CTCF can also associate with itself46, and these CTCF-CTCF 
interactions have been implicated in the formation of chromatin loops as detected by 3C-based 
techniques47,48. Interestingly, CTCF associates with cohesin and this seems to be required for 
insulating activity49,50. A study by Kagey et al. found that enhancers and promoters are associated 
with cohesin and mediator51, providing a potential mechanistic link between long-range CTCF-
CTCF interactions and enhancer-promoter communication. In recent years, this hypothesis has 
gained momentum due to the availability of genome-wide maps of the proteins that bind 
enhancers, promoters and insulators, together with information about the physical interactions 
that occur between them52-55. This information gave rise to a model in which each chromosome 
contains thousands of DNA loops, formed by the interaction of two CTCF molecules bound to 
different loci and reinforced by a cohesin ring. The proteins that bind to enhancers within the loop 
are constrained such that they tend to interact only with promoters in their vicinity. These CTCF-
CTCF loops have been termed “insulated neighborhoods” because they insulate enhancers and 
genes within the loop from enhancers and genes outside the loop (reviewed in56).  
Several lines of evidence support a function for insulated neighborhoods in activation and 
repression of gene expression. First, the majority of enhancer-promoter interaction occur within 
insulated neighborhoods (e.g. ~90% in human ESCs)54,55,57,58. Second, genetic or epigenetic 
perturbation of neighborhood boundaries leads to changes in local gene expression55,57-60. 
Finally, somatic mutations in CTCF-binding sequences overlapping with neighborhood 
boundaries were found in multiple tumor-types57,59,61. The insulated neighborhood model 
suggests an explanation for how enhancer-promoter specificity is obtained when a single gene 
occurs together with its regulatory elements within the neighborhood. However, it does not fully 
justify enhancer-promoter specificity when there are multiple genes within the loop. It was 
estimated that in neighborhoods with two genes, their expression patterns are concordant in 
~60% of the cases (i.e. both are active or both are silent), suggesting that they are co-regulated56. 
In Drosophila, there is evidence that an enhancer can target all genes within an insulated 
neighborhood62. Nonetheless, it is very likely that enhancer-promoter communication is 
determined, to a great extent, by the interaction of specific factors bound at these elements30-35. 
Functional roles of eRNAs 
Several reports over the past half a century hinted at the existence of short-lived RNA species in 
the nucleus. In 1959, it was found that the majority of nascent RNA is rapidly degraded and does 
not contribute to the pool of mRNAs63. However, it was only in the 1990’s that specific 
transcription at enhancers was documented in the LCR of the globin genes64-66. Additional 
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examples were found later at the LCRs of MHC Class II67 and GH168. However, widespread RNA 
transcription at enhancers only became apparent in recent years through the application of NGS 
technologies. Using total RNA-seq, Kim et al. found a broad pattern of transcription at active 
enhancers in neuronal cells12. Moreover, several studies identified RNAPII complexes enriched at 
putative enhancer regions by using ChIP-seq12,13,69. The discovery of pervasive transcription at 
enhancers indicates that eRNAs, in addition to introns, are important contributors to the lowly-
stable pool of nuclear RNA70. Genome-wide detection of nascent RNA by Global Run-on 
sequencing (GRO-seq) demonstrated that eRNAs are widely expressed in macrophages, breast, 
colon and prostate cancer cells71-75. Several studies reported that expression of eRNAs is 
responsive to extrinsic cues12,71,74,76, suggesting a role for these molecules in the regulation of 
gene expression. Indeed, it was demonstrated that transcription of eRNAs preceded the 
activation of target genes13,77 and their expression correlated with the expression of neighboring 
genes12,13. Additional evidence showed that eRNA expression is specifically regulated by signal-
dependent TFs, such as p53 and ER, and is highly correlated with changes in expression of 
target genes74,78. A causal role for eRNAs in transcriptional activation was demonstrated in a 
number of subsequent studies, in which the depletion of eRNAs led to specific repression of 
target genes in human cells74,78-81. It was also shown that transcriptional activation could be 
recapitulated in reporter assays, and this was dependent on the expression of eRNAs74,78,79. 
Moreover, Lam et al. provided evidence that reporter vectors containing eRNA-coding sequences 
have higher transcriptional activity compared to the ones containing the enhancer sequence 
alone81. The eRNA sequence seems to be important per se since the increased expression was 
abolished upon reversing its orientation relative to the enhancer81. Collectively, these studies 
indicate that expression of eRNAs is a hallmark of active enhancer elements and support a main 
role for them in transcriptional regulation. 
Mechanisms of eRNA function 
eRNAs were initially defined as non-coding RNAs produced from putative enhancer regions 
marked by high H3K4me1, low H3K4me3, and occupied by RNAPII12,13. Still, they are a poorly 
defined class of RNAs that is associated with different features and mechanisms of action. In 
general, eRNAs have a 5’ cap but are not spliced or polyadenylated70,81. Polyadenylated eRNAs 
are usually transcribed as a unidirectional unit, although enhancers with bidirectional transcription 
and non-polyadenylated transcripts are more common69. The half-life of eRNAs is low compared 
to mRNAs and long non-coding RNAs (lncRNAs), but their transcription initiation frequency is 
similar to that of protein-coding genes81. These features suggested that eRNAs have a nuclear 
function, and several mechanisms have been proposed to explain how eRNAs might contribute to 
gene regulation. It was observed that transcription activity at the -globin LCR correlated with its 
sensitivity to DNase I, hinting that intergenic non-coding RNAs can play a role in the maintenance 
of active chromatin states82. Additionally, Mousavi et al. proposed that eRNAs facilitate RNAPII 
recruitment the target promoter(s)83. They showed that eRNAs were critical for the expression of 
MyoD, and that their knockdown decreased RNAPII occupancy at the promoter but not at the 
enhancer. This is in agreement with earlier observations at the HS2 enhancer: inhibition of 
RNAPII elongation results in decreased recruitment of RNAPII to the -globin promoter but not at 
the HS2 enhancer84. This evidence also suggests that recruitment of RNAPII and transcription at 
enhancers is an early event and precedes the activation of target genes. Genome-wide studies of 
chromatin interactions revealed that enhancers engaged in looping with promoters express higher 
levels of eRNAs85,86. Moreover, eRNAs interact both with mediator80 and cohesin complexes74, 
suggesting that they might be involved in the establishment or maintenance of chromosome 
conformation. Importantly, depletion of eRNAs caused a strong decrease in enhancer-promoter 
interactions and a concomitant reduction of target gene expression74,80. Available data indicates 
that this might not be a general mechanism since enhancer-promoter interactions do not always 
require eRNAs (see General discussion). eRNAs might also exert their function by acting as a 
decoy for the negative elongation factor (NELF) complex. It was demonstrated that eRNAs are 
synthesized prior to target gene transcription and interact with a subunit of NELF87. Knockdown of 
eRNAs impaired the release of NELF from target promoters, which coincided with downregulation 
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of gene expression87. Together, these studies demonstrated that eRNAs are involved in almost all 
stages of transcriptional activation, from chromatin accessibility and loop formation to RNAPII 
loading and pause release. Future studies should aim at identifying the protein partners of eRNAs 
in order to provide comprehensive insights into their mechanisms of action.  
The role of enhancers in disease 
Enhancers are essential for orchestrating complex gene expression patterns that are required for 
the proper development of adult organisms. Therefore, it is not surprising that dysfunction of 
enhancers or the factors that bind to them is an important component in human disease. As 
mentioned above, enhancers translate extracellular signals to an intracellular response in the 
form of changes in gene expression. In general, this happens through a cascade of signaling 
events that culminate in the nucleus through the action TFs. A large number of cancer-associated 
genes are TFs or kinases that control their activity, and therefore, it is not surprising that many 
gene regulatory circuits are altered in cancer88. One of the most striking examples is p53, which is 
a TF that activates gene expression in response to diverse cellular stresses, thereby leading to 
DNA repair, cell cycle arrest and apoptosis (reviewed in89). Not surprisingly, p53 is the most 
frequently altered gene in human tumors, with mutation rates ranging from ~10% up to nearly 
100%90. The vast majority of mutations are located in the DNA binding domain of p53 - thereby 
impairing its functions as a TF and tumor-suppressor. Interestingly, genome-wide studies showed 
that a large fraction of p53 binding sites overlap with distal regulatory elements75,76,78, suggesting 
that p53 regulates its target genes by binding to enhancers. Another example is ER, which is a 
ligand-dependent transcription factor that promotes cell growth. ER is activated by estradiol, 
which is its natural ligand, or through phosphorylation events mediated by kinases such as 
MAPK/PI3K91. ER is expressed in ~70% of breast tumors and, therefore, it is a major target for 
hormonal therapy in this type of cancer91. Genome-wide analysis of ER binding by ChIP-seq 
identified many events at intergenic and intronic regions that display typical features of 
enhancers92,93. The vast majority of tumors that relapse after hormonal therapy still express 
ER94, underlining the importance of identifying the enhancers and target genes of this pathway. 
In recent years, a number of inhibitors were developed to target transcriptional regulators that 
bind enhancers. In particular, the use BET inhibitors for cancer treatment has generated great 
enthusiasm and their effect is currently under evaluation in clinical trials95. TFs are considered the 
Holy Grail of cancer therapy and, for many years, it was thought that they were 
undruggable. Their remarkable diversity and potency as drivers of tumorigenesis justifies a 
continued pursuit of novel drugs to target TFs. 
Similar to mutations in protein-coding genes, variation in enhancer sequences has been 
causally associated with several monogenic disorders (reviewed in96). A notable example is the 
dysregulation of SHH expression and limb malformations. The expression SHH is governed by a 
distal enhancer element, known as the ZPA regulatory sequence (ZRS), located approximately 1 
Mb away from its promoter. Point mutations within the ZRS have been linked to a congenital 
disease characterized by the formation of extra digits97, whereas deletion of the entire element 
causes truncation of limbs in mice98. Additional examples include mutations in the enhancers of 
Sox9 and Tbx5 that cause Pierre Robin anomaly99 and congenital heart disease100, respectively.  
The main evidence connecting genetic alterations in enhancers and cancer comes from 
GWAS. To date, these studies have identified more than 400 SNPs that significantly predispose 
individuals to various types of cancer101. Interestingly, the vast majority of disease-associated 
variants map to non-coding regions of the genome: 40% are intergenic and a similar percentage 
map to intronic regions102,103. A large fraction of cancer-risk SNPs occur in regions enriched in 
expression quantitative trait loci (eQTLs)104, DNase I hypersensitive sites105 and eRNA 
expression106, which are features indicative of enhancers. In recent years, a number of studies 
showed that genetic variation at enhancers can predispose individuals to cancer107-111. For 
example, a region upstream of MYC (8q24) contains genetic variants that confer increased risk 
for multiple cancer types, including prostate, breast, colorectal, bladder and chronic lymphocytic 
leukemia (CLL)112-115. This locus contains several functional enhancers, and it was shown that 
their activity is altered by the cancer-associated SNPs107-109. These studies suggest that genetic 
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variation at enhancers and other regulatory elements may be a general feature of susceptibility to 
cancer and other common diseases. 
Cancer is a complex genetic disease that arises from multiple genetic and epigenetic 
alterations in oncogenes and tumor-suppressor genes116. However, different tumor-types are 
characterized by a set of common hallmarks such as genomic instability and dysregulation of cell 
cycle117. Not surprisingly, cancer cells typically display copy number alterations that affect more 
than a quarter of their genome118. The majority of DNA amplifications involve oncogenes, but they 
have also been found exclusively in non-coding regions. The increased copy number of an 
enhancer can amplify its output and cause aberrant gene expression, providing tumor cells with a 
strong growth advantage. Amplification of non-coding regions seem to be under positive selection 
since it was observed that they accumulate over time119, and also that enhancers carrying a risk 
allele can be preferentially amplified120,121. Furthermore, it was shown that non-coding 
amplifications can specifically affect critical oncogenes (e.g. MYC) in different types of 
tumors122,123. The repositioning of enhancers next to oncogenes is a recurrent theme in cancer 
genomes. This can arise either through large deletions, which frequently occur in carcinomas, or 
translocations and inversions, which are commonly found in liquid tumors. The latter case is 
exemplified by chromosomal translocations found in T-cell acute lymphoblastic leukemia (T-ALL) 
that bring different oncogenes, including TLX1, TLX3, TAL1, TAL2, NOTCH1 and MYC, close to 
the regulatory region of the T-cell receptor124. Moreover, large structural rearrangements can 
affect multiple genes by changing the location of a single regulatory element. Groschel et al. 
showed that the repositioning of an enhancer through inv(3)/t(3;3) underlies the development of 
AML by deregulating the expression of both EVI1 and GATA2125. In addition to large 
rearrangements, a great number of somatic mutations, involving single-nucleotide alterations, 
insertions and deletions, are also found in the non-coding cancer genome. However, the 
identification of non-coding oncogenic mutations is a very challenging task, due to the large size 
of the non-coding genome, reduced number of whole-genome sequences available, difficulty to 
assess the function of the mutations and unknown rate background mutation rate. As a 
consequence, few recurrent mutations in the non-coding genome have been identified so far. 
Most of these mutations occur in or near promoter regions, such as the ones found upstream of 
TERT126,127 and PLEKHS1128. In particular, mutations in the promoter of TERT are frequently 
observed in different types of carcinomas, including bladder, liver, thyroid and melanoma129-131. 
On the contrary, mutations in enhancer elements are expected to be more specific to the tumor-
type. This hypothesis is supported by a limited number of cases, such as the mutations that 
create an enhancer de novo in CLL132 and T-ALL133. In addition to the alterations mentioned 
above, the activity of enhancers can spread locally due to small mutations or deletions that occur 
in CTCF/cohesin binding sites, which disrupt the boundaries of insulated neighborhoods57. 
Indeed, CTCF binding sites at insulators are among the most altered TF sequences in cancer 
cells134 and recent studies have identified recurrent deletions at such boundaries in multiple 
tumor-types61. The finding that proto-oncogenes can be activated through somatic mutations or 
epigenetic alterations that disrupt CTCF-CTCF loops provides additional evidence for the function 
of insulated neighborhoods57,59,61.  Altogether, these studies suggest that the disruption of 
chromosome architecture, and consequently enhancer activity, contributes to the development of 
cancer.  
CRISPR-Cas systems: from bacterial immunity to genome editing 
CRISPR systems were identified in bacteria as an adaptive immune mechanism that protects 
them from foreign nucleic acids, such as viruses or plasmids135,136. Type II-CRISPR systems 
incorporate invading sequences in the host bacterial genome between an array of repeated 
sequences. CRISPR repeat arrays are transcribed and processed into CRISPR RNAs (crRNAs), 
each containing a variable sequence (protospacer sequence) transcribed from the invading 
genome. A second RNA, known as transactivating CRISPR RNA (tracrRNA), hybridizes with 
each crRNA and together they form a complex with the Cas9 nuclease137,138. The protospacer 
directs Cas9 to cleave complementary target sequences, provided they are adjacent to a short 
13
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sequence known as protospacer adjacent motif (PAM). The PAM confers specificity to Cas9 
targeting, and enables distinguishing self from non-self DNA sequences137,138. 
The type II CRISPR from S. pyogenes was the first system to be engineered for targeted 
genome editing137. The most widely used form of this system is made of two components that 
must be expressed in cells or organisms to perform DNA editing: the Cas9 nuclease and a single 
guide RNA (sgRNA), which is a fusion of a crRNA and a fixed tracrRNA. Cas9 can be directed to 
a specific genomic location by a 20 bp sequence at the 5’ end of the sgRNA, which hybridizes 
with the target sequence by standard RNA-DNA complementary base-pairing rules137. The target 
sites must lie immediately upstream of a canonical PAM sequence (NGG in S. pyogenes). Using 
this system, the Cas9 nuclease can be directed to any DNA sequence of the form N20-NGG 
simply by changing the first 20 nucleotides of the sgRNA to match the target sequence. Additional 
CRISPR systems from other bacteria, which recognize alternative PAMs and use different 
crRNA/tracrRNA sequences, were also adapted for targeted genome editing in human cells139-141. 
The initial demonstration that Cas9 can be programed to cleave DNA in vitro137 propelled 
a number of studies showing that this platform also functions in a variety of cells and organisms. 
In 2013, it was shown that Cas9 can target endogenous genes in bacteria142, immortalized 
human cell lines143-146, human pluripotent stem cells143 and even in a whole organism (D. rerio)146. 
The first step for performing targeted genome editing using nucleases is the creation of a DNA 
double-strand break (DSB) at the target locus147. Nuclease-induced DSBs are usually repaired by 
one of two pathways: non-homologous end joining (NHEJ) or homology-directed repair (HDR). 
NHEJ is an error-prone repair mechanism that efficiently generates small insertions and deletions 
(indels) of variable size148, which can disrupt the coding frame of a gene or the binding site of a 
TF. HDR-based genome editing can be used to generate specific mutations or insert desired 
sequences through an exogenous DNA template149. The frequency of HDR upon Cas9-mediated 
DSBs is typically greater than 10% and, in some cases, can reach up to 60%150. Given these 
rates, desired mutations can be simply identified by screening without requiring a drug-resistance 
selection marker. Cas9 is able to introduce DSBs at multiple sites in parallel, which is a unique 
advantage of this system compared to other DNA editing tools like ZNFs and TALEs. This 
strategy has been used to induce large deletions143, inversions143,151, and simultaneous mutations 
in multiple genes152-154.
CRISPR-Cas9 genome editing has accelerated the generation of cellular and animal 
transgenic models, expanding biological research beyond genetically tractable model 
organisms155. For example, gene editing can be used to rapidly test the role of specific genetic 
variants found in the population, instead of relying on animal models that phenocopy a particular 
disease. This approach was applied in recent years to engineer isogenic ESCs and develop novel 
transgenic animal models152,156. CRISPR-mediated genome editing can also expedite the devel-
opment of large animal models, including in primates, and thereby accelerate the identification of 
suitable therapies for humans156. CRISPR-Cas9 has also been used for ex vivo and in vivo gene 
correction by HDR - either using exogenously supplied oligonucleotides or the endogenous WT 
allele157,158. In the study by Wu and colleagues, it was shown that the resulting mice were fertile 
and able to transmit the corrected allele to their progeny158, providing a proof of principle for using 
CRISPR-Cas9 to correct genetic diseases. There are serious ethical concerns surrounding 
germline modification of human embryos for correction of disease-causing mutations159,160. 
However, it may be possible to achieve therapeutic benefit for some disorders by correcting faulty 
genes in somatic cells. This was demonstrated independently by three research groups161-163 that 
used CRISPR-Cas9 in a mouse model to delete a mutation that causes Duchenne muscular 
dystrophy (DMD). This type of approach provides potential means of correcting mutations 
responsible for DMD and other monogenic disorders164,165 after birth. As of writing, a number of 
countries (e.g. Sweden, the UK, Japan and China) have approved research applications based 
on CRISPR-Cas9 genome editing in human embryos. In the meantime, ongoing clinical trials 
testing stem cell-based applications166,167 set the stage for next-generation genome editing 
therapies. Therefore, it is imperative that health safety investigations keep pace with 
technological advances of CRISPR systems to ensure an appropriate risk-benefit profile for future 
therapeutic interventions in human patients. 
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Genetic screens using CRISPR-Cas9   
The simplicity of CRISPR-Cas9 programming has inspired the generation of pooled sgRNA 
libraries using customized oligonucleotides. Using this approach, a complex pool of 
oligonucleotides is produced and directly cloned into a plasmid vector to generate a lentiviral 
library that is used for screening168. In 2014, this strategy was successfully employed for both 
positive and negative forward genetic screens in human and mouse cells169-171. These studies 
revealed both known and novel genes that are involved in fundamental cellular processes and 
drug/toxin resistance169-171. Genome-wide CRISPR screens were also successfully applied in vivo 
to identify protein-coding genes and miRNAs that dictate in cancer progression172. Importantly, 
CRISPR-Cas9 screens display very strong phenotypic effects, likely due to complete knockout of 
gene expression. Initial comparisons revealed that CRISPR-Cas9 outperformed RNAi in terms of 
reagent consistency and candidate validation169. Recent studies have systematically compared 
the performance of both technologies in loss-of-function screens173,174 and it seems that CRISPR 
has the upper hand in this case (see General discussion).  
In pooled CRISPR screens, Cas9 can be either stably expressed in the target cells or 
encoded in the same lentiviral vector that expresses the sgRNA175. The viruses are produced and 
purified in bulk, and the target cells must be transduced at low multiplicity of infection. This step 
needs to be optimized in order to avoid cells carrying more than one sgRNA, which can severely 
compromise the interpretation of the screen. After selection for stable transgene integrations, the 
mutagenized population of cells undergoes a phenotypic screening in order to identify genes 
involved in a specific biological process176. In positive selection (or enrichment) screens, a strong 
pressure is applied to select mutations that enhance cellular fitness. This approach is useful to 
identify genes involved in resistance to toxins171,177, pathogens178 and drugs169,170, but also 
cellular processes such as metastasis172. On the other hand, negative selection (or dropout) 
screens identify mutations that cause loss of cells during the selection procedure. This type of 
approach is mainly used to identify essential genes required for cell proliferation and survival179. 
Dropout screens are more sensitive to alterations in the representation of the library because the 
candidate genes are selected by comparing the abundance of sgRNAs before and after selection. 
Also, this approach is further complicated by a significant amount of neutral mutations generated 
by Cas9, which can potentially obscure the desired phenotype180. 
Over the last 30 years, the manipulation of non-coding DNA sequences mainly relied on 
homologous recombination techniques181-183. Recently, this task was greatly facilitated by the 
development of programmable nucleases, such as ZFNs and TALEs, which can be engineered to 
cut specific DNA sequences (reviewed in184). However, these technologies are low-throughput 
and, therefore, unsuitable to perform large-scale genetic screens of non-coding DNA sequences. 
The advent of CRISPR systems filled a technological gap and, not surprisingly, they were applied 
in forward genetic screens of non-coding DNA elements185,186. These studies identified novel 
enhancers and other regulatory elements involved in oncogene-induced senescence185, cancer 
cell growth185 and drug resistance186. Remarkably, it was observed that mutations in enhancers 
cause phenotypic effects comparable to that of mutations in their target genes185,186. These 
results emphasize the importance of identifying causal non-coding variants that contribute to the 
development of human diseases (see General discussion). To date, genetic screens of non-
coding DNA sequences have been confined to mutagenesis over regions of 2 kb to 1 Mb187. 
Given the fast pace of technological advances, it is safe to say that CRISPR-Cas9 screens are 
destined to generate an immense amount of data and contribute decisively to elucidate all the 
functions of the human genome. 
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Applying CRISPR-Cas9 tools to identify and characterize 
transcriptional enhancers 
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Enhancers were initially identified as 
distal regulatory elements that increase 
transcription independently of their 
orientation, position and distance relative 
to a target promoter1. These elements 
are essential for precise spatiotemporal 
regulation of gene expression, which is 
required for proper cell development, 
differentiation and homeostasis2. A key 
feature of enhancers is their ability to 
function as transcription factor binding 
platforms, and genetic alterations 
at these regions are associated with 
pathological states3–8.
Enhancers are usually defined by 
criteria unrelated to their endogenous 
biological function, such as the makeup of 
specific histone modifications, increased 
chromatin accessibility and the occurrence 
of bidirectional transcription in the loci 
in question9–11. Based on these features, 
several techniques have been used to 
identify putative enhancers and validate 
their activity in a high-throughput fashion 
(BOX 1). Nonetheless, these methods 
cannot fully determine whether a putative 
enhancer is required for transcription in 
its native context or which gene (or genes) 
it regulates.
The emergence of the CRISPR–Cas9 
technology has opened unprecedented 
Activating enhancer elements. 
CRISPR-mediated gene activation 
(CRISPRa) uses nuclease-deactivated Cas9 
(known as dCas9) fused to transcription 
activating domains (BOX 2). This approach 
was first tested on promoters using the 
transcription activation domains of the 
VP64 (a tetrameric repeat of herpes simplex 
virus protein VP16) and p65 (nuclear 
factor-κB p65 subunit) proteins. Indeed, 
dCas9–VP64 and dCas9–p65 could activate 
endogenous genes when targeted by one 
sgRNA to their promoter region16,20,21. 
Yet, each protein fusion required the 
combination of several sgRNAs per gene 
to achieve high expression levels of the 
target gene21,22. To overcome this limitation, 
several groups developed CRISPRa tools 
containing multiple activation domains23,24. 
These improvements made the simultaneous 
activation of dozens of genes as well as 
genome-wide activation screens possible.
The activating capacity of VP64 relies on 
the sequential recruitment of cofactors, such 
as the histone acetyltransferase p300 and 
TFIID25,26, suggesting that it can potentially 
be used to modulate enhancer activity. 
Indeed, a dCas9–VP64 fusion was shown 
to activate endogenous genes by recruiting 
p300 to acetylate H3K27 (histone H3 Lys27) 
at their cognate enhancer regions27. However, 
targeting dCas9–VP64 to the locus control 
region (LCR) of the haemoglobin genes 
failed to activate some of them; dCas9–VP64 
was able to induce H3K27 acetylation at the 
targeted enhancers but not at the cognate 
haemoglobin promoters, and this correlated 
with lack of activation of gene expression28. 
This suggests that the recruitment of 
transcription pre-initiation complex (PIC) 
components by VP64 (REFS 25,26) might 
not be sufficient to elicit enhancer activity. 
It is therefore not clear to what extent 
dCas9–VP64 can activate enhancer elements.
Repressing enhancer elements. The utility of 
CRISPR–Cas9-based tools in repressing gene 
expression (termed CRISPR interference 
(CRISPRi)) was first demonstrated by 
showing that a dCas9–sgRNA complex 
could block RNA polymerase elongation29. 
This strategy was also successfully applied to 
interfere with transcription factor binding, 
thereby disrupting enhancer activity27. 
opportunities for targeted genome editing 
in human cells12–15. The RNA-guided 
endonuclease, Cas9 can be targeted to 
any genomic locus by sequence-specific 
single guide RNA (sgRNA) to initiate 
double-stranded DNA cleavage (BOX 2). 
Importantly, Cas9 can be directed to 
non-coding transcriptional regulatory 
elements, such as promoters16,17 and 
enhancers18,19. This feature led to the 
development of several Cas9-based 
methods and tools to study non-coding 
regulatory elements in their native 
chromatin environment. Here, we 
summarize recent advances in CRISPR–
Cas9 systems that allow the modulation 
of the activity of enhancers by altering 
their transcriptional, epigenetic or genetic 
features, and discuss the current limitations 
of these technologies in the study of 
enhancers. We also provide a perspective 
on future developments of CRISPR–Cas9 
tools and their application in identifying 
and characterizing enhancers in an 
unbiased fashion.
Transcriptional modulation of enhancers
An attractive approach to studying 
enhancers in their endogenous context is 
the use of CRISPR–Cas9 tools to enforce 
enhancer activation or repression directly.
Applying CRISPR–Cas9 tools 
to identify and characterize 
transcriptional enhancers
Rui Lopes, Gozde Korkmaz and Reuven Agami
Abstract | The development of the CRISPR–Cas9 system triggered a revolution in 
the field of genome engineering. Initially, the use of this system was focused on the 
study of protein-coding genes but, recently, a number of CRISPR–Cas9-based tools 
have been developed to study non-coding transcriptional regulatory elements. 
These technological advances offer unprecedented opportunities for elucidating 
the functions of enhancers in their endogenous context. Here, we discuss the 
application, current limitations and future development of CRISPR–Cas9 systems 
to identify and characterize enhancer elements in a high-throughput manner.
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The use of dCas9 alone achieved only modest 
repression of gene expression in mammalian 
cells. To improve CRISPRi, dCas9 was 
fused with repressive effectors, such as the 
Krüppel-associated box (KRAB) domain 
of KOX1 (REFS 16,30). A dCas9–KRAB 
fusion was shown to efficiently repress the 
expression of protein-coding and non-coding 
genes on a genome-wide scale17. KRAB 
fusions were later shown to inactivate the 
expression of endogenous genes by targeting 
their distal enhancer elements27,31. Indeed, 
dCas9–KRAB can be directed to single 
Epigenetic modulation of enhancers
As noted above, enhancer activity is 
associated with dynamic epigenetic states, 
including acetylation and methylation of 
histone tails36,37. The ability to modulate these 
epigenetic modifications is essential to gain 
better understanding of their importance 
for enhancer function. This prompted the 
development of several epigenome-editing 
tools that are based on fusions of epigenetic 
regulators (writers and erasers) to dCas9 and 
allow direct manipulation of epigenetic states 
of gene regulatory elements.
Lys-specific histone demethylase 1 (LSD1) 
catalyses the removal of H3K4 methylation38. 
Recently, a dCas9–LSD1 fusion was targeted 
to a distal enhancer of the pluripotency 
gene Oct4 (also known as Pou5f1) and 
achieved specific gene repression and loss 
of pluripotency in embryonic stem (ES) 
cells34. It was also shown that enhancer 
targeting by dCas9–LSD1 caused a marked 
decrease in H3K4me2 and H3K27Ac 
marks34,38, consistent with reduced enhancer 
activity. However, dCas9–LSD1 was 
unable to repress genes when targeted 
to promoter regions34, a surprising 
result given the well-documented role of 
LSD1 in the repression of endogenous 
promoters38. A possible explanation for 
these results is that LSD1 alone is ineffective 
and may require additional cofactors 
to inactivate some regulatory elements, 
indicating that current LSD1 fusions may 
have low efficacy, compromising their 
application in high-throughput screens of 
enhancer elements.
A fusion protein of dCas9 with the 
catalytic core domain of p300 (dCas9–p300) 
was created recently28, and this allowed the 
manipulation of H3K27ac levels at both 
proximal and distal regulatory elements. 
Interestingly, dCas9–p300 was capable of 
activating genes with high specificity using 
one sgRNA per target gene28 and with higher 
transactivation capacity than dCas9-VP64 
(REF. 28). This was particularly evident at 
distal enhancer elements, where dCas9–
VP64 displayed little capacity to activate 
target genes28. These results establish dCas9–
p300 as a robust tool to modulate histone 
acetylation and activate gene expression. 
However, it is unclear whether dCas9–p300 
is suitable for use in genome-wide functional 
screens. The higher activity of dCas9–p300 
seems to be related to the direct acetylation 
of downstream target promoters, as 
opposed to the indirect recruitment of PIC 
by VP64 (REFS 25,26). Still, it remains to be 
determined whether acetylation of H3K27 
alone is sufficient for gene activation.
elements of composite enhancers and still 
achieve highly specific repression of genes32,33. 
This effect seems to be mediated by decreased 
chromatin accessibility at both enhancer 
and target promoters32. It was also noted 
that directing dCas9–KRAB to enhancer 
regions resulted in higher H3K9me3 (histone 
H3 Lys9 trimethylation) levels at the target 
promoter32,34. Therefore, it is possible that 
KRAB fusions generate off-target effects 
through heterochromatin spreading35, and 
that they silence promoter activity rather 
than inactivating the target enhancer.
Box 1 | Methods for genome-wide identification of putative gene regulatory elements
The comprehensive identification of transcriptional regulatory elements is a major challenge in 
genomic research. The emergence of next-generation sequencing propelled the development of a 
number of high-throughput methods that were used to identify putative enhancers based on their 
features and activity.
Transcription factor binding sites are the core building blocks of regulatory elements. ChIP–seq 
(chromatin immunoprecipitation followed by sequencing) is the most common technique to 
determine transcription-factor occupancy on a genome-wide scale72. This method is particularly 
suitable for identifying stimulus-induced changes or occupancy across different cell types, as well 
as for identifying binding sites of transcription cofactors (such as the histone acetyltransferase 
p300), which are frequently associated with enhancers73. Genome-wide mapping of histone 
post-translational modifications by ChIP–seq revealed that H3K4me1 (histone H3 Lys4 
monomethylation) and H3K27ac (H3K27 acetylation) are enriched at active-enhancer regions74, 
whereas active-promoter regions are marked by H3K4me3 and H3K27ac. This ‘histone code’ is 
widely used to annotate regulatory elements and corresponds well with heterologous reporter 
assays60, which have been commonly used to interrogate the activity of any genomic region. 
Cloning of a putative enhancer downstream or upstream of a reporter gene can reflect its 
functionality by inducing the expression of the reporter gene.
Active-enhancer regions are depleted of nucleosomes, leaving the DNA accessible to enzymatic 
cleavage. This has been exploited to identify regulatory regions across the genome, for example by 
coupling digestion by DNase I with DNase-seq (DNase I hypersensitive sites sequencing)75.
Distal enhancers are brought into spatial proximity with their target promoters through DNA 
looping. Chromosome conformation capture (3C)76 and its variants77 are useful for predicting 
putative enhancers and their target genes. Chromatin interaction analysis with paired-end tag 
(ChIA–PET) sequencing78 is a combination of 3C-based methods with ChIP, which enables the 
identification of proteins involved in the formation of specific chromosomal contacts.
Active enhancers support divergent transcription of their own loci79. The expression of these 
enhancer-associated RNAs (eRNAs) has been used to identify active enhancers in a cell type-specific 
manner, because eRNA expression correlates well with enhancer activity. eRNA expression can be 
detected by methods that measure nascent RNAs, such as global run-on sequencing80 (GRO-seq).
The ability to increase transcription from minimal promoters in heterologous reporter vectors is 
a hallmark of enhancer activity1, and has been used to identify enhancer elements both in cells 
and in animals. Initially, these methods had low throughput. The recent development of massive 
parallel reporter assays81,82 (MPRA) and self-transcribing active regulatory region sequencing83 
(STARR-seq) enables the evaluation of enhancer activity of thousands or even millions of DNA 
sequences simultaneously.
The combined application of the techniques mentioned above led to a tremendous increase 
in our understanding of transcriptional regulatory elements. DNase-seq in combination with  
ChIP–seq of epigenetic modifications was applied to predict putative enhancer regions. Yet, the 
epigenetic status of a region is not identical to enhancer activity, mostly owing to the use of 
arbitrary cut-offs of histone modifications ratios (for example, H3K4me1/H3K4me3) as a measure 
of activity84–86, which resulted in the estimation that the human genome harbours approximately 
one million enhancers84–86. Instead, when methods that directly measure transcriptional activity 
were used87, only 40,000 to 65,000 transcriptionally active putative enhancers were predicted 
(though any active but not transcribed enhancer would have been missed)9,88.
Altogether, these techniques cannot assess specific enhancer functionality because they provide 
only circumstantial evidence that the identified elements are actively engaged in transcription 
regulation. Thus, other methods are required for the identification of enhancers that drive gene 
expression in certain biological settings.
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The consequences of manipulating 
epigenetic states on transcription regulation 
are not completely understood, and the 
utilization of epigenome-editing tools might 
be associated with potential off-target effects. 
Nevertheless, the expansion of the current 
dCas9 epigenetic toolbox will be much 
needed to shed light on the connections 
between the epigenome and gene expression. 
Moreover, the precise manipulation of 
epigenetic modifications holds tremendous 
therapeutic potential.
Genetic manipulation of enhancers
The genomic features that define a 
regulatory element are poorly understood. 
For example, some enhancers consist of 
a single unit, whereas others — known as 
super-enhancers — are composed of multiple 
clusters of enhancers39. Genetic perturbation 
is a powerful approach to draw causal links 
between genetic information and cellular 
functions. The advent of the CRISPR–Cas9 
system facilitated genome editing and, 
recently, it has been applied to dissect the 
DNA sequences required for appropriate 
activity of enhancer elements in their 
native context.
The Cas9 nuclease can be directed by 
one sgRNA to induce a double-strand 
break (DSB) at a specific genomic region. 
These DSBs are generally repaired by the 
error-prone repair pathway non-homologous 
end joining (NHEJ), resulting in the 
formation of insertion and deletion (indel) 
mutations (usually smaller than 10bp). 
The initial application of CRISPR–Cas9 
for genome editing was centred on 
protein-coding genes, but it was soon 
adopted to target non-coding regulatory 
elements. Recently, it was found that 
CRISPR–Cas9 targeting by one sgRNA can 
produce comparable genetic effects to the 
deletion of a whole enhancer unit18 and 
cause phenotypes that are robust enough 
for screening19 (see below). The strong 
effects produced by one sgRNA go against 
the well-established idea that regulatory 
elements are robust and redundant. Indeed, 
functionally important sequences within the 
enhancer are known to be highly sensitive 
as well: even single-nucleotide alterations 
in these regulatory sequences can have 
substantial effects on gene expression and 
cause pathological conditions3,4,6–8. In line 
with this, it was recently proposed that small 
mutations can activate oncogenes in cancer 
cells by creating a new super-enhancer5. 
In this study, a single Cas9–sgRNA complex 
was used to delete the mutant sequence, 
resulting in the collapse of enhancer activity 
(GATA binding protein 2) expression40. The 
authors showed that this regulatory element 
is frequently translocated in leukaemia cells, 
leading to haploinsufficiency of GATA2 and 
activation of EVI1 (ecotropic viral integration 
site 1) oncogene. Cas9 nuclease can also be 
used to generate monoallelic deletions of 
enhancer elements. When targeting essential 
regulatory elements, a monoallelic deletion 
is performed to circumvent the cellular 
lethality associated with biallelic deletions. 
The combination of this targeted approach 
with gene expression profiling identified a 
distal enhancer cluster that is required for 
Sox2 (SRY (sex determining region Y)-box 2) 
transcription41,42 and ES cell differentiation41. 
Interestingly, deletion of this cluster did not 
affect other nearby genes, indicating that the 
regulation of gene expression by enhancers 
is highly specific41,42. The high precision of 
Cas9-mediated cleavage allows the deletion 
of individual constituents of composite 
enhancers18,33,43. Recent evidence suggests 
that deletion of a single element can have 
comparable effects to the deletion of the 
entire composite enhancer18. More studies 
are needed in order to understand whether 
and decreased expression of the TAL1 (T-cell 
acute lymphocytic leukemia protein 1)
proto-oncogene.
We note several limitations when using 
a single Cas9–sgRNA complex to target 
enhancer elements. First, one sgRNA might 
not fully disrupt enhancer activity owing to 
the small size of indels generated. The use of 
paired sgRNAs to delete genomic elements 
can address this issue (see bellow). Second, 
when working with a population of cells, 
the effect of a sgRNA might be diluted, 
as targeting by Cas9 results in different 
(heterozygous and homozygous) lesions in 
different cells. The isolation of individual 
mutant clones is a laborious process, but it 
can potentially solve this problem. Finally, 
some sgRNAs may suffer from intrinsic low 
DNA-editing efficiency (BOX 3). 
A regulatory element can be fully 
inactivated by Cas9 nuclease through the 
generation of a specific deletion. This 
can be easily achieved by targeting two 
sgRNAs to the borders of the target region. 
An example of this strategy comes from a 
report in which CRISPR–Cas9 was used to 
excise an enhancer that regulates GATA2
Box 2 | Genome editing and regulation using CRISPR–Cas9 systems
The CRISPR–Cas9 system is based on the 
molecular machinery of type II CRISPR bacterial 
immune system and has been repurposed for 
targeted gene editing, providing major advances 
in efficiency, speed and scale of genome 
engineering12,52,55,57. The endonuclease Cas9 has 
two nuclease domains, RuvC and HNH, and is 
directed to specific DNA sequences by pairing of 
a chimeric single guide RNA (sgRNA) with target 
DNA (see the figure)13,29. This requires the 
presence of a 5ʹ protospacer adjacent motif 
(PAM) in the DNA, which in 
Streptococcus pyogenes is usually NGG.
Genome engineering with Cas9 exploits DNA 
double-strand break (DSB) repair pathways to 
create mutations at specific genomic locations. In mammalian cells, DSBs are usually repaired either 
by homology-directed repair (HDR), for which an exogenous template is provided for the conversion 
of the endogenous sequence following the formation of DSBs by Cas9, or by non-homologous end 
joining (NHEJ), which is an error-prone mechanism that generates random insertion and deletion 
mutations at the targeted location. The continuous expression of the Cas9–sgRNA complex leads 
to near-complete allelic modification in a short time frame58. However, the use of Cas9 nuclease 
is potentially associated with the formation of off-target DSBs, which may cause undesired 
effects (BOX 3).
The enzymatic activity of Cas9 can be abolished by mutations in the RuvC and HNH domains, 
generating nuclease-deactivated Cas9 (dCas9), which can still be specifically targeted to DNA89. 
dCas9 can modulate transcription when fused to an effector domain (for example, a transcription 
activator or repressor) and expressed in concert with a sgRNA targeted to a regulatory element of 
interest16,29. An advantage of using dCas9 effectors is that their effect is reversible; moreover, dCas9 
fusions can be multiplexed and set to perform simultaneous transcription activation and repression 
of different loci71. Potential disadvantages of dCas9 systems include disruption of native chromatin 
architecture, steric hindrance with transcription factors24, and blocking of RNA polymerases29. 
In addition, the efficiency of activation or repression can fluctuate dramatically32,34. This can be 
explained by features of the target region, such as chromatin structure, and by the availability of 
additional cofactors32. Figure adapted from REF. 90, Nature Publishing Group.
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this is an exception or a rule. The use of 
paired sgRNAs enables control of the size 
of the deletion, in contrast with the random 
indels induced by using a single sgRNA. 
However, this method is far less efficient 
in inducing deletions44: the efficiency 
of targeted deletions by paired sgRNAs 
is approximately 25%, but it decreases 
substantially with increasing deletion 
sizes44. In addition, the introduction of two 
sgRNAs theoretically carries twice the risk 
of off-target effects (BOX 3) compared with 
one sgRNA.
These studies emphasize the importance 
of perturbing the endogenous state of 
enhancers to obtain greater insight into 
their biological function. The combination 
of CRISPR–Cas9-induced mutagenesis and 
genome-wide expression profiling allows 
specific locus by a short (20-nucleotide) 
sgRNA enables the rapid generation 
of sgRNA libraries for screening. The 
sgRNAs can be delivered by a lentiviral 
vector and stably integrated in the target 
cells, facilitating the screen readout using 
next-generation sequencing (FIG. 1). Recently, 
several research groups have taken advantage 
of these features to perform high-throughput 
functional screens of endogenous enhancers.
Dissecting enhancers using CRISPR–Cas9 
tiling screens. Single-nucleotide changes 
can substantially affect gene regulation44, 
and this finding led to the hypothesis 
that Cas9-mediated mutagenesis could 
uncover elements required for the function 
of enhancers. The basic strategy is to tile 
hundreds of sgRNAs across a putative 
enhancer to disrupt nearly its entire sequence 
(FIG. 2). The screen is then used to infer 
which enhancer sequences are potentially 
important for its function. However, the 
full spectrum of the driver mutations and 
potential regulatory DNA elements can 
only be examined at the validation stage 
using individual sgRNA transductions, as 
sgRNA enrichment scores might differ from 
expectations19. Importantly, the resolution 
of such tiling screens approaches saturation 
mutagenesis in situ, with average cleavage 
frequency ranging from 4 to 10 bp18,19. The 
application of this method enables the study 
of the regulation of single genes by multiple 
enhancer elements18,19,45,46.
Tiling screens were used successfully 
to dissect the human and mouse BCL11A 
(B-cell lymphoma/leukaemia 11A) 
composite enhancer18. Interestingly, the 
critical components of the composite 
enhancer were found to be different 
between human and mouse18, despite 
sharing sequence homology and chromatin 
signatures. As BCL11A regulates the 
switching from fetal to adult haemoglobin 
gene expression by repressing the expression 
levels of fetal heamoglobin, the results 
from this study suggest that genetic 
perturbation of the BCL11A enhancer might 
be a therapeutic option for β-haemoglobin 
disorders. Similarly, a CRISPR–Cas9 
tiling screen to identify critical sequences 
that contribute to the function of a distal 
enhancer of the p53 target gene CDKN1A19 
revealed that additional domains, besides the 
p53 binding site, are required for the activity 
of the enhancer and activation of CDKN1A 
expression upon oncogene-induced 
senescence. High-throughput CRISPR–
Cas9 mutagenesis was also employed to 
systematically interrogate putative regulatory 
the identification of enhancers and their 
target genes, which is a major advantage 
compared to previous technologies (BOX 1). 
This combination is suitable for matching 
an individual enhancer with its target gene, 
and cannot yet be used on a genome-wide 
scale. It is also worth noting that the function 
of some cis regulatory elements might be 
redundant (see below). This problem can 
be tackled by targeting Cas9 nuclease to 
multiple redundant enhancers and abolishing 
their activity in a combinatorial manner.
High-throughput screening of enhancers
The power of the CRISPR–Cas9 system 
relies on two main factors: the ease of 
RNA-mediated gene targeting and its 
efficient induction of mutations12,14. 
The capacity of targeting Cas9 to a 
Box 3 | Targeting specificity of CRISPR–Cas9 systems
Targeting accuracy of CRISPR–Cas9 systems is defined as the ratio between generation of DNA 
double-strand breaks (DSBs) at the intended locations (on-target effects) and at unintended 
locations (off-target effects) and is assessed for each single guide RNA (sgRNA) in terms of their 
consistency in targeting the same locus54,56–58. Nuclease-deactivated Cas9 (dCas9)-based screening 
(CRISPR-mediated gene activation (CRISPRa) and CRISPR interference (CRISPRi)) can modulate 
gene expression, and recent dCas9-based tiling screens improved their on-target effects and 
sgRNA consistency (that is, different sgRNAs efficiently targeting same region)17,23. The use of 
dCas9 for functional enhancer screens has not yet been evaluated, but the enzymatically active 
CRISPR–Cas9 system was recently demonstrated to be a powerful enhancer screening tool18,19,46. 
Nevertheless, sgRNAs display large variations in efficiency (a result of chromatin accessibility 
and the composition of the targeted sequence54,91,92), which may influence screening results.
The continuous expression of Cas9 leads to near-complete allelic modification owing to the 
irreversible modification of target DNA54,56,57. However, not every mutation will abolish gene 
function as DSB repair by non-homologous end joining generates different mutations in different 
cells. Moreover, the size of insertion and deletion (indel) mutations varies substantially between 
the targeted loci54,56,57,93. Generating a DSB in a constitutively spliced exon usually results in the 
formation of either a premature stop codon or frameshift mutations44,92. By contrast, the critical 
regulatory elements of enhancers are poorly defined, and therefore it is challenging to target them 
with one sgRNA. Cas9-induced mutations in regulatory elements can result in more variable 
effects on gene expression compared to mutations in protein-coding regions45,46. This is probably 
caused by a wide spectrum of mutations with different likelihood to disrupt critical DNA elements, 
such as transcription factor binding sites.
The specificity of CRISPR–Cas9 reagents is a major concern for their applicability in both 
research and clinical settings. Cas9 nucleases can tolerate up to five mismatches between the 
sgRNA and a genomic sequence94,95. Reassuringly, the majority of these off-target binding events 
do not lead to the generation of indels91,96, suggesting that imperfect matching of the sgRNA to the 
target sequence is insufficient for DNA cleavage97. dCas9-based tools were shown to be sensitive 
to even fewer mismatches17, and global gene expression analysis revealed highly specific activity of 
both transcriptional and epigenetic modulators16,17,28. Nonetheless, CRISPR reagents with 
improved specificity were developed, such as paired Cas9 nucleases that nick DNA at two adjacent 
sequences53,98, truncated sgRNAs99, and modified Cas9 proteins with high precision100,101. The D10A 
mutant of Cas9 nicks one strand of DNA, and directing paired Cas9(D10A) nucleases to a specific 
location results in fewer off-target effects compared with Cas9 (REFS 53,98). Truncated sgRNAs, 
which are designed according to the finding that PAM-distal regions of sgRNA usually have less 
effect on on-target cleavage efficiency, have reduced off-target effects (up to 5,000 times) while 
conserving on-target cleavage efficiency99.
Increasing CRISPR–Cas9 fidelity may also reduce false-negative rates in a screen (true hits that 
were missed in the screen). To our knowledge, false-negative rates have not been reported so far 
for CRISPR–Cas9 enhancer screens. It is possible that the effects of sgRNAs with low activity are 
missed, resulting in higher false-negative rates; if this is the case improving target specificity and 
sgRNA consistency should improve genetic screening approaches by reducing false-positive 
as well as false-negative rates.
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elements of POU5F1 in human ES cells46. 
In this case, a POU5F1–GFP reporter 
was used to determine the function of the 
candidate enhancer regions. The authors 
identified classical regulatory elements, but 
also a class of non-canonical enhancers, 
termed temporarily phenotypic (Temp) 
enhancers. Although they harbour 
common enhancer features, loss of these 
elements caused temporary and reversible 
transcriptional impairment owing to 
disruption of the local chromatin structure. 
Further work is required in order to 
understand the biological function of Temp 
enhancers and how they are regulated.
known epigenetic markers associated with 
regulatory elements. These results expose the 
shortcomings of correlative annotations to 
predict regulatory sequences and highlight 
the importance of direct perturbation to 
definitively characterize genetic elements.
Considering these successful 
experiments, high-throughput 
CRISPR–Cas9 tiling screens should be 
readily implemented to interrogate at 
near-nucleotide resolution the function of 
numerous non-coding regulatory elements. 
The Cas9 protein scans for a short DNA 
sequence known as protospacer adjacent 
motif (PAM; in Streptococcus pyogenes it 
Another high-throughput mapping 
of regulatory sequences is multiplexed 
editing regulatory assay (MERA)45. It is 
based on the integration of a pooled sgRNA 
library into a specific locus by homologous 
recombination and relies on the expression 
of a GFP-tagged gene locus to determine 
the effect of the mutations45. MERA led 
to the identification of expected promoters, 
enhancers and transcription factor binding 
sites, but also what might be a new class 
of elements, designated as unmarked 
regulatory elements (UREs). UREs were 
shown to regulate endogenous gene 
expression although they do not contain any 
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Figure 1 | Functional genetic screens of active enhancers using the 
CRISPR–Cas system. a | Bioinformatic design of a single guide RNA 
(sgRNA) library for global targeting of putative enhancer elements consists 
of three steps19. The first step is identification of the enhancers active in the 
specific experimental condition. The chromatin at active enhancers is typ-
ically marked with specific epigenetic modifications (high level of 
H3K4me1 (histone H3 Lys4 monomethylation) and H3K27ac (histone H3 
Lys27 acetylation), and low level of H3K4me3 (histone H3 Lys4 trimethyl-
ation)) and occupied by RNA polymerase II. Thus, publicly available ChIP–
seq (chromatin-immunoprecipitation followed by sequencing) data sets of 
chromatin modifications and of RNA polymerase II occupancy can be used 
to identify putative enhancer regions. Furthermore, enhancer RNA (eRNA) 
expression correlates well with enhancer activity and allows active regu-
latory elements to be distinguished; eRNA expression data sets are also 
publicly available. The second step is identification of active enhancer 
regions harbouring transcription factor binding sites (transcription factor 
binding sites (for example, p53 and oestrogen receptor-α (ERα)) are shown 
by yellow star and triangle symbols). Enhancer regulation depends on bind-
ing of specific transcription factor combinations, and each enhancer is 
responsive to a different set of transcription factors. Therefore, the inter-
section of active enhancer regions (as defined in step 1) with transcription 
factor activity relevant to the specific experimental condition (marked with 
a star) results in a final list of enhancers to be targeted by CRISPR–Cas9. 
The third step is identification of suitable Cas9 cleavage sites within the 
transcription factor binding sites, according to the availability of proto-
spacer adjacent motif (PAM) sequences. It is essential to target precisely 
the transcription factor binding site within the enhancer region; yet, the 
availability of such targetable sites varies according the availability of PAMs 
in the transcription factor consensus sequence. For instance, the consen-
sus motif of p53 has high NGG PAM content compared to ERα (resulting in 
~90% versus ~60% target availability, respectively), and some regions can 
be targeted with more than one sgRNA. b | The sgRNA oligonucleotides 
targeting the suitable Cas9 cleavage sites are synthesized, annealed with 
3ʹ and 5ʹ cloning primers, pooled and cloned into viral constructs to pro-
duce an enhancer-targeting sgRNA expression library (CRISPR enhLibrary), 
from which viruses are produced to confer stable expression of sgRNAs in 
cells. c | Virus transduction of cells should ideally be performed such that 
each cell expresses only one sgRNA, but that all the sgRNAs are expressed 
in the transduced cell population, to maintain the complexity of the library. 
The transduced cells are subjected to a proliferation-based screening 
selection to identify sgRNAs that confer cell growth advantage or 
disadvan tage according to the designed assay, and next-generation 
sequencing is used to assess which sgRNAs were enriched or depleted 
(shown in red) in the selected cell population. 
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is usually NGG) at the 3ʹ end of the target 
sequence to achieve a successful binding to 
the target region, and generates DSBs 3 bp 
upstream of the PAM. Therefore, the use 
of Cas9 orthologues and variants, which 
have different PAM requirements, could 
increase the resolution of CRISPR–Cas9 
in situ mutagenesis47–50. Alternatively, 
activating homology-directed repair (HDR) 
concomitantly with CRISPR–Cas9 could 
allow DNA editing at nucleotide resolution. 
The coupling of CRISPR–Cas9 mutagenesis 
and multiplex HDR has already enabled 
saturation editing of protein-coding genes51, 
suggesting that it can also be applied to 
dissect the function of regulatory elements 
with high resolution. However, we note that 
HDR in conjugation with CRISPR–Cas9 has 
low DNA-editing efficiency, that it is time 
consuming and might not be possible for 
every cell type.
In high-throughput screens of 
protein-coding genes, false identification 
of screen hits (false positives) can be 
avoided by designing a library containing 
multiple unique sgRNAs targeting the 
same gene. Only screen hits with distinct 
and resistance to drugs and toxins41,56,57. 
Likewise, high-throughput CRISPR–Cas9 
strategies are suitable for investigating the 
role of multiple enhancers in the regulation 
of multiple genes and their contribution to 
a specific phenotype for large-scale genetic 
screening of regulatory elements19.
Indeed, CRISPR–Cas9 was used in both 
positive and negative selection screens 
to identify functional enhancers19 by 
inactivating putative enhancers through 
the disruption of transcription factor 
binding sites and screening for phenotypic 
changes (FIG. 1). As a result, several novel 
enhancers were identified, which have key 
roles in p53-dependent oncogene- induced 
senescence and oestrogen receptor 1 
(ESR1)-mediated cell proliferation19. 
This screening method was found to 
be efficient and robust, generating high 
levels of mutagenesis, sgRNA consistency 
(that is, different sgRNAs with similar 
efficiency in targeting the same region) 
and strong phenotypic effects. In particular, 
the performance of Cas9 in the negative 
selection setting, as determined by high 
validation rates, was impressive19, as this 
type of screen requires higher sensitivity 
to detect changes in the representation of 
individual sgRNAs58.
Studies discussed above18,19,45,46 have 
produced some common results, despite 
being performed in completely distinct 
biological settings. First, both enhancers and 
super-enhancers can be susceptible to small 
mutations generated by single DSBs, which 
enabled these high-throughput functional 
screens18,19,45,46. However, we cannot rule 
out that some enhancers are robust and not 
affected by small indels. The development 
of methods to generate pooled libraries of 
paired sgRNAs can potentially address this 
limitation59. Second, the vast majority of 
sgRNAs were not enriched or depleted, 
whereas the ones that were, colocalized to 
discrete genomic regions18,19. This suggests 
that enhancer elements are composed of 
many redundant and only a few critical 
sequences. Finally, the pattern of mutations 
generated by a sgRNA can be used for motif 
discovery without a priori knowledge18,19,45. 
This can be done by mutagenizing enhancers 
in a population of cells using multiple, 
unique sgRNAs, applying selective conditions 
and comparing the initial and final 
abundance of mutations along the enhancer 
regions. In principle, the relative abundance 
of mutations at specific sequences should 
reflect their necessity for the function of an 
enhancer element. Altogether, these studies 
establish CRISPR–Cas9 as a powerful tool 
sgRNAs yielding the same phenotype 
are considered. Also, rational design of 
sgRNAs can minimize false positives owing 
to off-target effects52,53. It was shown that 
the PAM-proximal 10–12 bp of sgRNA 
sequence is the main determinant of 
specificity; thus, restraining the similarity 
between the target and off-target sites and 
allowing no more than three mismatches 
can reduce the off-target effects. However, 
when targeting regulatory elements with 
CRISPR–Cas9, the availability of PAM 
sequences is a limiting factor in the design 
of multiple unique sgRNAs targeting the 
same region. In this case, the performance 
of single sgRNAs should be evaluated in 
several independent experiments to identify 
a consistent effect. Finally, the inclusion 
of many control sgRNAs will facilitate the 
distinction between true- and false-positive 
screen results.
Genetic screens of enhancers. In recent 
years, CRISPR–Cas9-based genetic 
screens have been applied successfully to 
identify protein-coding genes involved 
in fundamental cellular processes54,55 
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Figure 2 | High-resolution dissection of active enhancer sequences (marked by H3K4me1 and 
H3K27ac) by CRISPR–Cas9 tiling screens to uncover novel regulatory elements. To gain detailed 
understanding of functionally important DNA elements (represented by the question mark) within 
enhancers, such as those important for binding of transcription factors or mediating DNA looping, all 
protospacer adjacent motif sites within a selected enhancer are identified by bioinformatics, and 
single guide RNAs (sgRNAs) densely covering (tiling) the region are produced and used for screening 
by an assay of interest. Following screening, the abundance of sgRNAs in the final cell population can 
be used to infer key elements that are required for the function of the enhancer, such as novel 
transcription binding sites. H3K4me1, histone H3 Lys4 monomethylation; H3K27ac, histone H3 
Lys27 acetylation.
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to dissect the functions of the non-coding 
genome in an unbiased fashion18,19,45,46.
A caveat of the sgRNA libraries used 
to date is that they target a limited set of 
enhancers and therefore cannot be used 
for unbiased screening in any biological 
setting. We envision that, in the near 
future, it will be possible to interrogate the 
function of all genomic regulatory elements 
using CRISPR–Cas9 tools. This will be a 
monumental task, given that the estimated 
number of enhancers in the human 
genome is estimated to be approximately 
one million (REFS 10,60). The identification 
of functional enhancers by CRISPR–Cas9 
on a genome-wide scale will require further 
technological advances to improve the 
coverage of libraries and speed of screening.
Future perspective
Since it was first used in genome engineering 
in 2013 (REFS 12–15), the CRISPR–Cas9 
system and its applications have continued 
to improve at an unprecedented rate. Here, 
we pinpoint future directions that can be 
applied to study transcriptional regulatory 
regions with this system.
Light-inducible systems. The development 
of light-inducible DNA binding proteins 
represents a breakthrough for genome 
engineering. Initially, this technology was 
applied to transcription activator-like 
effector proteins (TALEs)61 but it has 
recently been introduced to CRISPR–Cas9 
systems. These tools are incredibly versatile 
as they can be activated within minutes and 
do not require additional chemical cofactors. 
Light-inducible CRISPR–Cas9 systems have 
been used to control genome editing62 and 
modulate gene expression63,64 in a reversible 
manner. In principle, this technology can 
be adapted to modulate the activity of 
endogenous enhancers in space and time 
with very good resolution.
Modelling human diseases. The CRISPR–
Cas9 system simplified and accelerated 
the modelling of complex human diseases. 
For example, paired sgRNAs were used to 
engineer a chromosomal inversion and 
generate mouse models of human non-small 
cell lung cancers65. This approach can also 
be used to investigate human diseases 
associated with repositioning of enhancers 
by chromosomal rearrangements40. In recent 
years, it has become clear that the vast 
majority of disease-associated mutations 
and single-nucleotide polymorphisms 
are present in non-coding regions of the 
genome9,66. The clinical significance of these 
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genetic alterations is unknown as it is not 
clear whether they affect gene expression. 
The combination of CRISPR–Cas9-mediated 
mutagenesis and multiplex HDR promises 
to facilitate the interpretation of sequence 
variants of uncertain significance reported 
by clinical sequencing51.
Manipulation of high-order chromatin 
organization. Transcriptional regulation 
can also be achieved by customized editing 
of the genome architecture. It was recently 
demonstrated that disruption of topological 
boundaries by Cas9 nuclease resulted in 
loss of facultative heterochromatin and 
activation of gene expression67. Mutations 
affecting topological boundaries were found 
in different types of cancer, and this was 
recently proposed to be a mechanism of 
activation of proto-oncogenes by enhancer 
elements68. Forced chromatin looping using 
a synthetic zinc finger–LDB1 fusion protein 
resulted in the activation of developmentally 
silenced genes in mouse cells69,70. This 
suggests that programmable DNA looping 
could be a novel therapeutic approach 
for human diseases. Although there are 
no CRISPR–Cas-based tools available to 
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dCas9 has the potential to bring together 
two or more genomic loci through the use 
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which are capable of recruiting Cas9 and 
other sgRNAs71. The spread of this strategy 
to CRISPR–Cas9 systems could help to 
characterize the role of three-dimensional 
genome conformations in the function of 
regulatory elements and gene expression.
Concluding remarks. The future application 
of CRISPR–Cas9 systems in genetic screens 
of enhancers will certainly accelerate the 
identification of regulatory networks by 
connecting non-coding elements to their 
target genes and to a specific phenotype. 
We believe that the most comprehensive 
definition of the function of regulatory 
elements will arise from combining different 
strategies, including disruption of the DNA 
sequence and modulation of its activity. 
However, the majority of CRISPR–Cas9 
tools have only been applied to study a 
limited number of endogenous enhancers 
to date. It is paramount to evaluate these 
tools across many regulatory elements 
and in different biological settings to fully 
appreciate their potential. Together, we are 
privileged to live in the ‘CRISPR–Cas9 era’, 
a time in which our imagination seems to be 
the only limiting factor in discovering the 
secrets of the human genome.
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Chapter 3 
GRO-seq, a tool for identification of transcripts regulating gene 
expression 
Adapted from Methods Molecular Biology. 2017;1543:45-55.  
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GRO-seq, A Tool for Identification of Transcripts Regulating 
Gene Expression
Rui Lopes*, Reuven Agami, and Gozde Korkmaz*
Abstract
The advent of next-generation sequencing (NGS) technologies has revolutionized the way we do research 
on gene expression. High-throughput transcriptomics became possible with the development of microar-
ray technology, but its widespread application only occurred after the emergence of massive parallel 
sequencing. Especially, RNA sequencing (RNA-seq) has greatly increased our knowledge about the 
genome and led to the identification and annotation of novel classes of RNAs in different species. However, 
RNA-seq measures the steady-state level of a given RNA, which is the equilibrium between transcription, 
processing, and degradation. In recent years, a number of dedicated RNA-seq technologies were devel-
oped to measure specifically transcription events. Global run-on sequencing (GRO-seq) is the most widely 
used method to measure nascent RNA, and in recent years, it has been applied successfully to study the 
function and mechanism of action of noncoding RNAs. Here, we describe a detailed protocol of GRO-seq 
that can be readily applied to investigate different aspects of RNA biology in human cells.
Key words Sequencing, GRO-seq, Nascent transcription, Noncoding RNA, Enhancer, Running 
Head: GRO-seq
1 Introduction
RNA analysis was once limited to study individual molecules by 
Northern blot or real-time quantitative PCR. In the past decade, 
we witnessed a revolution in the RNA world caused by the rise of 
NGS. In particular, RNA-seq contributed decisively to make global 
gene expression analysis as a routine practice in many labs [1]. This 
technique does not only allow to qualitatively and quantitatively 
investigate messenger RNAs (mRNAs), but also novel noncoding 
RNA species (e.g., microRNAs, small interfering RNAs, and long 
noncoding RNAs) that are recognized nowadays as important 
players in the biology of the cell [2].
*These authors contributed equally to this work.
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The cellular levels of a given RNA molecule are determined by 
the interplay of transcription, processing, and degradation. 
Consequently, both transcriptional and posttranscriptional changes 
affect RNA levels as measured by RNA-seq. In recent years, a num-
ber of RNA-seq-based technologies were developed that can mea-
sure specifically nascent RNA transcription from actively engaged 
polymerases. Among them, the most widely used are global run-on 
sequencing (GRO-seq) [3], native elongating transcript sequencing 
(NET-seq) [4], and precision nuclear run-on sequencing (PRO-
seq) [5]. Here, we focus on GRO-seq, an assay that allows mapping 
and quantification of transcriptionally engaged RNA polymerases 
and provides a snapshot of genome-wide transcription. GRO-seq 
measurements are very sensitive and largely independent of RNA 
stability effects, making it particularly suitable to study noncoding 
RNA species that are lowly expressed and/or have high decay rate.
Recently, we and others have used GRO-seq to study different 
classes of noncoding RNAs such as promoter-associated RNAs [3], 
enhancer-associated RNAs [6], and long noncoding RNAs [7]. 
Below, we describe a detailed protocol of GRO-seq (Fig. 1), based 
on the original protocol from Core et al., Science (2008), which 
can be readily applied to study different aspects of RNA biology in 
human cells [8–10].
Fig. 1 Summarized scheme of the GRO-seq protocol steps (left panel) and cor-
responding sections (right panel) described in this article
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2 Materials
All solutions for the protocol must be freshly prepared. In order to 
reduce the risk of RNase activity, it is necessary to use nuclease-free 
water for the preparation of all solutions, as well as the addition of 
RNase inhibitors to all RNA reactions.
Buffers should be ice-cold during the protocol.
1. UltraPure DNase/RNase-Free Distilled Water.
2. PBS (DPBS, no calcium, no magnesium).
3. 1 MMgCl2.
4. 0.5 M EDTA, pH 8.0.
5. UltraPure 1 M Tris–HCI, pH 8.0.
6. UltraPure 1 M Tris–HCI Buffer, pH 7.5.
7. Tris/HCl pH 7.8: mix 1:1 volume/volume ratio of Tris/HCl,
pH 7.5 and Tris/HCl, pH 8.
8. RNase Inhibitor.
9. Swelling Buffer: 10 mM Tris/HCl pH 7.5, 2 mM MgCl2
3 mM CaCl2. Add 2 U/ml RNase Inhibitor immediately
before use.
10. Igepal CA-630.
11. Glycerol.
12. Lysis Buffer: 10 mM Tris–HCl pH 7.5, 2 mM MgCl2, 3 mM
CaCl2, 0.5 % (v/v) IGEPAL CA-630, 10 % (v/v) glycerol+
2 U/ml RNase Inhibitor.
13. Freezing buffer: 40 % (v/v) glycerol, 5 mM MgCl2, EDTA pH
8.0, 50 mM Tris/HCl pH 7.8, add 2 U/ml of SUPERase- In
immediately before use.
14. Trypan blue solution.
15. Hemocytometer.
16. Liquid nitrogen.
1. 5-bromouridine 5′-triphosphate (BrUTP).
2. Sarkosyl 20 % (N-lauryl sarcosine sodium sulfate).
3. ATP Solution (10 mM).
4. CTP Solution (10 mM).
5. GTP Solution (10 mM).
6. KCl (2 M).
1. TRIzol LS (Invitrogen).
2. Chloroform.
2.1 Isolation 
of Nuclei
2.2 NRO Reaction
2.3 RNA Extraction
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3. GlycoBlue Coprecipitant (15 mg/mL) (Ambion).
4. 2-Propanol.
1. RNA Fragmentation Reagents (Ambion).
1. Micro Bio-Spin Columns with Bio-Gel P-30 in Tris Buffer
(Bio-Rad).
2. TE buffer, pH 8.0.
Add 2 μl of 20 U/μL RNase Inhibitor for each 10 ml of the 
buffers.
1. BrdU (IIB5) AC (Santa Cruz Biotech, catalogue number
sc-32323 AC) (agarose conjugated BrdU antibody for IP
studies).
2. UltraPure SSPE, 20×.
3. Tween 20.
4. UltraPure BSA (50 mg/ml).
5. PVP (Polyvinylpyrrolidone solution).
6. Binding Buffer: 0.25× SSPE, 0.001 M EDTA pH 8.0, 0.05 %
Tween-20, 37.5 mM NaCl.
7. Blocking Buffer: 0.25× SSPE, 0.001 M EDTA pH 8.0, 0.05 %
Tween-20, 37.5 mM NaCl, 0.1 % PVP (final concentration),
1 μg/ml BSA.
Add 2 μl of 20 U/μL RNase Inhibitor for each 10 ml of the 
buffers.
1. PVP 40.000.
2. DTT.
3. 10 % SDS.
4. Low Salt Buffer: 0.25× SSPE, 0.001 M EDTA pH 8.0,
0.05 % (v/v) Tween-20.
5. High Salt Buffer: 0.25× SSPE, 0.001 M EDTA pH 8.0,
0.05 % (v/v) Tween-20, 100 mM NaCl.
6. TET Buffer: 1× TE buffer, 0.5 % (v/v) Tween-20.
7. Elution Buffer: 0.15 M NaCl, 0.05 M Tris pH 7.5, 0.001 M
EDTA pH 8.0, 0.1 % SDS. Add 0.02 M DTT immediately
before use.
1. Tobacco Acid Pyrophosphatase (TAP).
2. T4 Polynucleotide Kinase (PNK).
2.4 Fragmentation 
of NRO-RNA
2.5 Purification 
of Fragmented 
NRO-RNA 
Through p-30 RNase-
free Spin Column
2.6 Blocking 
the BrdU Beads for 
Immunoprecipitation
2.7 Immuno 
precipitation 
of NRO-RNA
2.8 End Repair 
of NRO-RNA (TAP/PNK 
Treatment)
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1. TruSeq Small RNA Library Preparation Kit (Illumina).
2. Agencourt AMPure XP (Beckman Coulter).
3. RNA 6000 Ladder (Ambion).
4. Agilent DNA 1000 or Agilent High Sensitivity DNA chip.
3 Methods
Perform all steps on ice or at +4 °C. Volumes below are described 
for 15 cm2 plate.
1. Wash cells three times with ice-cold PBS.
2. Aspirate the PBS.
3. Add 10 ml of ice-cold Swelling Buffer to the plate, and incubate
for 5 min on ice (see Note 1).
4. Scrape cells into the solution and transfer the solution into
15 ml tubes. Pellet cells by centrifuging at 400 × g (400 × g,
GH3.8 rotor) for 10 min at +4 °C.
5. Aspirate supernatant (SN) and resuspend cells in 500 μl of
Swelling Buffer/10 % glycerol solution containing 4 U/ml
RNASe inhibitor by gentle pipetting.
6. Vortex cells slowly (≈800 rpm, so that liquid rises about
1–2 cm) and drop wise add 500 μl of Swelling Buffer/10 %
glycerol/1 % IGEPAL CA-630 solution containing 4 U/ml
RNASe inhibitor.
7. Incubate cells on ice for 5 min.
8. Bring volume to 10 ml with Lysis Buffer and centrifuge at
600 × g (600 × g ) for 5 min at +4 °C.
9. Aspirate SN.
 10. Wash nuclei with 10 ml of Lysis Buffer (see Note 2) and
centrifuge at 600 × g (1550 rpm) for 5 min at +4 °C.
11. Aspirate the SN and resuspend the pellet in 1 ml of Freezing
Buffer.
12. Mix 10 μl of Freezing buffer containing isolated nuclei with
190 μl Trypan Blue (2:5 diluted in freezing buffer, so that the
nuclei will not swell) and count the cells by using
hemocytometer.
13. Pellet nuclei at 900 × g (900 × g ) for 6 min at +4 °C and aspi-
rate the SN without disturbing the pellet.
14. Resuspend the pellet to have 5 × 106 nuclei per 100 μl with
Freezing Buffer. Aliquots every 100 μl into individual 1.5 ml tube.
15. Snap-freeze nuclei in dry ice/methanol or liquid nitrogen or
proceed directly to the nuclear run-on reaction (NRO-rxn)
(see Note 3).
2.9 GRO-seq Library 
Preparation
3.1 Isolation 
of Nuclei
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1. Prepare the NRO master mix (2×) (Table 1) containing
1.165 μM final concentration of CTP (see Note 4).
2. Preheat the NRO-mix to +30 °C.
3. Mix 100 μl of pre-warmed NRO-mix with 100 μl nuclei (1:1
ratio) and place the reaction into the heat block (at +30  °C) to
perform run-on for 5 min with shaking at the 2nd and 4th min
(600–800 rpm) (see Note 5).
4. Immediately add 900–1000 μl of TRIzol LS and vortex solu-
tion for 30 s. This will stop the NRO-rxn (see Note 6).
5. Incubate for 5 min at RT.
6. It is advisable to keep the samples at −20 °C for short-term
storage or at −80 °C for longer storage. OPTIONAL
STOPPING POINT.
1. Add 240 μl of Chloroform to the 900–1000 μl of TRIzol LS
and shake by hand for 15 s.
2. Incubate for 2–3 min at RT and centrifuge at 12,000 × g for
15 min at +4 °C.
3. Take out the colorless upper layer containing RNA (middle
phase contains DNA, red phase contains proteins) and add 2 μl
of glycogen and same volume of isopropanol as sample and
inverse tube ten times (see Note 7).
3.2 NRO Reaction
3.3 RNA Extraction
Table 1 
Content of the NRO master mix (2×) for NRO Reaction
Reagent Stock[M] Final[mM] 500 μl
Tris–Cl 1 10 5
MgCl2 1 5 2.5
DTT 0.1 1 5
KCl 2 300 75
ATP 0.01 0.5 25
GTP 0.01 0.5 25
CTP 0.0001 0.002 10
32P-CTP 50
BrUTP 0.01 0.5 25
RNASe inhibitor 20 U/μl 0.4 10
2 % Sarkosyl 2 1 250
Water 17.5
482.50
500
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4. Incubate for 10 min at RT and centrifuge at 14,000 × g for
15 min at +4 °C.
5. Remove supernatant and wash the pellet twice with 75 %
EtOH (prepared with DNase, RNase free water), vortex, and
centrifuge at 7500 × g for 5 min at +4 °C.
6. Remove supernatant, spin and remove the remaining of super-
natant. Air-dry the pellet for 1 min at RT and be careful not to
over-dry the pellet.
7. Suspend the pellet in 10 μl of DNase, RNase free water con-
taining RNASe inhibitor enzyme (1 U/μl).
8. Incubate the solution for 5 min at 65 °C.
1. Add 2 μl of fragmentation reagents up to 20 μl NRO-RNA
solution and incubate for 10 min at +70 °C (see Note 8).
2. Add 2 μl of Stop solution and put on ice.
1. In order to prepare column, invert it several times to resuspend
the matrix. Spin at 1000 × g for 2 min to remove the flow
through. Put column into a new 1.5 ml tube. Do not let the
column dry out, prepare and use immediately.
2. Add 500 μl of TE buffer and centrifuge for 1 min at 1000 × g.
Discard the flow through. Repeat this step for two to three
times to change the buffer content.
3. Add sample (between 20 and 100 μl) into the column and
centrifuge for 4 min at 1000 × g. Keep the flow through which
contains fragmented NRO-RNA.
4. Check the radioactivity level with the Geiger counter. The flow
through should have more counts than the matrix. If the
matrix has more counts, it means that there is unincorporated
32P- CTP. Thus, NRO-rxn was not successful.
5. Sample can be frozen at −80 °C. OPTIONAL STOPPING
POINT.
1. Equilibrate BrdU beads in binding buffer by washing them
two times in 500 μl for 5 min with rotation (8 rpm). Spin
down beads at 1000 × g for 1–2 min. Place on ice for 1 min
before removing SN (see Note 9).
2. Block the beads in four to five times volume of blocking buffer
for 1–2 h at RT. Add an extra 2 μl RNASe inhibitor for every
ml of blocking buffer during this step.
3. Spin down the beads (1000 × g for 2 min) and discard the
supernatant.
4. Wash beads twice in 500 μl binding buffer.
3.4 Fragmentation 
of NRO-RNA
3.5 Purification 
of Fragmented 
NRO-RNA 
Through p-30 RNase-
free Spin Column
3.6 Blocking 
the BrdU Beads for 
Immunoprecipitation
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5. Spin down the beads (1000 × g for 2 min) and discard the
supernatant.
6. Resuspend beads in 400 μl binding buffer/reaction.
1. Bring purified and fragmented NRO-RNA volume to 100 μl
and add EDTA to reach a final concentration of 5 mM (add
1 μl of 0.5 M EDTA).
2. Heat the sample to +65–70 °C for 5 min and then place on ice
for 2 min (see Note 10).
3. Add 400 μl of binding buffer and 50–60 μl of bead slurry into
a 1.5 ml tube. Allow binding for +30–60 min (see Note 11).
4. Spin down the beads (1000 × g for 2 min) and discard the SN.
5. Wash one time in 500 μl of binding buffer for 5 min on rotat-
ing stand (8 rpm).
6. Spin down the beads (1000 × g for 2 min) and discard the SN.
7. Wash one time in 500 μl of low salt buffer for 5 min on rotat-
ing stand (8 rpm).
8. Spin down the beads (1000 × g for 2 min) and discard the SN.
9. Wash one time in 500 μl of high salt buffer for 3 min on rotat-
ing stand (8 rpm).
10. Spin down the beads (1000 × g for 2 min) and discard the SN.
11. Wash two times in 500 μl of TET buffer for 5 min on rotating
stand (8 rpm).
12. Spin down the beads (1000 × g for 2 min) and discard the SN.
13. Elute two times with 125 μl and one time with 250 μl of elu-
tion buffer that is heated to +42 °C. Place the tube in a heat
block (+42 °C) for 10 min with constant shaking at 500 rpm
and every few minutes increase the shaking to 900 rpm.
14. Spin down the beads and transfer the solution (eluate) con-
taining the NRO-RNA to a new tube.
15. Add 900–1000 μl of TRIzol LS and follow Subheading 3.3.
1. Heat RNA to +65–70 °C for 5 min, put on ice for 2 min.
2. Set up the following reaction in a 1.5 ml tube: 3 μl of 10× TAP
buffer, 5 μl of nuclease-free water, 1 μl of RNASe inhibitor,
1.5 μl of TAP (10 U/ml).
3. Mix by pipetting and incubate the reaction at +37 °C for 1.5 h.
4. Add 1 μl of PNK, and 1 μl of 300 mM MgCl2 to reach 10 mM
final concentration, mix by pipetting, and incubate the reac-
tion another 15 min.
5. Add 20 μl of PNK buffer, and 126 μl of nuclease-free water,
1 μl of RNAse inhibitor (20 U/μL), and another 1 μl of PNK.
3.7 Immuno 
precipitation (IP) 
of NRO-RNA (First IP)
3.8 End Repair 
of NRO-RNA (TAP/PNK 
Treatment)
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6. Mix by pipetting and incubate the reaction for 15 min.
7. Add 20 μl of 10 mM ATP and another 1 μl of PNK, mix by
pipetting, and incubate the reaction for 30 min.
8. Stop the reaction by adding 77 μl of nuclease-free water, 18 μl
of 5 M NaCl, and 5 μl of 500 mM EDTA.
9. Add 900–1000 μl of TRIzol LS and follow Subheading 3.3.
1. Repeat Subheadings 3.6 and 3.7.
2. Follow the manufacturer’s protocol for adapter ligation accord-
ing to the desired sequencing platform. For example, TruSeq
Small RNA kit should be used for Illumina sequencing system.
As an alternative, custom protocols for adapter ligation have
been previously described [11].
3. After 3′ and 5′ adapter ligation, repeat Subheadings 3.6 and 3.7.
1. Continue with the manufacturer’s protocol for RT-PCR fol-
lowed by Agencourt AMPure XP cleaning protocol. Use
1:2 (v/v) ratio for mixing sample and beads.
2. Elute in 25 μl for PCR Amplification.
1. Continue with the manufacturer’s protocol for PCR (max 12
cycles) followed by Agencourt AMPure XP cleaning protocol.
Use 1:1 (v/v) ratio for mixing beads and sample.
2. Repeat magnetic beads cleaning step.
3. Elute in 15 μl.
1. Run 1 μl of the GRO-seq library on a Bioanalyzer using an
Agilent DNA 1000 or Agilent High Sensitivity DNA chip. The
fragments should be dispersed between 200 and 400 bp (Fig. 2).
1. Amplicons can be sequenced in a HiSeq 2500 (Illumina) plat-
form using a standard 65 bp single-read reaction.
2. Sequenced reads can be aligned to the human genome (hg19)
using bowtie2 [12] tool.
3. HOMER software can be applied to detect transcriptional
units (TUs) [13]. The expression level of each TU can be cal-
culated in each sample by using HTseq package [14].
4. The identification and classification of promoter-associated
RNAs requires further bioinformatics analysis to associate their
expression with known transcriptional start sites.
3.9 Second IP, 
Adapter Ligation, 
and Third IP
3.10 Reverse 
Transcription (RT) 
and Cleaning-up 
with Magnetic Beads
3.11 PCR 
Amplification 
of the GRO-seq Library 
and Cleaning-up 
with Magnetic Beads
3.12 Quantification 
of GRO-seq Library
3.13 Sequencing 
of GRO-seq Library 
and Data Analysis
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4 Notes
1. It is important to equally expose the surface to swelling buffer.
Rock the plates occasionally to prevent drying.
2. Resuspend nuclei by flicking the tube before adding the Lysis
Buffer, and then invert tube several times.
3. In order to obtain better yields, it is advisable to use two sepa-
rate reactions for NRO-rxn (two times of 5 × 106 nuclei).
4. Sarkosyl level and final concentration of CTP need to be
adjusted according to the experimental system.
5. Having sarkosyl in NRO-mix causes the mixture to become
very viscous. In order to obtain a homogenous mixture, cut
the edge off a normal pipette tip and at least mix 15–20 times
before placing the mixture at +30 °C.
6. If needed, combine two of the same reactions.
7. It is not recommended to use any salt containing buffers at this
step. If you need to use salt containing buffer to obtain clear
RNA pellet, you should wash the pellet at least two times with
70 % EtOH to remove the residual salt.
8. Upon fragmentation, it is expected to obtain a distribution of
RNA fragments between 100 and 150 bp. The duration of the
fragmentation reaction requires optimization and a bioana-
lyzer profile of different time points can provide the requisite
information.
Fig. 2 Bioanalyzer result of a good-quality GRO-seq library is shown as an example. The fragments should be 
dispersed between 200 and 400 bp
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9. Handle the beads carefully because they do not form a rigid
pellet. Allow 30–50 μl of SN to remain in the tube, in order to
avoid losing your sample.
10. EDTA is needed to chelate divalent ions that catalyze cleavage
of the RNA with heat.
11. You can check if the binding is at or near completion by spin-
ning the beads down and removing the SN. Check the beads
and supernatant with the Geiger counter. If the SN has 5–10×
fewer counts than the beads, then the binding is likely
complete.
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Chapter 4 
Functional genetic screens for enhancer elements in the human 
genome using CRISPR-Cas9 
Adapted from Nature Biotechnology. 2016 Feb;34(2):192-8.
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Systematic identification of noncoding regulatory elements 
has, to date, mainly relied on large-scale reporter assays 
that do not reproduce endogenous conditions. We present 
two distinct CRISPR-Cas9 genetic screens to identify and 
characterize functional enhancers in their native context.  
Our strategy is to target Cas9 to transcription factor  
binding sites in enhancer regions. We identified several 
functional enhancer elements and characterized the role  
of two of them in mediating p53 (TP53) and ERa (ESR1) 
gene regulation. Moreover, we show that a genomic  
CRISPR-Cas9 tiling screen can precisely map functional 
domains within enhancer elements. Our approach expands 
the utility of CRISPR-Cas9 to elucidate the functions of  
the noncoding genome
Enhancers are genomic elements that regulate transcription of 
distantly located genes through chromatin looping. They function 
as binding platforms for transcription factors and are characterized 
by specific chromatin modifications1. Recent studies have shown 
that genetic alterations can affect enhancer activity and contribute to 
tumorigenesis2,3. Moreover, transcription factors and other enhancer-
associated proteins are frequently mutated in human tumors, and 
targeting these proteins with small-molecule inhibitors holds much 
therapeutic potential1,4. It is estimated that the human genome con-
tains >500,000 putative enhancers, a staggering number that poses 
a major challenge for the identification of functional regulatory 
elements. Current methods to systematically identify enhancers 
are based on massively parallel reporter sequencing. However, the 
intrinsically artificial nature of these methods is likely to have some 
effect on their ability to delineate and assess the activity of endog-
enous enhancers. The recent development of CRISPR-Cas9 (clustered, 
regularly interspaced, short palindromic repeats (CRISPR) and the 
CRISPR-associated protein 9 (Cas9)) technology has opened unprec-
edented opportunities for genome-wide targeted editing in human 
cells5. Previous functional genetic screens using CRISPR-Cas9 have 
mainly been restricted to protein-coding genes6,7. Here, we apply 
this technology to identify endogenous enhancer elements and to 
characterize the domains that are essential for their activity.
As a proof-of-principle demonstration, we focused on two tran-
scription factors, p53 and ERα, which play key roles in cancer initia-
tion and progression. p53 is known as the ‘guardian of the genome’, and 
is mutated in more than 50% of all human tumors8. Upon oncogene 
activation, one major function of p53 is to activate an irreversible 
cell-cycle arrest program named oncogene-induced senescence (OIS). 
OIS is a powerful tumor-suppressive mechanism; somatic mutations 
in p53, or in other components of its pathway, can overcome OIS and 
lead to tumorigenesis9. ERα is an estrogen-activated transcription 
factor that has a mitogenic role in breast cancer cells. The standard of 
care for ERα-positive breast tumors is treatment with selective ERα 
modulators and aromatase inhibitors. However, many tumors relapse 
after treatment and most of them still express ERα (also known as 
ESR1)10. Recently, both p53 and ERα have been shown to directly 
bind genomic regions that are characterized largely by features of 
distal-enhancer regions11,12. This evidence suggests that the identifi-
cation of p53- and ERα-bound enhancers and their target genes could 
be instrumental for diagnostics and therapeutics of cancer.
Initially, we set out to establish a genetic screen for p53-bound 
enhancers that are required for OIS (Fig. 1a). To build a CRISPR-
Cas9 single guide RNA (sgRNA) library, we followed a strategy that 
enabled us to target ≈90% of p53-bound enhancers (Fig. 1b and 
Supplementary Table 1). We cloned the sgRNAs into lentiCRISPRv2 
vector13 using a pooled strategy and generated a lentiviral library 
(CRISPR-p53-enhLib). We performed our screen in human BJ cells 
containing tamoxifen-inducible HRASG12V (BJ-RASG12V), which are a 
well-characterized cell model of OIS14,15. Accordingly, we transduced 
cells with three independent lentiviral pools of CRISPR-p53-enhLib, 
as well as with a nontargeting sgRNA pool (negative control) (Fig. 1c). 
After 4 weeks of culturing, we harvested the cells and performed 
next-generation sequencing to identify the sgRNAs present in the 
populations (Fig. 1c and Supplementary Fig. 1a).
Our screen detected eight substantially enriched sgRNAs (q < 0.1) 
in the RASG12V-induced cell populations (Fig. 1d and Supplementary 
Table 2). Notably, two independent sgRNAs targeted a putative 
enhancer located ~10 kb upstream of CDKN1A (formerly known 
as p21), which is a key effector of p53-dependent OIS (Fig. 1e; p53enh3507). 
Another top-scoring sgRNA mapped to a known p53-responsive 
Functional genetic screens for enhancer elements in 
the human genome using CrIsPr-Cas9
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element that is located proximal to the transcription start site of 
CDKN1A (Fig. 1e; p53enh3508). To validate the results of the screen, 
we repeated the OIS experiment using individual sgRNAs. In this 
assay, we included sgRNAs targeting the coding region of p53 and 
CDKN1A as positive controls, and a nontargeting sgRNA as a nega-
tive control. As additional negative controls, we tested three sgRNAs 
that did not show significant enrichment in our screen (p53enh1646, 
p53enh2736 and p53enh3962). These experiments validated four out of 
eight original hits, and identified three different enhancers that are 
required for OIS: p53enh3507, p53enh3508 and p53enh1396 (Fig. 1f and 
Supplementary Fig. 1b,c). Whereas p53enh3507 and p53enh3508 pre-
sumably co-regulate CDKN1A expression, p53enh1396 is located in 
an intron of the long noncoding RNA RP11-382A20. Of note, none 
of the negative-control sgRNAs caused OIS bypass, indicating the 
robustness of our assay. (Supplementary Fig. 1b,c).
We focused subsequent experiments on p53enh3507, which is a putative 
enhancer region that has not previously been functionally charac-
terized in human cells, and on p53enh3508, whose role in mediating 
p53-dependent CDKN1A regulation has been previously docu-
mented16. We performed BrdU labeling and senescence-associated 
β-galactosidase (β-gal) assays and found that sgRNA-p53enh3507 and 
sgRNA-p53enh3508 caused OIS bypass and continuous cell prolifera-
tion (Fig. 1g,h and Supplementary Fig. 2a). Next, we assessed the 
enhancer capacity of the p53enh3507 region by cloning it into a reporter 
vector and verified that it strongly induces transcription (Fig. 2a). 
We also observed a substantial reduction in enhancing activity upon 
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Figure 1 A comprehensive CRISPR-Cas9 genetic screen identifies p53-bound enhancers required for OIS. (a) Screening strategy for detecting  
p53-bound enhancers required to elicit OIS. RE, responsive element (b) Summary of pipeline used to establish a genome-wide CRISPR-Cas9–based 
library targeting p53-bound (termed CRISPR-p53-enhLib). (c) The functional genetic screen procedure. NGS, next-generation sequencing.  
(d) Enrichment score calculated for each sgRNA vector based on its prevalence in the pool, harvested after 4 weeks of tamoxifen (TAM) treatment 
(HRASG12V induction), relative to its prevalence in the untreated pool. The plot shows the distribution of standardized enrichment scores (Z-scores) 
for the entire CRISPR-p53-enhLib library. A red dot indicates two independent sgRNAs targeting p53enh3507; the yellow dot, an sgRNA that targets 
p53enh3508. n.s., not significant. (e) Genomic tracks for p53 binding events, histone modifications (based on publicly available data sets) and for 
transcriptional activity measured by GRO-seq in induced BJ-RASG12V (BJ-TAM) and noninduced BJ-RASG12V cells (BJ-CNT). The colors in the chromatin 
hidden Markov model track represent predicted chromatin function as follows: orange, strong enhancer; yellow, weak enhancer; red, promoter; green, 
transcriptional activity. (f) Light microscopy images of cell populations transduced with the indicated sgRNA vectors. Images were taken after 15 d  
of HRASG12V induction. (g) Proliferation of the various CRISPR-Cas9–transduced BJ-RASG12V cells was quantified using a BrdU assay. N = 2; for each  
condition, at least 150 cells were counted. ***P < 0.005, two-tailed Student’s t-test. For every condition, percentage of BrdU-positive cells was 
normalized to p53KO cells. (h) Senescence induction was quantified using senescence-associated (SA) β-gal assay. For every condition, percentage of 
β-gal-positive cells was normalized to Ctrl cells. Error bars, mean ± s.d. 
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siRNA-mediated knockdown of p53 (Fig. 2b). We obtained similar 
results for the p53enh3508 enhancer element (Supplementary Fig. 2b,c). 
Taken together, our results demonstrate that p53enh3507 controls OIS, 
and its transcription-enhancing activity is p53-dependent.
Active enhancer regions produce enhancer-associated RNAs 
(eRNAs), whose expression levels correlate with enhancer activity17. 
Indeed, we performed global run-on sequencing (GRO-seq) in 
BJ-RASG12V cells and detected strong induction of eRNA expression 
from the p53enh3507 region upon activation of OIS  (Fig. 2c). CRISPR-
Cas9–mediated knockout of p53, but not of CDKN1A, completely abol-
ished eRNA expression from this region, indicating p53-dependent 
regulation of p53enh3507 (Fig. 2c). GRO-seq data of MCF-7 cells treated 
with Nutlin-3a suggest that this region is an active p53-responsive 
enhancer in different types of human cells18 (Fig. 2c). Next, we meas-
ured eRNA expression from the p53enh3507 region and found that all 
three sgRNA-p53enh3507 caused about a tenfold reduction in eRNA 
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Figure 2 p53enh3507 is a p53-dependent enhancer region that regulates CDKN1A expression. (a) MCF-7 cells were transfected with the indicated 
reporter vectors, treated with Nutlin-3a 5–10 h later, and harvested 25–30 h after treatment. The relative luciferase activities (firefly/Renilla) were 
normalized to the control (Ctrl.) reaction. P-values for luciferase assay were calculated by two-tailed Student’s t-test. *P < 0.005, relative to empty 
vector; #P < 0.005, relative to untreated matching sample. (b) The same assay as in a, only that cells were co-transfected with control, or p53-targeting 
short interfering RNA (si-Cont.; si-p53). A reporter vector containing the enhancer region p53-BER4 was used as a positive control for p53-dependency. 
The efficiency of p53 knockdown was determined by immunoblot analysis. P-values for luciferase assay were calculated by two-tailed Student’s t-test. 
*P < 0.01, relative to empty vector. (c) GRO-seq analysis detected strong induction of eRNA expression at p53enh3507 upon RASG12V induction in
BJ cells. This induction was completely abolished by p53-KO but not affected by CDKN1A-KO. The knockouts of p53 and CDKN1A were verified by 
western blot analysis (Fig. 2f and Supplementary Fig. 3f). Activation by Nutlin-3a treatment in MCF-7 cells resulted in a strong induction of eRNA in 
this region. (d,e) qRT-qPCR measurements of either eRNAs transcribed from the p53enh3507 region (d) or mRNAs of CDKN1A (e). n = 3; ***P < 0.005, 
*P < 0.05, two-tailed Student’s t-test. (f,g) Immunoblot analysis for CDKN1A (f) and p53 (g) proteins in BJ-RASG12V cells transduced as indicated,
and treated with tamoxifen (TAM) for 12–15 d. HSP90 and β- Actin protein levels are shown as a loading control. (h) Using RNA-seq, we identified 
a set of 54 known direct target genes of p53 that were induced by at least twofold upon HRASG12V activation in BJ cells (Sen.C), and examined the effect 
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expression (Fig. 2d), and a corresponding ~2.5-fold reduction in 
CDKN1A mRNA (Fig. 2e) and protein (Fig. 2f) levels. Importantly, 
the reduction of p53enh3507 eRNA and CDKN1A mRNA expression 
occurred in conditions of elevated p53 protein levels and continu-
ous HRASG12V expression (Fig. 2g and Supplementary Fig. 3a). 
Finally, we performed RNA-seq in BJ-RASG12V cells and confirmed 
that the effect of sgRNA-p53enh3507 is specific to CDKN1A (Fig. 2h; 
red dot). In contrast, downregulation of p53 significantly (P = 6.1 ×  
10−13 for p53KD and P = 8.3 × 10−8 for p53KO; Wilcoxon’s test) 
reduced the expression of the majority of its target genes (Fig. 2h; 
blue dot). These results indicate that sgRNA-p53enh3507 disrupts 
the enhancing activity of this region and decreases the activation of 
CDKN1A upon OIS.
Cas9-nuclease activity generates DNA double-strand breaks that 
result in deletions and insertions in the vicinity of the sgRNA recogni-
tion site19. Therefore, we examined the spectrum of deletions caused 
by sgRNA-p53enh3507 in control and induced BJ-RASG12V cells. We 
found that sgRNA-p53enh3507 caused deletions ranging from 1–15 
nucleotides (Fig. 2i). The mutations were restricted to the p53 binding 
site following OIS induction, indicating that small deletions in key 
noncoding regulatory sequences are sufficient to cause a phenotypic 
change in vivo (Fig. 2i). We also tested the effect of CRISPR-Cas9–
induced mutations on the activity of p53enh3507 region in a reporter 
vector. In all cases, p53-dependent enhancer activity was abolished by 
the mutations (Supplementary Fig. 3c), indicating that an intact p53 
binding site is indispensable for the p53enh3507 enhancing function.
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summarizing the pipeline used to establish a CRISPR-Cas9 sgRNA 
library targeting ERα-bound enhancers. (b) Screening strategy 
based on negative selection of sgRNAs. (c) Distribution of sgRNAs’ 
relative enrichment Z-scores in MCF-7 and T47D cells relative to 
MDA-MB-231 cells. We selected for further validations the three  
ERαenh-sgRNAs (colored green) whose depletion effect was at least 30% 
stronger in both MCF-7 and T47D cells compared to MDA-MB-231. 
Red, positive controls (ERα-sgRNAs); black, sgRNAs used as negative 
controls for the validation. (d) Validation of candidate hits by a 
competitive proliferation assay in MCF-7 and MDA-MB-231 cells. Ctrl  
indicates a nontargeting sgRNA. An sgRNA targeting the coding region 
of ERα was used as a positive control (ERα CDS). sgRNAs enh128 and  
enh257 were used as negative controls. GFP levels were measured by 
flow cytometry. Values on day 3 (T = 3) and day 6 (T = 6) are normalized 
to day 0 (T = 0). n = 3; ***P < 0.005, **P < 0.01, *P < 0.05, two-tailed 
Student’s t-test. n.s., not significant. (e–h) MCF-7 and T47D stably 
expressing sgRNA-control and sgRNA-ERαenh588 were examined by 
ChIP-seq (e), qRT-PCR (f,g) and western blot (h) analysis to assess 
ERα binding, ERαenh588 eRNA, CCND1 mRNA and protein levels, 
respectively. For f and g, n = 3; ***P < 0.005, **P < 0.01, *P < 0.05, 
two-tailed Student’s t-test). For complete blots see Supplementary 
Figure 4c. (i) MCF-7 cells transduced with sgRNA-control and  
sgRNA-ERαenh588 were depleted of estrogens for 72 h and then stimulated with 17β-estradiol for 24 h. Relative expression levels of ERαenh588  
eRNA and CCND1 mRNA were measured by qRT-PCR. n = 3; ***P < 0.005, **P < 0.01, *P < 0.05, two-tailed Student’s t-test. (j) S-phase entry of 
sgRNA-control and ERαenh588-transduced MCF-7 cells was assayed by BrdU incorporation and measured by flow cytometry. n = 4; for each condition 
10,000 events were recorded. ***P < 0.005, **P < 0.01, *P < 0.05, two-tailed Student’s t-test. Error bars, mean ± s.d.
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Interestingly, concurrent disruption of p53enh3507 and p53enh3508 
resulted in further reduction of CDKN1A expression, suggesting an inde-
pendent regulation by both enhancer elements (Supplementary Fig. 3b; 
left panel). In comparison, downregulation of p53 resulted in even lower 
levels of CDKN1A, possibly due to indirect effects on CDKN1A expres-
sion18. However, BrdU and β-gal assays showed no additional effect 
by the combined sgRNAs compared with the singles, indicating that 
inactivation of one enhancer is sufficient to complete a phenotypic alter-
ation (Supplementary Fig. 3d,e). Collectively, these results demonstrate 
that p53enh3507 is an endogenous enhancer of CDKN1A and disruption 
of this region causes bypass of senescence in p53-WT cells. Moreover, 
cooperative action of p53enh3507 (distal enhancer of CDKN1A—deCD-
KN1A) and p53enh3508 (proximal enhancer of CDKN1A—peCDKN1A) 
is required to activate CDKN1A expression and initiate OIS.
Hit4 Hit147
Hit38 Hit108 Ctrl.
sgRNA-deCDKN1A
sgRNA-Ctrl
b c
H3K27Ac
+ Strand
– Strand
15
5BJ-TAM
H3K4Me1
H3K4Me3
CRISPR-deCDKN1A-enhLib
Tiling sgRNA
cut locations
Scale
chr6: 2 kb (hg19)
p53_ChIP-seq
deCDKN1A_tiling
p53 BS
Enrichment
(log2)
chr6:36,634,056-36,636,070
Hit4
Hit146/Hit147/Hit34
Hit38
2.23 _
–1 _
0 -
ChromHMM HMECNHLF
5X 5X
5X 5X 5X0
2
4
6
8
Hi
t1
46
 (p
53
 B
S)
Hi
t3
8
Hi
t3
4 
(p
53
 B
S) Hi
t4
Hi
t1
47
 (p
53
 B
S)C
um
ul
at
iv
e 
en
ric
hm
en
t (
lo
g 2
)
CDKN1A Average fold change
of p53 targets
TOP 5 scoring hits
0
0.2
0.4
0.6
0.8
1.0
1.2
Ct
rl.
Hi
t4
Hi
t1
47
Hi
t3
8
R
el
at
iv
e 
fo
ld
 c
ha
ng
e
sgRNA:
0
0.2
0.4
0.6
0.8
1.0
1.2
R
el
at
iv
e 
fo
ld
 c
ha
ng
e
sgRNA:
Ct
rl.
Hi
t4
Hi
t1
47
Hi
t3
8
Hit4
0
20
40
60
80
100 Hit38 Hit4
0
20
40
60
80
100
0
20
40
60
80
100
0
20
40
60
80
100
Hit147 
p53 BS
region
p53 BS
region
p53 BS
region
Upstream
of p53
BS region
p53 BS
CEBPB BS
p53
CEBPB
CEBPB p53
p53CEBPB CEBPB
CEBPB
p53CEBPB CEBPB
1.00 0.06 0.41 0.44 0.30
−2
0
2
4
Se
n.
C
p5
3.
KO
T_
Hi
t1
47
T_
Hi
t4
T_
Hi
t3
8
F
ol
d 
ch
an
ge
 (
lo
g 2
)
FC
(Condition/SenC)
deCDKN1ACDKN1A
TSS
peCDKN1AdeCDKN1A
OIS
(p53)
p53 CEBPB p53
≈2.5 fold
a
e f
g
d
0 1 2 3 4 5
Hit147
Hit38
deCDKN1A WT
Hit4 region
deCDKN1A-Hit4 ext
deCDKN1A WT
0 2 4 6 8
pGL3_prom 
p53 BS
Untreated Nutlin-3a
Relative luciferase ratio
h
k
*****
** **
*
***
0
0.5
1.0
1.5
2.0
2.5
Ctrl. Hit4 Hit147 Hit38
Ctrl. Hit4 Hit147 Hit38
Ctrl. Hit4 Hit147 Hit38
Ctrl. Hit4 Hit147 Hit38
Ctrl. Hit4 Hit147 Hit38
Ctrl. Hit4 Hit147 Hit38
%
 o
f i
np
ut
 deCDKN1A
*
p53 IgG
n.s. n.s.
0
0.5
1.0
1.5
2.0
2.5
%
 o
f i
np
ut
 peCDKN1A
0
0.5
1.0
1.5
2.0
2.5
%
 o
f i
np
ut
 BER4
0
4
8
12
%
 o
f i
np
ut
 
deCDKN1A
0
4
8
12
%
 o
f i
np
ut
 
peCDKN1A
0
4
8
12
%
 o
f i
np
ut
 BER4
CEBPB IgG
CEBPB IgG
CEBPB IgG
p53 IgG
p53 IgG
i j
*
*** **
n.s.
n.s.
n.s.
CDKN1A
Figure 4 CRISPR-Cas9 tiling screen uncovers novel elements required for enhancer function. (a) Top panel, a snapshot of the genomic region 
surrounding deCDKN1A. Each black line indicates one sgRNA (total 197 sgRNAs covering ~2 kb). At the middle, the result of the CRISPR-deCDKN1A-
enhLib screen is shown. Enrichment score was calculated for each sgRNA based on the ratio between its (normalized) prevalence in the HRASG12V-
induced and control BJ cells. Blue, OIS-depleted sgRNAs; orange, OIS-enriched ones; green, sgRNAs targeting novel candidate regulatory elements; 
red, positive control sgRNAs that target the p53 binding site (BS). UCSC tracks of p53-ChIP and chromatin annotation are as in Figure 1e. HMEC, 
human mammary epithelial cell; NHLF, human lung fibroblast; ChromHMM, chromatin state segmentation by HMM; H3K4Me1, histone H3 lysine 4 
monomethylation; H3K4Me3, histone H3 lysine 4 trimethylation; H3K27Ac, histone H3 lysine 27 acetylation. (b) Top five hits from the tiling screen 
and their cumulative enrichment from three independent screens. (c) Light microscopy images of cells transduced with the indicated sgRNAs.  
(d) Sequencing spectrums of cleavage sites of top tiling screen hits. The spectrum of Hit38 was very narrow and resembled the one induced by Hit147 
that targets the p53 BS. The spectrum of Hit4 was dominated by a deletion of ~20 nt. As control, we also sequenced the p53 BS region in cells 
targeted with Hit4. As the cleavage induced by Hit4 is located outside this genomic interval, there was no marked peak in this region. (e,f) qRT-PCR  
of CDKN1A mRNA (e) and deCDKN1A-eRNA (f) of BJ-RASG12V cells transduced with the indicated sgRNAs, and treated as in Figure 2d. n = 3;  
***P < 0.005, **P < 0.01, *P < 0.05, two-tailed Student’s t-test. (g) RNA-seq result depicted as violin plots to show the distribution of p53  
targets genes in each condition. Blue diamond indicates average induction of p53 targets; red dot indicates the level of CDKN1A mRNA induction.  
(h) Luciferase assay of MCF-7 cells transfected with the indicated reporter vectors and induced with Nutlin-3a. The relative luciferase activities  
(firefly/Renilla) were normalized to the control reaction. All P-values for luciferase assay were calculated by Student’s t-test. (i,j) Bar graphs of p53  
(i) and CEBPB (j) binding at deCDKN1A, peCDKN1A and p53-BER4 regions by ChIP-qPCR. BJ-RASG12V cells were infected with either sgRNA targeting 
Ctrl or each newly identified sgRNAs and treated with tamoxifen (TAM) for 12–15 d. n = 3; n.s., not significant, ***P < 0.005, **P < 0.01, *P < 0.05, 
two-tailed Student’s t-test. (k) A schematic model showing that p53 binding at both distal and proximal (deCDKN1A and peCDKN1A, respectively) 
regions is required for sustained high level of CDKN1A, and for OIS. Error bars, mean ± s.d.
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To demonstrate the generalizability of our screening approach, we 
designed a dropout screen to identify novel ERα-bound enhancers. 
First, we selected two breast cancer cell lines (MCF-7 and T47D) that 
require ERα for cell proliferation, and one (MDA-MB-231) that lacks 
ERα expression. We generated a sgRNA library to target 73 ERα binding 
sites according to the strategy shown in Figure 3a (CRISPR-ERα- 
enhLib; Supplementary Table 3). For this library, we used eRNA 
expression measured by GRO-seq in MCF-7 cells as a criteria for 
active enhancers12. As positive controls, we included in the library 
three sgRNAs targeting the coding region of ERα. Accordingly, we 
transduced the three different cell lines with the CRISPR-ERα-enhLib 
and allowed the cells to proliferate for 20 d (Fig. 3b). After identifying 
the sgRNAs present in the cell populations, we ranked the hits by nega-
tive effect on cell proliferation and selected sgRNAs that were strongly 
depleted (at least 30%) in both MCF-7 and T47D compared to MDA-
MB-231 cells. Using these criteria, we identified two positive controls 
that target the ERα and three candidate sgRNAs (ERαenh588, ERαenh1830 
and ERαenh1986) that affect the proliferation of MCF-7 and T47D cells 
(Fig. 3c and Supplementary Table 4). We validated the candidates 
with a competitive proliferation assay in MCF-7 and MDA-MB-231 
cells (Fig. 3d). As expected, sgRNA-ERα reduced the proliferation of 
MCF-7 cells but had no effect on MDA-MB-231 cells. Remarkably, all 
three candidates identified in the screen also significantly decreased the 
proliferation of only MCF-7 cells. In contrast, two sgRNAs (ERαenh128 
and ERαenh257) that were not depleted in the screen, and a nontar-
geting sgRNA control, had no significant effect on cell proliferation. 
These results indicate that our CRISPR-Cas9 dropout screening 
approach is specific, and led to the identification of three novel 
enhancers that are required for breast cancer cell proliferation.
One of the validated candidates, ERαenh588, has not been endog-
enously characterized to date. A ChIA-PET (chromatin-interaction 
analysis by paired-end tag) study in MCF-7 cells has previously 
identified ERαenh588 as a hotspot for ERα binding20. Analyses of this 
data set showed that ERαenh588 interacts with the promoter region 
of Cyclin D1 (CCND1) (Supplementary Fig. 4a), suggesting that 
ERαenh588 is a putative regulator of CCND1 expression by ERα. 
CCND1 oncogene plays a central role in cell-cycle progression and 
is overexpressed in more than 50% of breast tumors21. We started by 
cloning ERαenh588 WT region in a reporter vector and verified that it 
has strong ERα–dependent transcription-enhancing activity, since 
mutations in the ERα binding site completely abolish the enhancer 
activity and response to 17β-estradiol (Supplementary Fig. 4b). Next, 
we examined endogenous ERα binding at ERαenh588 region by ChIP-
seq and observed a substantial decrease in both MCF-7 and T47D 
cells expressing sgRNA-ERαenh588 (Fig. 3e). Because CCND1 is a puta-
tive target of ERαenh588, we verified the endogenous expression of 
ERαenh588 eRNAs and CCND1 mRNA and protein in MCF-7 and T47D 
cells transduced with sgRNA-ERαenh588. Reassuringly, we found that 
the expression of eRNA, mRNA and protein is significantly decreased 
(P < 0.01; about twofold) in both cell lines (Fig. 3f–h). These results 
indicate that ERαenh588 is a bona fide enhancer element that regu-
lates the expression of CCND1. Next, we assessed the dependency of 
ERαenh588 and CCND1 endogenous expression on estrogen signaling 
by qPCR (Fig. 3i). As expected, we confirmed that both ERαenh588 
eRNA and CCND1 mRNA are upregulated in MCF-7 cells upon treat-
ment with 17β-estradiol. However, we found that sgRNAenh588 severely 
compromises the induction of eRNA expression and completely abol-
ishes CCND1 mRNA activation in MCF-7 cells. These results suggest 
that the activation of CCND1 expression by estrogen in breast can-
cer cells requires a fully active ERαenh588 enhancer element. Finally, 
as CCND1 is a crucial component of the G1-S phase transition, we 
examined the phenotypic outcome of disrupting ERαenh588 activity. 
Figure 3j shows that MCF-7 cells transduced with sgRNAenh588  
display a ~2.5-fold reduction in S-phase entry, compared to control-
transduced cells, due to decreased CCND1 expression.
The genetic code that enables enhancer activity is poorly understood. 
We reasoned that each enhancer is likely to contain multiple regulatory 
elements, and adopted CRISPR-Cas9 technology to pinpoint critical 
domains of enhancers. For that purpose, we performed a pooled high-
throughput genetic tiling screen to identify additional elements, apart 
from the p53 binding site, that are required for the p53enh3507 region 
to regulate CDKN1A expression and function in OIS.
We targeted a genomic region of ~2 kb centered at the p53 bind-
ing site of deCDKN1A (Fig. 4a). We identified protospacer-adjacent 
motifs (PAMs) within this region and designed a library of 197 
sgRNAs (CRISPR-deCDKN1A-Lib) that direct CRISPR-mediated 
cleavage every 10 bp on average (Supplementary Table 5). We per-
formed an OIS screen with the CRISPR-deCDKN1A-Lib following the 
same procedure described in Figure 1c, which identified five enriched 
sgRNAs (Fig. 4b and Supplementary Table 6). Three of the most-
enriched hits targeted the p53 binding site (Hit146, Hit147 and Hit34), 
and thus served as positive controls and as indicators of the robust-
ness of the assay. The other two hits, Hit4 and Hit38, targeted novel 
candidate regulatory domains located 0.9 kb upstream and 0.1 kb 
downstream of the p53 binding site, respectively (Fig. 4a, middle 
panel). For validation, we used individual sgRNAs and confirmed 
that Hit4 and Hit38, similarly to the positive control Hit147, caused 
bypass of OIS (Fig. 4c). We analyzed the spectrum of mutations gen-
erated by these two sgRNAs and verified that it was very similar to 
the one caused by sgRNAs that directly targeted the p53 binding site 
(Figs. 2i and 4d). Importantly, sgRNA-Hit4 and sgRNA-Hit38 
caused genomic alterations that did not overlap with the p53- 
binding site within this enhancer region, indicating that they disrupt 
other enhancer domains required for OIS (Fig. 4d).
To characterize the function of these two regulatory domains, we 
first examined the expression of CDKN1A mRNA and deCDKN1A 
eRNA in BJ-RASG12V cells transduced with sgRNA-Hit4 and sgRNA-
Hit38. We observed a significant (P < 0.005, and < 0.01; and P < 0.01 
and < 0.05, respectively) reduction in both mRNA (Fig. 4e) and eRNA 
(Fig. 4f) expression levels, which was similar in magnitude to that 
of the positive control sgRNA-Hit147. Gene expression profiling 
by RNA-seq also supported a specific effect of these two sgRNAs 
on CDKN1A expression (Fig. 4g). However, unlike mutations in 
the p53 binding site, deletion of the Hit4 or Hit38 region did not 
affect enhancer function in a reporter assay (Fig. 4h), suggesting that 
these domains only have a functional role in their endogenous con-
text. Next, we analyzed endogenous p53 binding to the deCDKN1A 
region using ChIP-qPCR. As expected, Hit147 significantly (P < 0.05) 
reduced p53 binding to this region, whereas both Hit4 and Hit38 had 
no significant effect (Fig. 4i). For this experiment, we used peCD-
KN1A and p53BER4 regions as negative controls (Fig. 4i). We used 
PROMO22 to identify transcription factors that potentially bind to 
these regulatory domains and identified a perfect matching consensus 
binding site for CEBPB at the cleavage site of Hit38 (Supplementary 
Fig. 5). In contrast, no putative transcription factor binding site was 
predicted for the Hit4 region. Accordingly, we analyzed endogenous 
CEBPB binding to deCDKN1A by ChIP-qPCR and observed a marked 
reduction in BJ-RASG12V cells transduced with sgRNA-Hit38 com-
pared to control cells (Fig. 4j). These results suggest that the DNA 
element targeted by sgRNA-Hit38 contributes to CEBPB recruitment 
to deCDKN1A and to its function in OIS (Fig. 4k). In addition, Hit147 
also decreased CEBPB binding, possibly due to an additional CEBPB 
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binding site located adjacent to the p53 binding site. Also, Hit4 had a 
weak but significant (P < 0.005, < 0.01 and < 0.05) effect on CEBPB 
binding at the deCDKN1A region (Fig. 4j). Finally, we tested whether 
Hit4 and Hit38 had a cooperative effect on CDKN1A expression but, 
unlike deCDKN1A and peCDKN1A, this proved not to be the case 
(Supplementary Fig. 3b, right panel). Altogether, our results indicate 
that a CRISPR-Cas9 tiling strategy can precisely pinpoint regulatory 
domains within enhancer regions.
In summary, we present CRISPR-Cas9–based screens to identify 
and characterize functional enhancers in human cells. In total, we 
identified six enhancer elements that potentially control cell prolifera-
tion, and characterized two of them in detail—one regulates CDKN1A 
activation during OIS and the other mediates CCND1 expression in 
response to ERα signaling (Figs. 2 and 3). We observed different rates 
of validation of candidates between the two genetic screens presented 
here, with the ERα-bound enhancer showing higher specificity. We 
speculate that this difference might be related to the intrinsic nature 
of the two screens (enrichment vs. dropout) or to the selection proce-
dure of candidates (selecting ERα-bound enhancers based on eRNA 
expression). Of note, none of the control candidates from either 
screen showed any phenotypic activity. This evidence suggests that 
our screening approach has comparable specificity and sensitivity to 
genetic screens of protein-coding genes  performed to present23.
Recently, a dCas9-LSD1 fusion has been proposed to annotate 
native enhancers24, yet the sensitivity and specificity of this tool has 
never been tested in large-scale genetic screens. Our method expands 
the utility of the CRISPR-Cas9 tool beyond the coding genome and 
can be applied to systematically identify functional enhancers bound 
by different sequence-specific transcription factors. At the present 
date, all CRISPR-Cas9–based systems require a PAM motif to direct 
DNA cleavage, and therefore cannot guarantee full coverage of the 
entire human genome. In our approach, about 90% and 60% of the 
candidate p53- and ERα-bound enhancers were targeted, respec-
tively, but this rate might be different for other transcription factors. 
However, the use of CRISPR-Cas9 nucleases with altered or reduced 
PAM specificities25 can increase the coverage of our approach to target 
enhancers in large-scale genetic screens. The selection of candidate 
enhancer regions for this study was based on ENCODE, ChIP-seq and 
GRO-seq data sets, but in principle our approach does not require 
prior data on transcription factor binding site. As an alternative, active 
enhancer regions can be detected by transcriptomic profiling of eRNA 
expression and targeted in an unbiased fashion using a CRISPR-Cas9 
tiling approach such as we present here and as others have recently 
demonstrated for  the enhancer of BCL11A26.
Our study shows that CRISPR-Cas9 technology is a robust tool to 
identify and characterize functional enhancers in an unbiased fash-
ion. We envision that our approach will be widely used to unravel the 
function of the noncoding portion of the human genome under both 
normal and pathological conditions.
MEthOdS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. GEO: GSE75627 (RNA-seq); GSE75779 (ChIP-seq).
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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ONLINE MEthOdS
Cell lines and chemical reagents. BJ-RASG12V, HEK293-T, MCF-7, T47D 
and MDA-MB-231 cells were cultured in DMEM medium (Gibco), supple-
mented with 10% FCS (Hyclone), and 1% penicillin/streptomycin (Gibco). 
For the estrogen-depletion experiment, MCF-7 cells were cultured in DMEM 
phenol red–free medium (Gibco) supplemented with charcoal stripped serum 
(Gibco). 17β-estradiol was obtained from Sigma. All cell lines were obtained 
from the American Type Culture Collection, and they have been tested for 
mycoplasma contamination.
CRISPR-enhancer library design. For the p53-bound enhancers screen, 
we first took the union of the results of five publicly available p53 ChIP-seq 
analyses to create a combined set of 4,237 genomic sites that were bound by 
p53 in at least one cell line (MCF-7, CAL51 or IMR90) and in response to at 
least one stress (Nutlin-3a, 5-FU, RITA or ionizing radiation)27,28. We then 
scanned these sites for occurrences of the p53-binding motif using the p53scan 
tool29 and found that 2,626 sites contained strong matches. To increase the 
chance that the candidate sites were functional ones, we intersected them with 
genomic locations of predicted enhancers in six different cell lines. These 
predictions, which are based on various histone marks, were downloaded 
from the UCSC Genome Browser (Broad ChromHMM track). 764 sites with 
a strong match for the p53-binding motif overlapped a predicted enhancer 
in at least one cell line. Last, we identified the sites that could be targeted by 
a CRISPR-Cas9 sgRNA that cleaves that DNA within the p53 binding motif, 
taking into account that Cas9 endonuclease cuts the DNA 3 nt upstream of 
the PAM (NGG). (In cases that p53scan tool predicted an occurrence of the 
p53 motif that contained a spacer, we required that the cleavage would be out 
of the spacer). Overall, we designed 1,116 sgRNA vectors that target the p53-
binding motif within 685 different genomic binding sites. For the ERα-bound 
enhancers, we took the top 2,000 ChIP-seq binding sites12 and identified the 
ERα consensus motif (up to one mismatch) in 740 of them. 406 of these sites 
could be targeted by the CRISPR-Cas9 system. As a further step to narrow 
down the candidate list and focus the screen on active enhancers, we inter-
sected these regions with eRNA expression measured by the same study using 
GRO-seq12. Overall, 73 enhancers met these three criteria: (i) ERα binding 
detected by ChIP-seq; (ii) ERα motif that could be targeted by CRISPR-Cas9; 
and (iii) bidirectional eRNA expression. These 73 enhancers were targeted by 
97 sgRNAs that comprise our CRISPR-ERα-enhLib. A list containing custom 
sgRNAs designed for this study can be found in Supplementary Table 7.
Pooled library cloning. We used standard de-salted DNA oligonucleotides, 
synthesized and purchased from IDT (Integrated DNA Technologies), to con-
struct sgRNA libraries for p53-bound enhancers (1,116 sgRNAs), ERα-bound 
enhancers (97 sgRNAs) and deCDKN1A (197 sgRNAs). Complementary sin-
gle-stranded oligos were phosphorylated and annealed by combining  100 µM 
oligos, 1× T4 PNK Buffer, 1 mM ATP, 5 U T4 PNK and incubating the reaction 
at 37 °C/30 min, 95 °C/5 min followed by a ramp down to 25 °C at  5 °C/min. 
Annealed oligos were pooled into three independent replicates (pool #1, #2, #3), 
diluted at 1:1,000 in sterile water, and ligated to plasmid vector lentiCRISPRv2 
(gift from Feng Zhang (Addgene plasmid #52961)) using the following param-
eters: 50 ng BsmBI (Fermentas) digested plasmid, 1 µl diluted oligo duplex, 
1× Ligation Buffer (Roche), 5 U T4 DNA Ligase (Roche) incubated at RT/30 min. 
We did five independent ligation reactions per pool, and used them to transform 
highly competent Escherichia coli cells (EletroSHOX -  Bioline, BIO-85038) 
according to the manufacturer’s protocol. In order to assess the complexity of 
our libraries, we plated 1 µl of cell transformation mixture on Luria-Bertani 
agar plates containing ampicillin, incubated them overnight at 37 °C, and 
counted individual bacterial colonies after 16 h. At this point, we estimated that 
each individual sgRNA is covered >100×, ensuring that our libraries have high 
complexity and are suitable for pooled screening. Transformation mixtures 
were combined, grew in liquid LB until  OD600 = 0.8 was reached, and plasmid 
DNA was harvested using Genopure Plasmid Maxi kit (Roche).
Lentivirus production, purification and transduction. To produce lentivirus, 
4 × 106 HEK293T cells per pool were seeded in ten 100-mm dishes 1 d before 
transfection. For each dish, we diluted 15 µg of CRISPR-enhancer plasmid 
library, 3.5 µg of pVSV-G, 5 µg of pMDL RRE and 2.5 µg of pRSV-REV in 450 µl 
of 0.1× TE/H2O, added 50 µl of CaCl2 and incubated 5 min at RT. Plasmid 
DNA was precipitated by adding 500 µl 2× HBS to the solution while vortex-
ing at full speed. The precipitate was added immediately to the plate and the 
cells were incubated for 14 h at 37 °C, after which the medium was refreshed. 
Lentivirus-containing supernatants were collected 60 h post-transfection, 
filtered through a 0.45 µm membrane (Milipore Steriflip HV/PVDF) and 
stored at −80 °C. All cell types and lentivirus batches tested were titrated in 
order to achieve a multiplicity of infection of 0.4–0.5. Cell lines were infected 
with lentivirus supernatants supplemented with 8 µg/ml polybrene (Sigma). At 
24 h post-infection, medium was replaced and cells were selected with 2 µg/ml 
puromycin (Gibco). Antibiotic selection was stopped as soon as no surviving 
cells remained in the no-transduction control plate.
CRISPR-Cas9 screen for OIS in BJ-RASG12V cells. In both OIS screens, we 
infected ~3,500 BJ-RASG12V cells per vector, to ensure that every sgRNA was 
present in the cell population at the start of the experiment. Cells infected 
with CRISPR-enhancer or nontargeting CRISPR library pools were allowed to 
proliferate for 48 h after antibiotic selection to clear potentially toxic sgRNAs 
from the population. At this time point, half of the cells infected with CRISPR-
enhancer library pools were harvested (T = 0), and the remaining cells were 
placed in culture and treated with 100 nM tamoxifen (4-hydroxytamoxifen, 
Sigma) to induce HRASG12V expression. Cells infected with CRISPR-enhancer 
and nontargeting CRISPR pools were allowed to proliferate, while we monitored 
them for senescence or continuous proliferation. After 4 weeks of treatment, 
we harvested cells infected with CRISPR-enhancer pools (T = 4 weeks). Cell 
pellets harvested at T = 0 and T = 4 weeks were stored at −80 °C, and processed 
later on for further analysis. The validation of individual hits identified in both 
screens was done following the same procedures described above. Enrichment 
scores were calculated by comparing the normalized frequency of each sgRNA 
vector present in the cell populations at T = 0 with T = 4 weeks.
CRISPR-Cas9 dropout screen in breast cancer cells. MCF-7, T47D and MDA-
MB-231 cells were infected with two independent pools of CRISPR-ERα-enhLib. 
We infected ~3,500 cells per vector, to ensure that every sgRNA was present in 
the cell population at the start of the experiment. Following antibiotic selec-
tion, cells were allowed to proliferate for 48 h to clear potentially toxic sgRNAs 
from the population. At this time point, we harvested half of the cells infected 
with CRISPR-ERα-enhLib pools (T = 0). The remaining cells were placed in 
culture, allowed to proliferate for 20 d, and then harvested  (T = 20). Cell pellets 
were stored at −80 °C, and processed later on for  further analysis. Enrichment 
(depletion) scores were calculated for each sgRNA vector, in each cell line 
(MCF-7, T47D and MDA-MB-231) by comparing its normalized frequency at 
T = 20 and T = 0 pools. Then the differences between these enrichment scores 
(in log2) were calculated for MCF-7 and T47D compared to MDA-MB-231 
cells (which serve as controls in the screen as they are not dependent on 
ERα). These “Delta enrichment scores” calculated for MCF-7 and T47D were 
averaged and standardized (Z-scores). For validation, we selected sgRNA 
vectors whose repressive effect on proliferation was at least 30% stronger in 
both MCF-7 and T47D cells compared to  MDA-MB-231 cells.
Genomic DNA sequencing to identify sgRNAs. Frozen cell pellets were 
thawed and genomic DNA (gDNA) was isolated with DNeasy Blood and 
Tissue kit (Qiagen). Identification of sgRNAs was done by PCR in two steps. 
For the first PCR, the amount of input gDNA was calculated to achieve >200× 
coverage over the CRISPR-enhancer libraries (assuming that 106 cells con-
tain 6.6 µg gDNA), which resulted in 2 µg for CRISPR-p53-enhLib, 200 ng 
for CRISPR-ERα-enhLib and 300 ng for CRISPR-deCDKN1A-Lib. For each 
sample, we performed two separate reactions (max. 1 µg gDNA per reac-
tion) using Phusion DNA polymerase (Thermo Scientific) and combined the 
resulting amplicons. In the first PCR, we used the following primer sequences 
to amplify lentiCRISPR-enhancer sgRNAs:
PCR1_F1
ACACTCTTTCCCTACACGACGCTCTTCCGATCTXXXXXXGGCTTTA
TATATCTTGTGGAAAGGACG (XXXXXX represents a 6-bp barcode)
PCR1_R1
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACTGACGGGC
ACCGGAGCCAATTCC
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A second PCR was performed to attach Illumina adaptors and index 
samples. The second PCR was done in 50-µl reaction volume, including 5 µl 
of the product from the first PCR, and using the following primers:
PCR2_P5
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC
GCTCTTCCGATCT
PCR2_P7
CAAGCAGAAGACGGCATACGAGATXXXXXXGTGACTGGAGTTCAG
ACGTGTGCTCTTCCGATCT (XXXXXX represents a 6-bp index).
Amplification was carried out with 18 cycles for both first and second PCR. 
After the second PCR, resulting amplicons were purified using Agencourt 
AMPure XP beads (Beckman Coulter), quantified in a Bioanalyzer 2100 
(Agilent), mixed and sequenced in a HiSeq 2500 (Illumina).
Identification of sgRNAs enriched in BJ-RASG12V cells. Based on deep 
sequencing of sgRNAs in BJ control and HRASG12V–induced populations 
(done in independent triplicates for each), we estimated the enrichment of 
each sgRNA vector in HRASG12V relative to control cells. This was done, by 
counting the number of reads corresponding to each sgRNA in each popula-
tion, normalizing these counts to 1 M and taking the ratio of the normalized 
counts between HRASG12V and control cells. We averaged these enrichment 
scores (in log2 scale) for each sgRNA over the triplicates, and, last, calculate 
Z-scores (Fig. 1c and Supplementary Table 1). (To avoid inflation of ratios 
calculated for sgRNAs with low read counts, counts below 20 were set to 20.)
Genomic DNA sequencing to identify CRISPR-induced mutations. Cell pel-
lets were collected and gDNA was isolated with DNeasy Blood and Tissue kit 
(Qiagen). Amplification of target regions for sequencing was done by PCR in 
two steps. For each sample, we used 500 ng of gDNA as input for the first PCR 
(done in duplicate). Resulting amplicons were combined and we used 5 µl as 
input for the second PCR. Amplification was carried out with 18 cycles for both 
first and second PCR. After the second PCR, amplicons were purified using 
Agencourt AMPure XP beads (Beckman Coulter), quantified in a Bioanalyzer 
2100 (Agilent), mixed and sequenced in a HiSeq 2500 (Illumina).
Competitive proliferation assay. MCF-7 and MDA-MB-231 cells were 
infected with indicated sgRNAs to validate the results of the CRISPR-ERα-
enhLib screen. Separately, we generated polyclonal MCF-7 and MDA-MB-
231 cells stably expressing GFP using pLX304-GFP30 (gift from David Root; 
Addgene plasmid # 25890). GFP expressing cells were mixed in a 1:3 ratio with 
cells containing individual sgRNAs. The percentage of GFP-expressing cells 
was assessed by flow cytometry at the beginning of the experiment (T = 0) and 
every 72 h onwards (T = 3 d and T = 6 d). For every condition, 10,000 events 
were recorded, and the data were analyzed using FlowJo software.
Western blot analysis. Whole-cell lysates were prepared as previously 
described31. Membranes were immunoblotted with the following antibodies: 
TP53 (DO-1, Santa Cruz; 1:1,000), CDKN1A (Sc-397, Santa Cruz; 1:1,000), 
HRAS (C-20, Santa Cruz; 1:1,000), Cyclin D1 (M-20, Santa Cruz; 1:1,000), 
HSP90 (H-114, Santa Cruz; 1:10,000), beta-Actin (C4, Santa Cruz, 1:10,000). 
Protein bands were visualized using corresponding secondary antibodies 
(Dako) and ECL reagent (GE Healthcare).
Senescence-associated b-gal assay. BJ-RASG12V cells were transduced 
with  lentiCRISPRv2 constructs, selected with puromycin, plated in triplicate 
and treated for 15 d with 100 nM 4-OHT to induce HRASG12V expression. 
β-galactosidase  activity was determined with Senescence β-galactosidase 
staining kit (Cell Signaling), and at least 100 cells were analyzed for  each 
condition.
BrdU proliferation assays. Cells were pulsed for 3 h with 30 µM bromo-
deoxyuridine (BrdU, Sigma), fixed with ethanol (70% solution), permea-
bilized, treated with NaOH to denature DNA, incubated with anti-BrdU 
(GE Healthcare), washed in blocking buffer (PBS, Tween 0.05%, 2% BSA), 
and finally incubated with anti-rabbit AF488 secondary antibody (Dako). 
BrdU incorporation was measured either by immunofluorescence (at least 
200 cells were scored for each condition) or by flow cytometry (10,000 
events were recorded for each sample). Flow cytometry data were analyzed 
using FlowJo software.
Luciferase reporter assays. Sense and antisense region of deCDKN1A and 
peCDKN1A were PCR amplified from gDNA of BJ-RASG12V cells whereas 
ERαenh588 was amplified from MCF-7 cells. All regions were cloned into 
pGL3-promoter vector. Constructs were transfected into MCF-7 cells and 
treated with 8 µM Nutlin-3a (Cayman Chemical), 10−8 M 17β-estradiol 
(Sigma) or vehicle for 30 h. Reporter activity was measured 36 h after transfec-
tion using Dual-Luciferase system (Promega) according to the manufacturer’s 
instructions.
RNA isolation, reverse-transcription and quantitative real-time PCR 
(qPCR). Total RNA was extracted using TRIsure (Bioline) reagent and fol-
lowing the manufacturer’s protocol. cDNA was produced with SuperScript III 
(Invitrogen) using 5 µg of total RNA per reaction. qPCR reaction was 
performed with SYBR green I Master mix in a LightCycler 480 (Roche). 
TATA-binding protein (TBP) was used as an internal control. Primers used in 
qPCR are listed in Supplementary Table 7.
GRO-seq. GRO-seq was performed as described before with minor modifica-
tions. Briefly, 5 × 106 nuclei were isolated and incubated 5 min at 30 °C with 
equal volume of reaction buffer (10 mM Tris-Cl pH 8.0, 5 mM MgCl2, 1 mM 
DTT, 300 mM KCL, 20 units of SUPERase In, 1% sarkosyl, 500 µM ATP, GTP 
and Br-UTP, 0.2 µM CTP+32P CTP) for the nuclear run-on. The reaction was 
stopped and total RNA was extracted with Trizol LS (Invitrogen) according 
to the manufacturer’s instructions. RNA was fragmented using fragmenta-
tion reagents (Ambion) and the reaction was purified through p-30 RNase-
free spin column (BioRad). BrU-labeled RNA was immunoprecipitated with 
anti-BrdU agarose beads (Santa Cruz), washed one time in binding buffer, one 
time in low salt buffer (0.2× SSPE, 1 mM EDTA, 0.05% Tween-20), one time 
high-salt buffer (0.25× SSPE, 1 mM EDTA, 0.05% Tween-20, 137.5 mM NaCl) 
and two times in TET buffer (TE with 0.05% Tween-20). RNA was eluted 
with elution buffer (20 mM DTT, 300 mM NaCl, 5 mM Tris-Cl pH 7.5, 1 mM 
EDTA and 0.1% SDS) and isolated with Trizol LS. After the binding step, 
BrU-labeled RNA was treated with tobacco acid pyrophosphatase (TAP, 
Epicenter) to remove 5′-methyl guanosine cap, followed by T4 polynucle-
otide kinase (PNK; NEB) to remove 3′-phosphate group. BrU-containing RNA 
was treated with T4 PNK again at high pH in the presence of ATP to add 
5′-phosphate group. The reaction was stopped and RNA was extracted with 
Trizol LS. Sequencing libraries were prepared using TruSeq Small RNA kit 
(Illumina) following manufacturers instructions. Briefly, end-repaired RNA 
was ligated to RNA 3′ and 5′ adapters, followed by RT-PCR amplification. cDNA 
was purified using Agencourt AMPure XP (Beckman Coulter) and amplified 
by PCR for 12 cycles. Finally, amplicons were cleaned and size-selected using 
Agencourt AMPure XP (Beckman Coulter), quantified in a Bioanalyzer 2100 
(Agilent), and sequenced in a HiSeq 2500 (Illumina). Sequenced reads were 
aligned to the human genome (hg19) using bowtie2 (ref. 32).
RNA-seq. RNA-seq samples were processed with TruSeq RNA library prep kit 
v2 (Illumina) and sequenced in a HiSeq 2500 (Illumina). Sequenced reads were 
aligned to the human genome (hg19) using TopHat2 (ref. 33) and gene expression 
counts were calculated using HTseq34 based on Ensembl’s human gene annota-
tions (v69)35. Expression levels were normalized using quantile normalization.
ChIP. BJ-RASG12V (5 × 106) cells were fixed with 1% formaldehyde at RT/8min 
and quenched with 125 mM glycine for 5 min on ice. The cells were centri-
fuged at 470g/10 min and resuspended in 300 ml of cold lysis buffer (50 mM 
Tris-HCl, pH 8.0, 10 mM EDTA and 1% SDS) supplemented with protease 
inhibitor cocktail (Roche). The suspension was sonicated for 20 min (30 s 
on/off at maximum power) and diluted with 800 ml of dilution buffer (10 mM 
Tris-HCl, pH 7.5, 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA and 1% Triton 
X-100). The lysate was centrifuged at 14,000 r.p.m./10 min and the soluble 
fraction was transferred to a new tube. For each reaction, 100 ml of chromatin 
preparation was diluted in 300 ml of dilution buffer and incubated overnight 
with indicated antibody amount at 4 °C on a rotator. To each ChIP reaction, 
30 ml of protein A/G beads, previously blocked (PBS/BSA (0.1%) for 1 h), 
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was added and incubated 3 h at 4 °C. The immuno-precipitated chromatin was 
washed 2 × 5 min with dilution buffer and 1 × 5 min with TE (50 mM Tris-HCl 
pH 8.0 and 10 mM EDTA) and eluted overnight in 300 ml elution buffer (20 mM 
Tris-HCl pH 7.5, 5 mM EDTA, 50 mM NaCl and 1% SDS) at 65 °C in an 
orbital shaker. Eluted samples were purified using QIAquick PCR purifica-
tion kit (Qiagen) and analyzed by real-time qPCR. The following antibodies 
and amounts were used in this experiment: 3 µg p53 (DO-1, Santa Cruz), 
3 µg C/EBP beta (C-19, Santa Cruz). Primers used in ChIP-qPCR are listed 
in Supplementary Table 7.
ChIP-sequencing data analysis. Sequencing reads were aligned to the 
human genome (hg19) using bwa v 0.7.5 with default parameters. Number 
of aligned reads per sample can be found in Supplementary Table 5. Peaks 
in control MCF-7 and T47D cell lines were called with MACS36 (default 
parameters) and DFilter37 (parameters: −bs = 50 −ks = 30 −refine −nonzero) 
algorithms. In-house MCF-7 mixed input was used for peak calling of MCF-7 
cell line; T47D input from a previous study38 was used for calling T47D data. 
Intersect of the two peak calling algorithms was used for further analysis. 
27020 and 6702 ERα peaks were detected in MCF-7 and T47D cell lines, 
respectively.
27. Botcheva, K., McCorkle, S.R., McCombie, W.R., Dunn, J.J. & Anderson, C.W. 
Distinct p53 genomic binding patterns in normal and cancer-derived human cells. 
Cell Cycle 10, 4237–4249 (2011).
28. Rashi-Elkeles, S. et al. Parallel profiling of the transcriptome, cistrome, and epigenome 
in the cellular response to ionizing radiation. Sci. Signal. 7, rs3 (2014).
29. Smeenk, L. et al. Characterization of genome-wide p53-binding sites upon stress 
response. Nucleic Acids Res. 36, 3639–3654 (2008).
30. Yang, X. et al. A public genome-scale lentiviral expression library of human ORFs. 
Nat. Methods 8, 659–661 (2011).
31. Agami, R. & Bernards, R. Distinct initiation and maintenance mechanisms cooperate 
to induce G1 cell cycle arrest in response to DNA damage. Cell 102, 55–66 (2000).
32. Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. 
Nat. Methods 9, 357–359 (2012).
33. Kim, D. et al. TopHat2: accurate alignment of transcriptomes in the presence of 
insertions, deletions and gene fusions. Genome Biol. 14, R36 (2013).
34. Anders, S., Pyl, P.T. & Huber, W. HTseq--a Python framework to work with high-
throughput sequencing data. Bioinformatics 31, 166–169 (2015).
35. Cunningham, F. et al. Ensembl 2015. Nucleic Acids Res. 43, D662–D669 (2015).
36. Zhang, Y. et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 
(2008).
37. Kumar, V. et al. Uniform, optimal signal processing of mapped deep-sequencing 
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Supplementary Figure 1
Light microscopy images of cell populations transduced with the indicated sgRNA vectors. 
(a, b and c) Images were taken after 15 days of HRASG12V induction. 
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Supplementary Figure 2
p53enh3508 region exhibits a p53-dependent enhancer activity that is required for OIS activation. 
(a) Senescence induction was quantified using senescence-associated β-gal assay. (b) MCF-7 cells 
were transfected with the indicated vectors, treated with Nutlin-3a 5-10 hours later, and harvested 25-
30hr after treatment. The relative luciferase activities (Firefly/Renilla) were normalized to the Ctrl 
reaction. (All p-values for luciferase assay were calculated by Student’s t-test. * indicates the 
significance relative to empty vector; # indicates the significance relative to untreated matching 
sample). (c) The same assay as in panel b, only that cells were co-transfected with control, or p53-
targeting siRNAs. A reporter vector containing the enhancer region p53-BER420 was used as a 
positive control for p53-dependency. The efficiency of p53 knockdown was determined by 
immunoblot analysis. (All p-values for luciferase assay were calculated by Student’s t-test. * indicates 
the significance relative to empty vector). 
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Supplementary Figure 3
deCDKN1A contains key enhancer elements that regulate OIS in a p53-dependet fashion.
(a) The same cell extracts as in Figure 2g were blotted with an antibody against HRAS. (b) qRT-PCR 
analysis of CDKN1A mRNA levels performed with the indicated BJ-indRASG12V cell populations 
following induction of RASG12V. (n=3; *P<0.05, two-tailed Student’s t-test). (c) MCF-7 cells were 
transfected with the indicated reporter vectors, treated with Nutlin-3a 5-10 hours later, and harvested 
25-30 hours later. The relative luciferase activities (Firefly/Renilla) were normalized to the Ctrl 
reaction. (d and e)  The same cell populations as in b panel were subjected to BrdU labeling and β-
gal assays to assess proliferation and OIS, respectively. N=2; for each condition at least 150 cells 
were count. *P<0.05, two-tailed Student’s t-test. (f) Western blot analysis of BJ-indRASG12V CDKN1A 
KO and control cells. P53 and HSP90 were used as controls.  
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Supplementary Figure 4
ER enh588 regulates CCND1 activity in an estrogen-dependent manner.
(a) Screenshot of ChIA-PET analysis in MCF-7 cells showing a strong chromatin interaction between 
enh588 and CCND1 promoter. (b) MCF-7 cells were seeded with charcoal-treated medium and 
transfected with the indicated reporter vectors. 16 hours later the medium was refreshed and either 
supplemented or not with 17β-estradiol. 24 hours later cells were harvested and luciferase activity 
was measured. The relative luciferase activities (Firefly/Renilla) were normalized to the Ctrl reaction. 
(c) Complete blot shown in Figure 3h. 
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Supplementary Figure 5
Results of PROMO analyses are shown for regions surrounding the p53 BS and Hit38. 
The p53 BS and the sgRNA-Hit38 targeting region are indicated, and the sequences representing 
potential CEBPB binding are underlined. 
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Chapter 5 
CUEDC1 is a primary target of ER that is essential for the 
growth of breast cancer cells 
Manuscript in preparation
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Abstract
Breast cancer is the most prevalent type of malignancy in women, and each year ~1.7 million new cases 
are diagnosed. Nearly 70% of breast tumors express ER (ESR1), which is a ligand-dependent 
transcription factor (TF) that activates the expression of critical genes involved in cell proliferation (e.g. 
CCND1 and MYC). The main treatment of ER-positive breast cancer is based on hormonal therapies 
(e.g. tamoxifen and aromatase inhibitors), which aim to inhibit the activity of ER in cancer cells. Despite 
the extensive use of these drugs, a substantial number of tumors relapse after initial treatments and 
eventually patients develop resistance to therapy. Importantly, ChIP-seq experiments revealed that the 
vast majority of ER binding events map to regions that have features of enhancer elements. Moreover, it 
was found that ER controls the expression of ~3,000 genes and ~1200 enhancers in breast cancer cells. 
This evidence underlines the great challenge of identifying the direct target genes of ER and 
understanding their contribution to the proliferation of cancer cells. Recently, we performed genetic 
screens to identify enhancers that are required for the growth of ER-positive breast cancer cells. We 
validated several candidates, including a putative enhancer located in the first intron of CUEDC1. Here, 
we show that CUTE (CUEDC1 Transcriptional Enhancer) is a ER-responsive enhancer that controls the 
expression of CUEDC1 in breast cancer cells. Moreover, genetic alterations in CUTE decrease the 
expression of CUEDC1 and reduce the proliferation of cancer cells. Finally, the expression of CUEDC1 is 
increased in ER-positive tumors and this is associated with poor clinical outcome of cancer patients. 
Altogether, our work suggests that CUEDC1 is a primary target gene of ER and a potential biomarker of 
human breast cancer. 
Introduction 
Breast cancer is the most prevalent type of malignancy in women, and each year ~1.7 million new cases 
are diagnosed1. Approximately 70% of breast tumors express ER (ESR1), which is a ligand-dependent 
transcription factor (TF) that plays a critical role in cell proliferation2. ER is activated by estradiol (E2), 
which is its natural ligand, or through phosphorylation events mediated by kinases such as MAPK/PI3K2. 
ER is a ligand-dependent TF that is recruited directly or indirectly to the chromatin, in order to activate 
the expression of its target genes3. The current treatment of ER-positive breast cancer is mainly based 
on hormonal therapies, which either compete with E2 for binding to ER (e.g. tamoxifen)4 or prevent the 
synthesis of E2 (e.g. aromatase inhibitors)5. Despite the extensive use of these drugs, a substantial 
number of tumors relapse after initial treatments and patients develop resistance to therapy6. 
ER regulates the expression of several genes that play a central role in the development of 
breast cancer, including CCND1, E2F1 and MYC7. ChIP-seq experiments revealed that the vast majority 
of ER binding events map to regions that are distantly located from gene promoters and have features 
of enhancer elements8,9. Enhancers are non-coding regulatory elements that control gene expression in 
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space and time, which is essential for specifying different cell-lineages during the development of 
organisms10. Therefore, it is not surprising that genetic alterations in enhancers are associated with the 
development of cancer11,12. Genome-wide mapping of nascent RNA by GRO-seq identified ~1200 
enhancers that express eRNAs upon activation of ER in breast cancer cells13,14. eRNA expression is a 
hallmark of active enhancer elements15-18 and there is abundant evidence suggesting that these 
transcripts are required for the activation of target genes of ER13,14. The studies mentioned above 
contributed to elucidate the mode of action of ER and provided a comprehensive map of its binding sites 
throughout the genome8,13,14. However, they are inherently descriptive and do not fully explain the 
function and mechanisms of ER-regulated enhancers. Moreover, it is not clear which are the primary 
target genes of ER and how they contribute to the proliferation of breast cancer cells. Therefore, 
answering these questions is critical to elucidate the role of ER in gene regulation, and to improve 
current diagnosis and therapies of breast cancer. 
Traditionally, it is challenging to study the function of enhancers due to a lack of genetic tools to 
manipulate them in a high-throughput manner. The development of CRISPR-Cas9 systems opened 
exciting possibilities for targeted genome editing. Of note, Cas9 can be directed to virtually any genomic 
sequence by a single guide RNA (sgRNA), provided that there is a protospacer adjacent motif (PAM) 
downstream of the target sequence19. Cas9 is a nuclease that efficiently induces double-strand breaks 
(DSBs), which give rise to small insertions and deletions when repaired by non-homologous end joining 
(NHEJ). Cas9 is capable of cleaving multiple target sequences in parallel20,21, making it particularly 
suitable to perform genome-wide genetic screens22,23. Recently, we and others pioneered the application 
of CRISPR-Cas9 to map functional regulatory elements in human cells24-27. In our work, we performed 
genetic screens to identify enhancers that are required for the growth of ER-positive breast cancer 
cells25. We validated several candidate hits from the screen, including a putative enhancer located in the 
first intron of CUEDC1 (CUE Domain Containing 1) – a poorly characterized gene that was not previously 
associated with breast cancer. Here, we show that CUTE (CUEDC1 Transcriptional Enhancer) is a bona
fide enhancer that activates CUEDC1 expression in response to ER signaling. The inactivation of CUTE 
by genetic alterations decreases the expression of CUEDC1 and reduces the proliferation of cancer cells. 
Finally, we found that the expression of CUEDC1 is significantly increased in ER-positive tumors and 
this is associated with poor clinical outcome of cancer patients. Altogether, our work suggests that 
CUEDC1 is a primary target gene of ER that is required for the growth of breast cancer cells in vivo.  
Results 
To study the function of CUTE, we started by analyzing the genomic landscape around its locus. CUTE is 
located in the first intron of CUEDC1 (Fig. 1A; yellow vertical line), and this region is predicted to be an 
enhancer in different human cell-types according to ENCODE data (Fig. 1B; yellow and orange colors). In 
MCF7 cells (ER-positive), the CUTE locus is marked by high H3K27Ac and low H3K4me3 levels (Fig. 
1C). This pattern of histone modifications is indicative of enhancers and often used to annotate this type 
of elements28,29. The H3K27Ac signal spans over 8 kb and encompasses three DNase I-hypersensitive 
sites (DHSs) (Fig. 1C). Of note, the DNase I signal overlapping with CUTE is increased upon treatment 
with E2 (Fig. 1C), suggesting that it is an ER-responsive regulatory element. In line with this, we 
detected transcription of eRNAs by GRO-seq in MCF7 cells (Fig. 1D). Importantly, the expression of 
eRNAs in MCF7 cells is increased upon activation of ER14, whereas in MDA-MB-231 (ER-negative) 
they are not detectable (Fig. 1D). Finally, we observed that the binding of ER at CUTE overlaps with 
p300 (Fig. 1E), which is a coactivator protein that is often found at enhancers30. Altogether, these results 
suggest that CUTE is a putative enhancer regulated by ER in breast cancer cells.  
Enhancers are known to activate gene expression regardless of their orientation relative to the 
target gene31. To address this point, we cloned a DNA fragment containing CUTE (~1 kb), in forward and 
reverse orientations, into pGL3-promoter vector. We transfected these constructs into MCF7 cells and 
observed a strong activation of luciferase activity (~8 fold; P-value<0.001) independently of the orientation 
of CUTE (Fig. 2A). Next, we tested the responsiveness of CUTE to estrogen activation by transfecting the 
constructs into MCF7 cells and treating them with E2. We observed a significant increase (~30 fold; P-
value<0.001) in the activity of luciferase (Fig. 2B), which indicates that the enhancing capacity of CUTE is 
dependent of ER. To test this hypothesis, we generated mutations in the estrogen-responsive element 
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(ERE) of CUTE using CRISPR-Cas9 gene editing (Fig. 2C). We observed that the transcriptional activity 
of CUTE is severely compromised by small deletions (<10 bp) in its ERE (Fig. 2B,C), thereby confirming 
that CUTE is a bona fide enhancer regulated by ER. 
As mentioned above, we identified CUTE as a putative enhancer in a previous CRISPR-Cas9 
screen25 (candidate sg1830). Here, we transduced MCF7 cells with sg1830, which targets the ERE of 
CUTE (Fig. 3A), and performed targeted DNA-seq of this region to assess the effects of CRISPR-Cas9 
editing (Fig. 3B). We observed that the vast majority of deletions generated by Cas9 are small (<5 bp) 
and map to the expected cleavage site (Fig. 3B). Next, we measured the binding of ER by ChIP-seq in 
WT (sgCtrl) and mutant (sg1830) MCF7 cells to test the specificity of CRISPR-Cas9 targeting. 
Remarkably, the binding of ER is only decreased at the CUTE locus (e1830) in mutant MCF7 cells 
(Pearson = 0.92; P-value = 0) (Fig. 3C). Of note, two known EREs (e588 and e1896)25 were not affected 
by sg1830 (Fig. 3C). It is known that the binding of ER is frequently associated with FOXA1, and this is 
thought to be required for the activation of target genes of estrogen32. Interestingly, FOXA1 binding to 
CUTE was also decreased in MCF7 cells expressing sg1830 (Pearson = 0.94; P-value = 0) (Fig. 3D). 
These results suggest that the disruption of ER binding causes loss of FOXA1, which can affect the 
enhancing activity of CUTE. Consistent with this hypothesis, we found that the activating histone mark 
H3K27Ac is significantly decreased at the CUTE locus in mutant MCF7 cells (Pearson = 0.96; P-value = 
0) (Fig. 3E). Our results indicate that sg1830 specifically impairs the binding of ER to CUTE, which may 
compromise the function of this enhancer. 
The identification of functional enhancers and their target genes is a major challenge in the field 
of transcriptional research33. Here, we combine multiple techniques and analyzes to identify the target 
gene of CUTE in breast cancer cells. First, we reanalyzed chromatin interactions identified by ChIA-PET 
and found that CUTE interacts with several regions nearby CUEDC1 (Fig. 4A). Interestingly, the 
interactions with the promoter of CUEDC1 involve both ER and RNAPII (Fig. 4A), suggesting that they 
might be functional. Then, we performed RNA-seq in WT and mutant MCF7 cells in order to identify 
genes regulated by CUTE. We analyzed changes in gene expression in the vicinity of CUTE (+/- 500 kb) 
and found that CUEDC1 is the most downregulated gene in mutant MCF7 cells (Fig. 4B). We confirmed 
by qPCR analysis that the expression of CUEDC1 is significantly decreased in mutant MCF7 cells (~70%; 
P-value<0.01) (Fig. 4C). On the other hand, CUEDC1 expression was not affected by sg1830 in MDA-
MB-231 cells (Fig. 4C), suggesting that CUTE is active in ER-positive cells. In line with this, the 
expression CUTE eRNAs is decreased in mutant MCF7 but not in mutant MDA-MB-231 cells (Fig. 4D). 
Next, we reanalyzed publicly available GRO-seq data of MCF7 cells treated with E2 in order to identify 
genes regulated by ER. We focused our analysis on the CUTE locus (+/- 500 kb), and identified 
CUEDC1 as the most upregulated gene upon ER activation (Fig. 4E). We validated these results by 
performing a time-course experiment in MCF7 cells treated with E2. We found that the expression of 
CUEDC1 is significantly increased (~2.5 fold) already 4h after E2 treatment and remains relatively stable 
over the course of 24 h (Fig. 4F), indicating that CUEDC1 is a primary target gene of ER. The 
expression of eRNAs transcribed from CUTE follow a similar pattern in MCF7 cells (Fig. 4F), supporting 
the notion that CUTE is responsive to ER. So far, our results suggest that CUTE mediates the activation 
of CUEDC1 expression through ER. In order to test this hypothesis, we treated WT and mutant MCF7 
cells with E2 and measured the expression of CUEDC1 by qPCR. Reassuringly, we found that the 
induction of CUEDC1 expression by E2 was severely compromised in mutant MCF7 cells (Fig. 4G), 
thereby confirming that CUTE is an enhancer of CUEDC1 in breast cancer cells. 
We showed previously that the mutation of CUTE by CRISPR-Cas9 (sg1830) is associated with 
decreased growth of MCF7 cells25. Given that CUTE is an enhancer of CUEDC1, we hypothesized that 
this gene is required for cell growth mediated by ER. Indeed, we observed a significant decrease in the 
proliferation of MCF7 cells transduced with two different sgRNAs targeting the coding sequence of 
CUEDC1 (sgCUEDC1 exon#1 and exon#2) (Fig. 5A). These effects seem to be specific since two 
sgRNAs targeting a different intron of CUEDC1 (sgCUEDC1 intron#1 and intron#2) did not cause 
substantial effects on cell growth (Fig. 5A). Of note, the sgRNAs targeting CUEDC1 (sgCUEDC1 exon#1 
and exon#2) phenocopy the disruption of CUTE (sg1830) (Fig. 5A), suggesting that this gene is required 
for the growth of MCF7 cells. Indeed, we found that the ectopic expression of CUEDC1 in mutant MCF7 
cells completely rescues the proliferative defect caused by the mutation of CUTE (Fig. 5B,C). 
Our results demonstrate that CUEDC1 is a target gene of ERthat is essential for the 
proliferation of MCF7 cells. If this holds true in vivo, the expression of CUEDC1 should be associated in a 
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positive manner with ER expression in breast tumors. To test this hypothesis, we reanalyzed breast 
cancer samples (n=759) from TCGA and found that CUEDC1 expression is significantly higher in ER-
positive than in ER-negative tumors (P-value = 10-10) (Fig. 6A). Moreover, the expression of CUEDC1 is 
positively correlated with ER expression in breast tumors (R = 0.3; P-value = 10-7) (Fig. 6B). These 
results indicate that CUEDC1 might be essential for the growth of breast cancer cells in vivo. Finally, we 
evaluated the prognostic value of CUEDC1 expression for the clinical outcome of breast cancer patients. 
For this purpose, we reanalyzed publicly available data corresponding to 1,809 samples34 and found that 
elevated CUEDC1 expression is associated with decreased overall survival (HR = 1.04) (Fig. 6C) and 
distant metastasis-free survival (HR = 1.16) (Fig. 6D), although these trends are not statistically 
significant. Importantly, high expression of CUEDC1 predicts worst relapse-free survival for patients (HR 
= 1.25; P-value = 0.0001) (Fig. 6E), suggesting that CUEDC1 is a potential biomarker of resistance to 
breast cancer therapy.  
Discussion 
The identification of direct target genes of ER is a fundamental question in current breast cancer 
research35. Genome-wide analysis using GRO-seq identified ~3,000 protein-coding genes that are 
regulated by estrogen in breast cancer cells17. This number is substantially higher than what was 
previously determined using expression microarrays, and corresponds to ~33% of all expressed genes in 
MCF717. Despite these advances, it is not clear which are the direct targets of this pathway since ER 
mostly binds to distal enhancer elements8,9. Recently, we showed that functional enhancers can be 
annotated in an unbiased manner by CRISPR-Cas9 screens25,36. Moreover, we demonstrated that 
combining genome editing with differential gene expression analysis is a powerful method to identify the 
target genes of enhancers. Here, we applied our strategy to characterize CUTE and found multiple 
evidence suggesting that it is an enhancer is responsive to estrogen and regulates the expression of 
CUEDC1 in breast cancer cells: first, the binding of ER to CUTE in MCF7 cells is increased upon 
treatment with E2 (Fig. 1E); second, mutations in the ERE of CUTE specifically decrease the binding of 
ER in this region (Fig. 3C); third, long-range chromatin interactions between CUTE and the promoter of 
CUEDC1 involve ER(Fig. 4A); fourth, the activation of CUEDC1 expression by estrogen is totally 
dependent on the ERE (Fig. 4G); finally, the expression of CUEDC1 is positively correlated with ER 
expression in breast tumors (Fig. 6A,B).  
Our findings suggest that CRISPR-Cas9 has high specificity of targeting at enhancer elements. 
This is supported by ChIP-seq data showing that the binding of ER is specifically decreased at CUTE by 
sg1830 (Fig. 3C). The fact that a single locus is affected by CRISPR-mediated gene editing is quite 
remarkable since ER binds to tens of thousands of EREs across the genome37. We observed similar 
effects at additional ER-regulated enhancers in multiple breast cancer cell lines25, further supporting the 
application of CRISPR-Cas9 to characterize transcriptional enhancers in situ36. We observed that the loss 
of ER binding is associated with decreased binding of FOXA1 and H3K27Ac at the CUTE locus in 
mutant MCF7 cells (Fig. 3D,E). FOXA1 is a pioneer factor that is required for ER-mediated gene 
regulation32, whereas H3K27Ac is a mark frequently associated with active enhancers28,29. Additionally, 
the expression of eRNAs is decreased in mutant MCF7 cells (Fig. 4D), suggesting that the activity of 
RNAPII is impaired. We conclude that ER is an essential component of CUTE since the disruption of 
binding causes loss of enhancer-associated marks and decreased transcriptional activity. However, we 
cannot rule out that there are additional sequences, besides the ER binding site, which are critical for 
the activity of CUTE. This question can be addressed by saturation mutagenesis experiments using 
CRISPR-Cas9, which allow dissecting regulatory DNA sequences at near-nucleotide resolution24,25,27. 
The concept of “super-enhancers” has been recently proposed to describe regulatory elements 
that drive exceptionally high levels of transcription38-40. Super-enhancers typically comprise a cluster of 
regulatory elements, spanning up to 12.5 kb, which exhibit highly synergistic activities41. Our results 
suggest that CUTE is a strong enhancer in human cells: in reporter assays, it is able to activate gene 
expression in a robust manner (~30 fold upon ER activation) (Fig. 2B); and genetic alterations in its 
sequence cause a dramatic reduction in CUEDC1 expression (~70%) (Fig. 4C). Interestingly, we noted 
that the CUTE locus fulfils the bioinformatic criteria of super-enhancers38: extended signal of H3K27Ac 
(~8 kb), multiple DHSs located in close proximity (~4kb) and active transcription by RNAPII (Fig. 1). 
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Moreover, the two DHSs in the vicinity of CUTE are also bound by cell-type-specific TFs (e.g. FOXA1, 
GATA3; data not shown) and co-activator p300 (Fig. 1E). Given the available evidence, it is tempting to 
speculate that these DHSs are enhancers that collaborate with CUTE to regulate the expression of 
CUEDC1. However, further experiments (e.g. deletion of each constituent element) are required to clarify 
whether they are functional elements and if they act as a super-enhancer of gene expression42,43. 
To date, not much is known about the biological functions of CUEDC1, though available evidence 
points in the direction of the ubiquitin pathway. CUE domains are sequences of ~40 amino acids that bind 
monoubiquitin in yeast and human44 and regulate chain formation by E3 ligases45. Interestingly, CUEDC1 
was recently identified in a proteome-wide screen for ubiquitin interactors46. Zhang and colleagues 
showed that CUEDC1 binds to K33 and K63 diubiquitin in different human cell-types, suggesting that it 
might be involved in protein trafficking, signal transduction and degradation pathways47. The connection 
of CUEDC1 to cancer is thinner, although its expression is significantly upregulated in metastatic cervical 
tumors compared to primary tumors48. In conclusion, our work revealed that CUEDC1 is a direct target 
gene of ERthat is essential for the growth of cancer cells (Fig. 5B), and suggest that it is a potential 
biomarker of human breast cancer. 
Figures 
Figure 1 CUTE is a putative enhancer element regulated by ER. (A) RefSeq genes track from NCBI showing the 
genomic location of CUTE (yellow vertical line). (B) Chromatin State Segmentation by a hidden Markov model from 
ENCODE/Broad in eight human cell-types. Color code: yellow/orange - enhancer; green - active transcription; blue - 
insulator; grey - low signal. (C) ChIP-seq (H3K27Ac and H3K4me3) and DNase-seq (Vehicle and E2) data of MCF7 
cells. (D) GRO-seq data of MCF7 and MDA-MB-231 cells. The two bottom tracks display GRO-seq data of MCF7 
cells treated with vehicle and E214. Sequencing reads mapping to the sense and antisense DNA strands are 
displayed as positive and negative values, respectively. (E) ChIP-seq of ER
E2. The bottom track corresponds to ChIP-seq data of p300 in MCF7 cells. 
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Figure 2 The transcriptional activity of CUTE is dependent of ER. (A) MCF7 cells were co-transfected with Renilla 
and pGL3-based vectors and luciferase activities were measured after 48h. The SV40 enhancer (pGL3-SV40) was 
used as a positive control in this assay. The relative luciferase activities (Renilla/firefly) were normalized to pGL3-
empty.  Data represent mean ± s.d of n = 3. ***P < 0.001, two-tailed Student’s t-test relative to pGL3-empty. Fw, 
forward. RV, reverse. (B) MCF7 cells were co-transfected with Renilla and pGL3-based vectors and treated with 
vehicle or E2 for 24h. The relative luciferase activities (Renilla/firefly) were normalized to pGL3-empty vehicle. Data 
represent mean ± s.d of n = 3. ***P < 0.001, two-tailed Student’s t-test relative to pGL3-empty vehicle. (C) Schematic 
representation of pGL3-CUTE constructs used in reporter assays. The mutant sequences of CUTE (mut. #4 and #6) 
were generated by CRISPR-Cas9 gene editing in MCF7 cells, amplified by PCR and cloned into pGL3-promoter. 
 
Figure 3 The specific disruption of ER binding by sg1830 is associated with loss of FOXA1 and H3K27Ac binding at 
the CUTE locus. (A) Schematic representation of the targeting of CUTE by CRISPR-Cas9 (sg1830). (B) DNA-seq 
profile of the CUTE locus (100 bp) in MCF7 cells stably expressing sg1830. The prevalence of deletions that occurred 
at each position within this interval was calculated relative to the total number of reads that contained any deletion. 
(C-E) ChIP-seq of ER(C), FOXA1 (D) and H3K27Ac (E) in WT (sgControl) and mutant (sg1830) MCF7 cells. e588 - 
ERE 588. e1830 - ERE 1830. e1986 - ERE 1986. CPM, counts per million.
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Figure 4 CUTE is an ER-responsive enhancer that regulates the expression of CUEDC1 (A) ChIA-PET data of ER 
and RNAPII in MCF7 cells. Violet arcs represent long-range chromatin interactions that are statistically significant. (B) 
RNA-seq was performed in MCF7 cells transduced with sgCtrl (WT) and sg1830 (Mut). Differential expression 
analysis was restricted to genes located -/+ 500 Kb of CUTE. ACTB was used as a negative control. (C, D) Analysis 
of CUEDC1 mRNA (C) and CUTE eRNA (D) expression by qPCR in WT (sgCtrl) and mutant (sg1830) MCF7 and 
MDA-MB-231 cells. Gene expression levels are normalized to TBP. Data represent mean ± s.d of n = 3. **P < 0.01, 
two-tailed Student’s t-test relative to MCF7 sgCtrl (E) GRO-seq data of MCF7 cells treated with vehicle (Veh) and 
estradiol (E2). Differential expression analysis was restricted to genes located -/+ 500 Kb of CUTE. ACTB was used 
as a negative control. (F) Analysis of CUEDC1 mRNA (solid bars) and CUTE eRNA (striped bars) expression by 
qPCR in MCF7 cells treated with vehicle (Veh) or estradiol (E2). Gene expression levels are normalized to TBP. Data 
represent mean ± s.d of n = 3. **P < 0.01., two-tailed Student’s t-test relative to Vehicle-4 h (G) Analysis of CUEDC1 
mRNA expression by qPCR in WT (sgCtrl) and mutant (sg1830) MCF7 cells treated with vehicle (Veh) or estradiol 
(E2). CUEDC1 expression levels are normalized to TBP. Data represent mean ± s.d of n = 3. **P < 0.01, two-tailed 
Student’s t-test relative to sgCtrl-Vehicle. n.s., non-significant. 
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Figure 5 CUEDC1 is required for the growth of MCF7 cells. (A) MCF7 cells were transduced with the indicated 
sgRNAs and allowed to proliferate for nine days. Cell growth is represented as percentage of GFP, which is 
normalized to the beginning of the experiment (T = 0). Data represent mean ± s.d of n = 3. **P < 0.01. ***P < 0.001.  
n.s., non-significant. Two-tailed Student’s t-test relative to sgCtrl. (B) MCF7 cells were sequentially transduced with 
the indicated sgRNAs and with pLX304-empty or pLX304-CUEDC1. The cells were allowed to proliferate for nine 
days and their growth is represented as percentage of GFP (normalized to T = 0). Data represent mean ± s.d of n = 
3. ***P < 0.001.  n.s., non-significant. Two-tailed Student’s t-test relative to sgCtrl-empty. (C) Western blot analysis of 
MCF7 cells expressing pLX304-empty and pLX304-CUEDC1. The V5 tag was used to detect expression of CUEDC1. 
HSP90 was used as a loading control.  
Figure 6 CUEDC1 expression is significantly increased in ER-positive tumors and associated with poor clinical 
outcome of breast cancer patients. (A) The expression of CUEDC1 was analyzed in breast tumor samples (n = 759; 
data available on TCGA), which were grouped according to ESR1 status (positive or negative). ***P < 0.001 (B) The 
expression of CUEDC1 and ESR1 in breast tumor samples (n = 402; data available on TCGA) was used to calculate 
correlation coefficients (R). R = 0.3; P-value = 10-7. (C-E) The prognostic value of CUEDC1 expression for overall 
survival (C), distant metastasis-free survival (D) and relapse-free survival (E) of breast cancer patients was analyzed 
using the Kaplan-Meier plotter tool34. The survival curve, hazard ratio (HR) with 95% confidence intervals and logrank 
P-values are displayed. 
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Methods 
Cell lines and chemical reagents. MCF7, MDA-MB-231 and HEK293T cells were cultured in DMEM 
(Gibco), supplemented with 10% FCS (Hyclone), and 1% penicillin/streptomycin (Gibco). For the 
estrogen-stimulation experiments, MCF7 cells were cultured in DMEM phenol red–free medium (Gibco) 
supplemented with 5% charcoal stripped serum (Gibco) for 72h prior to E2 treatment. E2 (17β-estradiol) 
was purchased from Sigma. All cell lines were obtained from the American Type Culture Collection, and 
they were tested for mycoplasma.  
 
Cloning of sgRNAs. Custom sgRNAs were designed using CRISPR Design tool (http://crispr.mit.edu/) 
and cloned into lentiCRISPRv2 (gift from Feng Zhang (Addgene plasmid #52961) according to the 
protocol described by the Zhang lab49. The oligos were purchased from IDT and their sequences are 
listed on Table 1. 
 
Transduction of human cell lines. To produce lentivirus, 3 x 106 HEK293T cells were seeded in 100 
mm dishes one day prior to transfection. For each dish, we mixed 10 μg of the target lentiviral construct, 
3.5 μg of pVSV-G, 5 μg of pMDL RRE and 2.5 μg of pRSV-REV in a total volume of 450 μl, added 50 μl 
of CaCl2 and incubated 5 min at RT. Plasmid DNA was precipitated by adding 500 μl 2x HBS to the 
solution while vortexing at full speed. Lentivirus-containing supernatants were collected 48h post-
transfection, filtered through a 0.45 μm membrane (Milipore Steriflip HV/PVDF) and stored at −80 °C. All 
cell types and lentivirus batches tested were titrated in order to achieve a multiplicity of infection (MOI) of 
~0.3. Cell lines were infected with lentivirus supernatants supplemented with 8 μg/ml polybrene (Sigma). 
At 24 h post-infection, medium was replaced and cells were selected with 2 μg/ml puromycin (Gibco) until 
there were no cells surviving on the negative control plate (non-transduced cells). 
 
DNA-seq. Cell pellets were collected and gDNA was isolated with DNeasy Blood and Tissue kit (Qiagen). 
For each sample, we used 500 ng of gDNA as input for the first PCR. We used 5 μl of PCR product as  
input for the second PCR. Amplification was carried out with 18 cycles for both first and second PCR. 
After the second PCR, amplicons were purified using Agencourt AMPure XP beads (Beckman Coulter), 
quantified in a Bioanalyzer 2100 (Agilent), and sequenced using a HiSeq 2500 (Illumina). 
 
RNA isolation, reverse transcription and qPCR. RNA was harvested using TriSure (Bioline) reagent for 
cell lysis and Rneasy mini kit (Qiagen) to isolate total RNA according to the manufacturer’s protocols. 
cDNA was produced from RNA using Superscript III (Invitrogen). qPCR experiments were performed in a 
Lightcycler 480 (Roche) using SensiFAST SYBR (Bioline) according to the manufacturer’s protocol. The 
primers used for this experiment are listed on Table 2.  
 
Western blot. Whole-cell lysates were prepared as previously described25. Membranes were 
immunoblotted with the following antibodies: V5 (ab27671, Abcam); HSP90 (H-114, Santa Cruz 
Biotechnology). Protein bands were visualized using corresponding secondary antibodies (Dako) and 
ECL reagent (GE Healthcare). 
 
Cell proliferation assay. MCF7 cells were transduced with lentiCRISPRv2 containing sgRNAs of interest 
(listed on Table 1). Separately, we generated MCF7 cells stably expressing GFP using pLX304-GFP (gift 
from David Root; Addgene plasmid #25890). GFP-expressing cells were mixed with cells containing 
individual lentiviral constructs in a 1:3 ratio. The percentage of GFP-expressing cells was assessed by 
flow cytometry at the beginning of the experiment (T = 0) and at subsequent time-points. We recorded at 
a minimum of 10,000 events for each condition, and the data were analyzed using FlowJo software. 
 
Luciferase reporter assays. A DNA fragment (~1 kb) containing CUTE (hg19 assembly- 
chr17:55,976,833-55,977,839) was amplified by PCR from gDNA of MCF7 cells and cloned into pGL3-
promoter using KpnI/NheI. The constructs were transfected into MCF-7 cells and treated with 10−8 M E2 
or vehicle (DMSO) for 24 h. Reporter activity was measured 40 h after transfection using Dual-Luciferase 
system (Promega) according to the manufacturer’s instructions. 
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RNA-seq. RNA-seq samples were processed with TruSeq RNA library prep kit v2 (Illumina) and 
sequenced in a HiSeq 2500 (Illumina). Sequenced reads were aligned to the human genome (hg19) 
using TopHat250 and gene expression counts were calculated using HTseq34 based on Ensembl’s 
human gene annotations (v69)51. Gene expression levels were normalized by quantiles. 
 
ChIP-seq experiments and data analysis. ChIP-seq of ER, FOXA1 and H3K27ac in WT and mutant 
MCF7 cells were performed as described before52 using the following antibodies: ER (SC-543; Santa 
Cruz Biotechnology); FOXA1 (SC-6554; Santa Cruz Biotechnology); H3K27ac (39133; Active Motif). 
Sequencing reads were aligned to the human genome (hg19) using bwa v 0.7.5 with default parameters. 
Peaks in control MCF7 cells were called with MACS36 (default parameters) and DFilter37 (parameters: 
−bs = 50 −ks = 30 −refine −nonzero) algorithms. In-house MCF7 mixed input was used for peak calling of 
MCF7 cell line. Intersect of the two peak calling algorithms was used for further analysis. ChIP-seq data 
sets of ER-Vehicle and ER-E2 in MCF7 cells was obtained from GEO. The raw files were aligned to 
hg19 using Bowtie53. Unique reads were converted into bigWig files using BEDTools54 for visualization in 
the UCSC Genome Browser. 
 
ChIA-PET data. ChIA-PET data (publicly available on the Washington University Epigenome browser) of 
ER and RNAPII in MCF7 cells was reanalyzed to identify long-range chromatin interactions at the CUTE 
locus.  
DNase-seq data. DNase-seq data sets from the ENCODE project were reanalyzed to identify open 
chromatin regions at the CUTE locus. Available tracks were uploaded to the UCSC genome browser for 
visualization.  
 
GRO-seq experiments and data analysis. GRO-seq experiments in MCF7 and MDA-MB-231 cells were 
performed as described before25. We also used publicly available GRO-seq data of MCF7 cells treated 
with E2 that was obtained from14. Data points were downloaded from the UCSC genome browser using 
table browser. Transcription levels were quantified by calculating of the sum of data points per gene and 
normalizing to their length.  
 
Analysis of gene expression and patient survival in breast tumor samples. The Regulome Explorer 
tool (explorer.cancerregulome.org) was used analyze the expression of CUEDC1 in breast tumor samples 
from TCGA (ID: BRCA). The prognostic value of CUEDC1 expression was analyzed in publicly available 
breast cancer datasets using the Kaplan-Meier plotter tool (probe 219468_s_at)34. 
 
Table 1. Sequences of sgRNAs 
Name Oligo 1 (forward) Oligo 2 (reverse) 
sg1830 caccgtttacagcattggtaaggtc  aaacgaccttaccaatgctgtaaac  
sgCUEDC1 exon#1  caccgaccacatgcacgtgttcgac  aaacgtcgaacacgtgcatgtggtc  
sgCUEDC1 exon#2 caccgtaggctggcggggagtacac  aaacgtgtactccccgccagcctac  
sgCUEDC1 intron#1  caccgtaacaagagtttgaactgcg aaaccgcagttcaaactcttgttac 
sgCUEDC1 intron#2 caccgtaaggcttgaggtcaacgat aaacatcgttgacctcaagccttac 
 
Table 2. Primers used for qPCR experiments 
CUEDC1 Forward aaggaactgcaacggaacc 
CUEDC1 Reverse ggattcgtatttcaatcgatctct 
CUTE Forward acaccagcttcctggttcc 
CUTE Reverse ctgaggtccttccctgcac 
TBP Forward ggagagttctgggattgtac 
TBP Reverse cttatcctcatgattaccgcag 
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Chapter 6 
General discussion 
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Genome-wide mapping of regulatory elements by GRO-seq
At present date, putative regulatory elements are commonly identified through a variety of biochemical, 
genetic and evolutionary methods1. High-throughput biochemical techniques include ChIP-seq2,3, DNase-
seq4 and MPRA5,6. However, they have important limitations that restrict their application in identifying 
regulatory elements. For example, ChIP-seq requires high-affinity antibodies for TFs or histone 
modifications, and must be performed separately for each target. On the other hand, high-throughput 
reporter assays like STARR-seq are able to identify elements that are inactive in situ because they are 
independent of native chromatin context7. In recent years, it became clear that active regulatory elements 
are transcribed by RNAPII8-10. We describe a detailed protocol of GRO-seq in chapter 3, which is a 
variant of nuclear run-on assays coupled with NGS. This technique has high sensitivity and allows 
detection of transcribed regions that are not readily identified by measuring steady-state RNA levels8. 
GRO-seq can be used for identifying unannotated transcripts that are responsive to signaling cues, which 
is a significant advantage for detecting novel regulatory RNAs11-18. In our work, we used GRO-seq to 
identify genome-wide transcriptional changes mediated by p5319. As expected, we observed activation of 
several canonical target genes of p53 (e.g. CDKN1A), as well as known eRNAs regulated by p5320. 
Bioinformatic analysis identified 50,502 putative enhancers, of which 6,270 were differentially transcribed 
upon p53 activation. The intersection of GRO-seq and ChIP-seq data resulted in the identification of 
enhancers that are regulated by p53. Surprisingly, we also found a large group of p53-activated 
enhancers that were not associated with binding of p53. The regulatory mechanisms of many of these 
regions remain elusive, and further studies are required to elucidate whether they have a biological 
function in the p53 pathway. 
GRO-cap is a variant of the original GRO-seq method that includes an enrichment step for 5′-
capped RNAs, which further improves the sensitivity and specificity to detect nascent RNAs21. 
Nonetheless, both GRO-seq and GRO-cap rely on the assumption that active regulatory elements are 
transcribed - which is a major limitation of these techniques18. According to GRO-seq data the number of 
active regulatory elements in a given cell-type is in the order of tens of thousands11-13,15,16,19. This 
estimation is in agreement with ChIP-seq and DNase-seq data22-25, although there is great variability 
between studies likely due to cell-type specificity. Of note, active regulatory elements identified by GRO-
seq are also enriched in H3K27Ac, binding of TFs and eQTLs18, suggesting they are actively involved in 
transcriptional regulation. The proportion of the human genome assigned to candidate biological functions 
varies markedly among the different approaches, with estimates from biochemical studies being 
considerably larger than those of genetic and evolutionary analysis1,26,27. These contradictory results 
highlight the importance of integrating different approaches and developing new high-throughput 
technologies to characterize the functional DNA elements of the human genome. 
The role of eRNAs in gene regulation 
In chapter 4, we used GRO-seq to measure eRNA expression and infer the location of enhancers in a 
genome-wide scale28. This approach is supported by evidence from different studies showing that eRNA 
expression is a robust and independent indicator of enhancer activity10,13,15,29-32. For example, transcribed 
enhancers exhibit higher levels of chromatin accessibility, binding of transcriptional coactivators and 
active histone marks15,29,31,33 compared to non-transcribed enhancers. Additionally, enhancers that 
produce eRNAs are more likely to display transcriptional activity in reporter assays than non-transcribed 
enhancers10. It was also shown that transcriptional regulatory elements can be predicted solely through 
eRNA expression without using chromatin marks18,21. These results illustrate the predictive power of 
eRNA expression for annotating enhancers, and also support a role for these transcripts in gene 
regulation. 
Data from different studies suggest that there are ~40,000-65,000 eRNAs10,34, which constitutes a 
large faction of transcription events in human cells35.  Still, it is unclear what is the biological significance 
of enhancer transcription and how eRNAs contribute to the activation of gene expression. To date, 
several mechanisms were proposed to answer these questions, including regulation of chromatin 
accessibility36, TF binding37, RNAPII loading36,38 and pause release39. There is also evidence supporting a 
role for eRNAs in the initiation or maintenance of enhancer-promoter looping13,40. However, several 
studies found no effect on enhancer-promoter interactions upon knockdown of eRNAs20,39 or chemical 
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inhibition of RNAPII elongation15. Moreover, the contribution of eRNAs to the recruitment of mediator and 
cohesin remains elusive. These conflicting results might reflect different mechanisms at specific 
enhancers and target genes, and prompt further studies to clarify the role of eRNAs in DNA looping. This 
question can be addressed by performing tethering experiments using dCas9-eRNA fusions and 
assessing enhancer-promoter interactions. Future studies should also aim at identifying the protein 
partners of functional eRNAs41,42 in order to obtain detailed biochemical insights into their mechanisms of 
action.     
Another open question in the field is whether eRNAs activate transcription in cis or in trans. The 
fact that eRNAs are (1) usually lowly expressed, (2) predominantly act on neighboring genes and (3) 
mainly localize to the nucleus supports the cis hypothesis. Li et al. performed ChIRP-seq of an estrogen-
induced eRNA (FOXC1-eRNA), but failed to identify any target genes in trans13. However, there are 
several examples of lncRNAs (e.g. Jpx43 and NeST44) that activate their targets in trans, suggesting that 
this might also be the case for eRNAs. Indeed, two studies found that depletion of eRNAs (KLK3-eRNA 
and DRR-eRNA) affected the expression of multiple genes, some of which were located in different 
chromosomes36,45. Both KLK3-eRNA and DRR-eRNA are polyadenylated whereas FOXC1-eRNA is not, 
leading to the hypothesis that eRNAs with relatively high stability can function in trans. This is supported 
by knockdown experiments of enhancer-like lncRNAs, which affected the expression of hundreds of 
genes46. It should be stressed that none of the eRNA functions mentioned above has been proved to be 
independent of the enhancer sequence. Therefore, additional evidence from imaging experiments (e.g. 
single-molecule RNA labeling), genetic manipulation (e.g. RNAi and CRISPR-Cas9) and functional 
assays (e.g., tethering eRNAs to target loci) is required to confirm that these transcripts act in trans.      
What are super-enhancers? 
Genome-wide profiling of H3K27Ac and H3K4me1 identified a putative new class of regulatory elements 
termed “super-enhancers”. These regions are bound by the Mediator complex, span ~5-50 kb in length 
and are flanked by CTCF-binding sites47,48. According to this definition, there are more than 200 super-
enhancers in the human genome, and most of them seem to be associated with critical developmental 
genes47. Since the term was initially proposed in 2013, hundreds of studies were published about the 
function of super-enhancers in different cell-types and biological settings49. Yet, it is not clear whether 
they constitute a novel paradigm in gene regulation50. It is possible that super-enhancers have a similar 
function to the previously identified LCR and GCR, which coordinate the expression of linked genes in 
specific cell-types. In fact, the LCRs of -globin and -globin are strikingly similar to super-enhancers: 
they contain several enhancers, each bound by multiple TFs51,52, and fit the bioinformatics criteria for 
super-enhancers53. Recent studies addressed the question of how the constituent elements of a super-
enhancer contribute to activate the expression of a target gene. Hay et al. deleted individual constituents 
within the -globin super-enhancer and found that they act independently and in an additive manner to 
regulate gene expression53. Shin et al. used a similar approach to characterize the WAP super-enhancer 
and found that its individual constituent enhancers have partially redundant roles54. Mathematical 
modeling of these two datasets53,54 indicates that individual enhancers contribute to the activity of a 
super-enhancer in a linear function55. Altogether, these studies found no evidence of novel functional 
properties of super-enhancer regions: each element seems to contribute to gene expression as an 
individual enhancer in an additive rather than synergistic manner. 
According to the super-enhancer model, these elements confer stronger activation of gene 
expression compared to “typical” enhancers47,48. Moorthy et al. performed a systematic comparison 
between enhancers and super-enhancers by deleting tens of loci in mouse ESCs. They found that 
deletion of super-enhancers resulted in highly variable effects on the expression of target genes 
(decreased levels ranging from 12% to 92%). Moreover, a substantial number of highly transcribed genes 
in ES cells are not associated with a super-enhancer56. In chapter 4 and 5, we studied the contribution of 
individual enhancers to gene expression by generating mutations in their genetic sequence. In all cases, 
we observed a strong reduction in the expression of their targets (>50%), some of which are known 
tumor-suppressor genes and oncogenes (e.g. CDKN1A and CCND1). Despite not fitting the criteria of 
super-enhancers, these enhancers mediate a strong activation of gene expression and are required for 
critical phenotypes in human cells such as senescence and G1/S transition. Based on available evidence, 
it seems that enhancers and super-enhancers have an equivalent role in the regulation of single or 
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multiple genes56. Moreover, the super-enhancer model likely ignores a large number of functional 
enhancers in human cells, and exaggerates the importance of clustered enhancers compared to isolated 
enhancers. 
Identification of disease-causal mutations in the non-coding genome 
In chapter 4, we studied the function of a distal enhancer of CDKN1A (deCDKN1A) by mutating it with 
CRISPR-Cas9 system. In reporter assays, the transcriptional activity of deCDKN1A is completely 
abolished by single-nucleotide deletions within the p53-binding motif. This result goes against the well-
established notion that enhancer sequences redundant and robust to small mutations57, and suggests 
that single-nucleotide alterations can markedly influence gene expression by changing the activity of 
regulatory elements. This hypothesis is supported by data of GWAS, which identified a large number of 
SNPs that are associated with cancer and other common diseases58. However, the functional outcome of 
mutations in enhancer elements can differ substantially from that of mutations in protein-coding genes. 
Mutations in enhancers are largely constrained to effects in cis, whereas mutations in protein-coding 
sequences can alter several aspects of gene regulation - mRNA processing, stability and translation, or 
even protein structure and activity59. In addition, the impact of genetic alterations in regulatory elements is 
predicted to have less detrimental effects than those in protein-coding genes since their activity is often 
restricted in space and time60. Nonetheless, both germline variants and somatic mutations in enhancers 
have been causally linked with a range of human diseases58,61. It is worth noting that the impact of 
germline and somatic alterations in gene expression can differ substantially. Usually, germline variants 
modify the binding affinity of TFs and change mildly the activity of enhancers. This can lead to increased 
risk of cancer development, without affecting the fitness of the entire organism. In contrast, somatic 
mutations do not have to be carried through the germline and, therefore, can have a much greater impact 
on gene expression. This is illustrated by the identification of mutations in enhancers that activate proto-
oncogenes and drive cancer development62.  
The majority of genetic alterations in enhancers was identified by targeted DNA sequencing after 
their function has been characterized; or otherwise, by the identification of large deletions or 
rearrangements that were subsequently shown to involve enhancer elements. These approaches are 
relatively inefficient compared with exome sequencing, which is very successful in detecting recurrent 
mutations in protein-coding genes. The large amount of evidence that is required to assert causality to a 
non-coding variant remains a great challenge in biomedical research. In recent years, the application of 
whole-genome sequencing led to the discovery of recurrent mutations in regulatory elements in different 
types of tumors63, and this tendency is likely to increase as the costs of NGS technologies continue to 
fall64. However, as in classic Mendelian diseases involving protein-coding, it is possible to implicate a 
non-coding variant by combining multiple lines of evidence, including human genetics (e.g. fine mapping, 
trans-ethnic studies) and functional studies (e.g. reporter assays, genome editing). Ultimately, the goal is 
not solely to determine which variants are causal, but also to understand the genetic pathways they 
regulate and harness this knowledge to develop more efficient therapies. 
A clash of titans: RNAi vs CRISPR-Cas9
The success of RNAi technologies is illustrated by more than ninety thousand studies published since the 
discovery of gene silencing in C. elegans 65,66. RNAi reagents can be used to target both coding and non-
coding RNAs and produce knockdown of gene expression. However, they frequently yield false-negative 
results due to inefficient knockdown of the target RNA. In addition, the high prevalence of off-target 
effects, where additional genes are unintentionally perturbed, leads to false-positive results. Such issues 
are the most probable cause of poor reproducibility between RNAi screens67, and considerable effort has 
been made to improve both methods and reagents. For example, current shRNA libraries contain many 
independent constructs (up to 25) targeting each gene68. In this way, it is possible to overcome limitations 
of individual reagents to identify high-confidence candidates by pooling the results of each of them. 
Nevertheless, working with ultra-complex libraries is a very laborious process and requires performing 
extensive follow-up analyses to identify the most robust candidates. In chapter 4 and 5, we relied 
extensively on CRISPR-Cas9 to study both protein-coding genes and non-coding regulatory elements. In 
contrast to RNAi, CRISPR-Cas9 reagents often generate loss-of-function mutations in the target cells69-72. 
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Moreover, they circumvent a major limitation of RNAi libraries due to the capacity of Cas9 to induce stable 
and heritable mutations on target DNA sequences. The fact that Cas9 can be targeted to virtually any 
genomic sequence makes CRISPR systems very suitable to the function of regulatory elements73. We 
and others have used CRISPR-Cas9 to disrupt the genetic sequence of enhancers and screen for various 
phenotypes (e.g. cell proliferation28 and drug resistance74). Alternatively, CRISPR systems based on 
fusions of dCas9 with activator (e.g. p30075,76) or repressor (e.g. KRAB77,78) molecules can be used to 
perform gain-of-function or loss-of-function studies, respectively. The ability to perform gain-of-function 
experiments, such as activation of enhancers by dCas9-p30075,76, is a major advantage of CRISPR 
compared to RNAi systems. Nevertheless, both siRNA and shRNA are invaluable tools to target 
transcripts derived from regulatory regions, such as lncRNAs46 and eRNAs13,20. To date, there are no 
large-scale RNAi libraries available to perform genetic screens of lncRNAs or eRNAs. The systematic 
manipulation of regulatory elements by CRISPR and RNAi tools can elucidate the functions and 
mechanisms of non-coding DNA sequences and their transcripts.  
Recent studies have systematically compared the performance of shRNA and sgRNA libraries in 
genetic screens. One of them concluded that CRISPR-Cas9 reagents have higher consistency and lower 
off-target effects compared to RNAi 79. The other concluded that both technologies perform similarly, 
although it was noted that CRISPR-Cas9 identified many more essential genes using a much smaller 
library80. It is clear that both RNAi and CRISPR-Cas9 technologies have sensitivity and specificity issues, 
but the combination of both screening methods can better discriminate positive from negative control 
genes. Indeed, parallel genome-wide knockdown and knockout screens were successfully used to probe 
the mechanism of action of anti-viral drugs81. These results demonstrate that the combined application of 
both technologies is more powerful than either alone because each method identifies only a subset of 
relevant genes81. This suggests that combining RNAi and CRISPR-Cas9 can be a valuable method for 
screening complex phenotypes, such as the identification of therapeutic targets or developmental 
processes.  
A major limitation of current CRISPR-Cas9 systems is the requirement of a specific PAM, 
immediately downstream of the target site, for efficient gene editing82,83. The most widely used system is 
the type II CRISPR from S. pyogenes which requires the presence of a PAM in the form of NGG. As a 
result, it is often difficult to target DSBs with precision for specific genome editing applications like HDR 
and non-coding genetic screens. The work described on chapter 4 clearly illustrates this problem, as we 
were able to target only a fraction of p53- and ER-bound enhancers (90% and 60%, respectively)28. The 
number of TF binding sites that are targetable by Cas9 can be even lower for DNA motifs poor in C/G 
nucleobases (e.g. GATA3 and FOXA1). Two main strategies have been used to broaden the targeting 
range of Cas9: engineering of CRISPR systems from bacterial species that have different PAM 
requirements than S. pyogenes84-86; and altering the PAM requirements of Cas9 proteins by directed 
molecular evolution87,88. Recently, Cpf1 was identified as an additional type II CRISPR endonuclease that 
requires a TTN PAM89,90, providing an attractive alternative to target T-rich sequences. Moreover, Hirano 
et al. created a variant of F. novicida Cas9 that recognizes a shorter and less stringent PAM (YG)91. The 
identification or creation of novel nucleases that require smaller PAMs will dramatically increase the 
applications of CRISPR systems and broaden the scope of genome-wide genetic screens.  
Towards a comprehensive identification of functional regulatory elements in the human genome 
The identification of functional enhancers and their target genes is a major challenge in the post-Human 
Genome Project era. In chapter 4, we showed that it is possible to identify enhancers and characterize 
their function in an unprecedented scale. We started by identifying putative enhancers through histone 
marks, eRNA transcription and TF binding. This yielded a confident set of candidate enhancers that are 
active in a specific biological setting. Second, we built CRISPR-Cas9 libraries to screen putative 
enhancers in a high-throughput fashion. This allowed us testing multiple enhancers and their contribution 
to a specific phenotype. Of note, this approach proved to be successful in identifying functional enhancers 
in both enrichment and dropout genetic screens. Finally, we used differential gene expression profiling by 
RNA-seq to identify the targets of each enhancer. The usefulness of this method is highlighted in chapter 
5, where we characterized the regulation of CUEDC1 expression by ER. In MCF7 cells, ERbinds to 
more than 14,000 loci92 and regulates the expression of ~3,000 protein-coding genes15. These genome-
wide studies revealed that ER regulates gene expression by binding mostly to distal enhancers. 
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However, they cannot elucidate the function of these enhancers nor pinpoint the primary targets of 
estrogen. Therefore, it is not surprising that only a few number of genes was shown to be required for 
ER-mediated cell proliferation (e.g. CCND1 and MYC)93. We identified CUTE in a CRISPR-Cas9 screen 
for enhancers that are essential for the proliferation of ER-positive cells28. Following the steps 
mentioned above, we found that ER activates the expression of CUEDC1 through CUTE. CUEDC1 is a 
fairly unknown gene and not much is known about its biological functions so far. Our work revealed that 
CUEDC1 is required for cell proliferation mediated by ER and is a potential biomarker of breast cancer. 
These findings highlight the power of genetic manipulation by CRISPR-Cas9 to determine the function of 
regulatory elements and genes that were previously uncharacterized. 
It is worth noting that our work is a proof-of-concept that has intrinsic limitations. For example, the 
first step of our approach relied on the assumption that enhancers contain specific genetic and epigenetic 
marks, such as TF binding motifs and histone modifications. Therefore, we likely missed candidate 
enhancers simply because they did not contain these features. This limitation is underlined by the findings 
of Rajagopal et al., which identified active regulatory elements that are not marked by known biochemical 
features94. Additionally, the design of sgRNAs is constrained by the availability of PAMs in the target loci. 
The magnitude of non-coding CRISPR-Cas9 screens performed to date is far from comprehensive, as 
they were confined to regions of ~2 kb to ~1 Mb and tested the function of a few thousand candidates73. 
The identification of all regulatory elements in the human genome is a monumental task, which will 
probably require technological improvements (e.g. tools to efficiently generate large deletions), increased 
speed of screening (e.g. using robotics) and, most importantly, collaborative work between different 
research institutes (e.g. a large research consortium like the Human Genome Project). The exact number 
of functional enhancers in the human genome is debatable, but it is predicted that the human genome 
contains roughly one million enhancers24,25. A back-of-the-envelope calculation indicates that there are 
~20.000 enhancers in the smallest autosome, whereas the biggest contains ~80.000 (assuming that 
chromosome 1 and 22 correspond to ~8% and ~2% of the total genomic DNA, respectively; and that 
enhancers are evenly distributed throughout the genome). Therefore, it is completely feasible to perform 
genetic screens for all putative enhancers on a chromosome-wide scale at present date - as a 
comparison the human genome has ~22.000 protein-coding genes95. This type of experiments has the 
potential to identify enhancers in a comprehensive manner, and also reveal the elusive mechanisms that 
underlie their biological functions. I think that this information is invaluable per se, and can contribute 
decisively to the ultimate goal of mankind - defeating human disease. 
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Scope of the thesis 
The identification of enhancers and their target genes is a major challenge in the post-Human Genome 
Project era. Evidence from different studies indicates that active enhancers are transcribed by RNAPII - 
giving rise to so-called enhancer-associated RNAs (eRNAs). These transcripts are generally lowly-
abundant and, therefore, it is challenging to detect them by standard RNA-seq. In chapter 3 we 
described a protocol of GRO-seq, which is a variant of nuclear run-on assays coupled with NGS. This 
technique has higher sensitivity compared to RNA-seq, enabling the detection of transcripts that are not 
readily identified by measuring steady-state RNA levels. In chapter 4 we asked if the expression of 
eRNAs can predict the location of enhancers that are responsive to specific TFs in a genome-wide scale? 
For that purpose we used GRO-seq to measure the expression of eRNAs and combined that information 
with ChIP-seq data of p53 and ER. The data obtained by GRO-seq is complementary to other datasets 
obtained by NGS (e.g MPRA), but it has an added value of predicting the activity of enhancers in their 
native context. However, these techniques cannot reveal the contribution of enhancers to specific 
biological processes. In chapter 4 we interrogated the function of hundreds of enhancers in parallel by 
performing genetic screens in human cells. Our experimental strategy is based on the disruption of the 
sequence of enhancers by CRISPR-Cas9, which led to the identification of enhancers that regulate the 
expression of oncogenes and tumor-suppressor genes in human cells. Additionally, we showed in 
chapter 5 that CUEDC1 – a previously uncharacterized gene - is regulated by ER through an intronic 
enhancer and is required for the proliferation of breast cancer cells. In conclusion, we demonstrated that 
the combination of gene expression analysis and genetic screening allows characterizing enhancers and 
their target genes in an unprecedented scale. We propose that this type of experiments can elucidate the 
function and mechanism of action of enhancers, and ultimately contribute to improve the diagnosis and 
therapies of human pathologies. 
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Summary 
The sequence of DNA is a code that contains all the information that is required for life (as we know it). 
DNA is stored inside the nucleus of cells and its sequence is replicated during cell division to ensure that 
the genetic information is transmitted to the daughter cells. The information contained in DNA is copied 
into RNA by a process called transcription. RNA acts as a messenger (mRNA) to carry the information 
between the nucleus and the cytoplasm, where it is used as a template to produce proteins through a 
process called translation. Proteins are the main effectors of all biological functions in the cell. However, 
the information required to make proteins (called “coding DNA sequence”) comprises only a small portion 
(~2%) of the entire human genome sequence. For several decades, it was generally accepted that the 
remaining 98% of the genome sequence had no biological function and, because of that, it was dubbed 
“junk DNA”. The discovery of non-coding DNA sequences that control the expression of genes challenged 
this idea, and revealed that there is biological function beyond protein-coding sequences. These non-
coding sequences are called “regulatory elements” and they are classified into four classes according to 
their function: promoters, enhancers, insulators and silencers. Among them, enhancers play a critical role 
in activating the expression of genes in response to intra- and extra-cellular stimuli – which is essential for 
the development of complex organisms. Previous studies suggest that the human genome might contain 
more than one million enhancers – a much higher number compared to the number of protein-coding 
genes (~22.000). However, not much is known about the biological function of most enhancers since only 
a handful of them were studied in detail to present date.  
In recent years, the use of next-generation sequencing technologies (e.g. RNA-seq) revealed that 
the vast majority of the human genome is transcribed into non-coding RNA species. Initially, it was 
thought that these transcripts were “junk RNA” transcribed from “junk DNA”. This hypothesis was refuted 
by thousands of studies reporting that non-coding RNAs regulate a remarkably broad spectrum of cellular 
processes – including transcription and translation. Moreover, it was shown that the dysregulation of 
regulatory elements (and the non-coding RNAs transcribed from them) is associated with different human 
pathologies such as cancer. In this work, we describe a detailed protocol of Global Run-on sequencing 
(GRO-seq), which is a high-throughput sequencing technique that measures nascent RNA transcription. 
We applied GRO-seq to detect enhancer-associated RNAs (eRNAs), which are non-coding RNAs 
transcribed from active enhancers. Our experiments identified thousands of enhancers that are activated 
by critical transcription factors (e.g. p53 and ER) and might play a role in cancer development. In order 
to characterize their function, we used a recently developed technology called CRISPR-Cas9. This 
system is composed of a protein that can cleave DNA (Cas9) and a nucleic acid sequence that can guide 
Cas9 to the target site (CRISPR). CRISPR-Cas9 triggered a revolution in biology because it allows editing 
specific DNA sequences in a very fast and easy way. Importantly, Cas9 can be directed to virtually any 
sequence of the human genome, thus allowing to study the function of enhancers and other regulatory 
elements in a comprehensive manner. We pioneered the application of CRISPR-Cas9 to test the function 
of enhancers by mutating them and examining the resulting phenotype in a high-throughput manner (i.e. 
genetic screening). Our experiments led to the identification of several enhancers that regulate the 
expression of critical genes (e.g. CCND1) and poorly-characterized genes (e.g. CUEDC1) in human cells. 
In both cases, we showed that these enhancers are absolutely required for the growth of cancer cells, 
and our findings provide the basis for better diagnosis and therapies of human cancer. 
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Samenvatting 
De sequentie van DNA is een code die alle informatie bevat die benodigd is voor leven (zoals we dat 
kennen). DNA wordt opgeslagen in de kern van cellen en de sequentie wordt gekopieerd tijdens de 
celdeling om ervoor te zorgen dat de genetische informatie wordt overgedragen aan de dochtercellen. De 
informatie die DNA bevat wordt gekopieerd in RNA door een proces genaamd transcriptie. RNA fungeert 
als boodschapper (“messenger” of “mRNA”) om de informatie van de kern naar het cytoplasma van de cel 
te dragen, waar het gebruikt wordt als sjabloon om eiwitten te produceren, via een proces genaamd 
translatie. Eiwitten zijn de belangrijkste uitvoerders van biologische functies in de cel. Echter, de 
informatie om eiwitten te maken beslaat slechts een klein deel van het menselijk genoom (~2%). 
Gedurende meerdere decennia was het algemeen geaccepteerd dat de resterende ~98% van het 
menselijk genoom geen functie had, en werd daarom bestempeld als “rommel DNA” (“junk DNA”). De 
ontdekking van niet-coderende DNA sequenties die de expressie van genen kunnen reguleren zorgde dat 
dit idee werd betwist en onthulde dat DNA sequenties die niet voor eiwit coderen ook functies kunnen 
hebben. Deze niet-coderende sequenties worden “regulerende elementen” genoemd, en worden in vier
klassen verdeeld naargelang hun functie: promotoren, versterkers (“enhancers”), isolatoren en 
verzwakkers (“silencers”). Onder hen spelen enhancers een cruciale rol in het activeren van genen als 
reactie op intra- en extracellulaire stimuli - hetgeen essentieel is voor de ontwikkeling van complexe 
organismen. Voorgaande onderzoeken suggereren dat het menselijk genoom meer dan een miljoen 
enhancers kan bevatten - en aantal veel groter dan het aantal eiwit-coderende genen (~22000). Er is 
echter niet veel bekend over de functie van de meeste enhancers, aangezien tot op heden slechts een 
klein aantal in detail onderzocht is.  
In de afgelopen jaren heeft het gebruik van next-generation sequencing technologie (bijvoorbeeld 
RNA-seq) aangetoond dat de overgrote meerderheid van het menselijk genoom wordt getranscribeerd tot 
(niet-coderend) RNA. Aanvankelijk werd gedacht dat deze transcripten “junk RNA” van het “junk DNA”
weerspiegelen. Deze hypothese werd later afgewezen door duizenden studies die aangeven dat deze 
niet-coderende RNA transcripten een opmerkelijk breed spectrum aan cellulaire processen regelen - 
waaronder transcriptie en translatie. Bovendien bleek dat de dysregulatie van regulerende elementen (en 
van de niet-coderende RNA transcripten die van hen worden getranscribeerd) in verband staat met 
verschillende menselijke pathologieën zoals kanker.In dit werk beschrijven we een gedetailleerd protocol 
van “Global Run-on sequencing (GRO-seq)”, wat een high-throughput sequencing techniek is die net-
onstane RNA transcripten meet. We hebben GRO-seq toegepast om enhancer-geassocieerde RNAs 
(eRNAs) te detecteren. Deze eRNAs zijn niet-coderende RNA transcripten, gemaakt door transcriptie van 
enhancer elementen. Onze experimenten hebben duizenden enhancers geïdentificeerd die geactiveerd 
worden door belangrijke transcriptie-factoren (bijvoorbeeld p53 en ER-alpha) en kunnen een rol spelen bij 
de ontwikkeling van kanker. On hun functie verder te karakteriseren hebben we een recent ontwikkelde 
technologie genaamd CRISPR-Cas9 gebruikt. Dit systeem bestaat uit een eiwit dat DNA kan splitsen 
(Cas9) en een nucleïnezuursequentie die het Cas9-eiwit kan leiden naar het doel (CRISPR). CRISPR-
Cas9 bracht een revolutie in de biologie teweeg omdat het het mogelijk maakt om specifieke DNA-
sequenties op een zeer snelle en eenvoudige manier te bewerken. Belangrijk is dat Cas9 kan worden 
toegepast op vrijwel alle sequenties in het menselijk genoom, waardoor het mogelijk is om de functie van 
enhancers en andere regulerende elementen op een uitgebreide manier te testen. Met CRISPR-Cas9 
hebben we pionierswerk gedaan om de functie van enhancers te testen, door ze te muteren en het 
resulterende fenotype te onderzoeken met hoge doorloop (een zogenaamde genetische screen). Onze 
experimenten hebben geleid tot de identificatie van meerdere enhancers die de expressie van cruciale 
genen (bijvoorbeeld CCND1) en slecht gekarakteriseerde genen (bijvoorbeeld CUEDC1) in menselijke 
cellen regelen. In beide gevallen hebben we aangetoond dat deze enhancers absoluut noodzakelijk zijn 
voor de groei van kankercellen, en onze onderzoeksresultaten vormen de basis voor een betere 
diagnose en betere therapieën van kanker. 
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